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Chapter 1
g e n e r a l  i n t roduc t ion  a n d  a i m s  of  t h e  s t u dy :
du r at ion  of  t u be rc u l o s i s  t r e at m e n t
1.1 Incentive
1.2 Current treatment and logical basis for treatment
Based on: van Loenhout-Rooyackers JH, Lambregts-van Weezenbeek CSB, 
Veen J, onder medeverantwoordelijkheid van de redactiecommissie. De behandeling
van tuberculose anno 1997. Geneesmiddelen bulletin 1997;31:75-81
1.3 Aims of the study
1.4 Structure of the thesis
1.5 References

1 . 1  i nc e n t i v e
Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis, for
which long-term treatment is recommended. Treatment is considered to be suc-
cessful when the patient is cured, is no longer infectious and does not suffer
relapse. By combining the correct chemotherapeutic agents and monitoring
treatment compliance, it should be possible to prevent resistant mutation. With
the increasing availability of efficacious chemotherapeutic agents, the duration
of treatment has gradually been shortened from 12-18 months to 6-9 months.
Research has shown that the relapse rate after 4 months treatment was 12% [1].
It is possible for a patient to be complaint-free and no longer infectious before
his chest X-ray has normalised. At this point, it cannot be established which
patients will suffer relapse. Consequently, patients may have been receiving
treatment for longer than is strictly necessary [1].
The direct incentive for writing this thesis was the difference in pulmonary
tuberculosis treatment duration between the Netherlands and other countries,
such as the United Kingdom and the United States. Since 1978, international
studies have shown that a treatment duration of six months is sufficient for pul-
monary tuberculosis caused by M. tuberculosis with normal sensitivity, provided
that treatment compliance is high. This treatment regimen comprised an inten-
sive phase with at least isoniazid (H), rifampicin (R) and pyrazinamide (Z) for
two months, possibly with the addition of ethambutol (E) and/or streptomycin
(S), followed by a secondary phase of four months with isoniazid and
rifampicin.
In the late nineteen eighties, both the British Thoracic Society (BTS) and the
American Thoracic Society (ATS) recommended a treatment duration of six
months for patients with pulmonary tuberculosis based on these studies [2,3].
Far fewer studies have been performed on the effectiveness of chemotherapeu-
tic treatment for extrapulmonary forms of tuberculosis. Probable reasons for
this are that extrapulmonary forms of tuberculosis are less common than pul-
monary tuberculosis and that extrapulmonary forms are not usually infectious,
so they are of less importance to public health. Although both pulmonary and
extrapulmonary forms of tuberculosis are caused by the same mycobacteria, it
is more difficult to obtain bacteriological evidence and perform bacteriological
treatment monitoring of the extrapulmonary forms. These two findings plus
the fact that extrapulmonary forms are often recognised at a late stage, which
means that irreversible organ damage can have occurred, have given rise to the
theoretical discussion on whether chemotherapeutics adequately reach the
source of infection. The ATS took into consideration that for extrapulmonary
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forms of tuberculosis, such as tuberculous lymphadenitis and spinal tuberculo-
sis, longer durations of treatment might be necessary. In contrast, the BTS rec-
ommended six months treatment, even for tuberculous lymphadenitis and
spinal tuberculosis, but 12 months for tuberculous meningitis.
In view of the good treatment results in the Netherlands, the National Tubercu-
losis Policy Committee (CPT), part of the Royal Netherlands Tuberculosis
Association (KNCV), were not prepared to adopt these recommendations
without looking into the matter themselves first. Any missed doses of chemo-
therapeutics during the first six months of treatment would be compensated for
by a longer treatment duration. Thus the number of patients who ultimately
suffer relapse because of non-compliance will remain low. Therefore, an obvi-
ous course of action was to perform a thorough literature search on the treat-
ment duration of pulmonary and extrapulmonary forms of tuberculosis, with
relapse rate as the major parameter. On the basis of insights into the action of
chemotherapeutic agents valid at that time and on the basis of experience with
tuberculosis patients, it was decided that for the analysis, only studies would be
considered that had a treatment duration of six months or longer and a treat-
ment regimen that included isoniazid (H), rifampicin (R) and pyrazinamide (Z).
1 . 2  c u r r e n t  t r e at m e n t  a n d  l o gic a l  
ba s i s  f or  t r e at m e n t
General
The aim of the treatment is to cure that patient (of interest to the individual) and
therefore limit the transmission of tubercle bacteria (of interest to public
health). A patient is considered cured when no viable tubercle bacteria can be
demonstrated and the risk of relapse is low. No absolute norm for a relapse rate
has ever been established. The risk of relapse depends on the potency of the sep-
arate chemotherapeutic agents, on the combination administered and on the
duration of treatment. In general, the treatment will be longer when the
chemotherapeutics are less effective.
Action of chemotherapeutic agents
Tuberculosis patients are infected with bacteria that have varying levels of
metabolic activity. Bacteria in oxygen-rich regions can divide rapidly. In poorly
oxygenated and more acidic regions, such as caseous-filled caverns (i.e. cavities
in which necrosis has occurred), division is much slower, whereas within a
macrophage, cell division will almost be halted [4]. Bacteria that divide slowly
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and/or are localised in inaccessible regions with poor blood circulation, are dif-
ficult to eliminate.
There is no single treatment that can eliminate all the bacteria simultaneously.
An English physician, Mitchison, developed a theoretical model based on the
localisation of the bacteria (intracellular or extracellular), the growth cycle
(dividing, dormant or semidormant) and the activity of the various chemother-
apeutics. In order to prevent resistance and because the modes of action of
chemotherapeutics are different, treatment for active tuberculosis generally
starts with three or four chemotherapeutics for a duration of two months
(intensive phase) and is followed by treatment with two chemotherapeutics in
the secondary phase.
Isoniazid (1952) is bactericidal and is active intracellularly in the macrophages
and extracelluarly. Its mode of action is not fully understood, but it is known to
inhibit the production of mycolic acid, which is an important component of the
cell wall of bacteria [5]. The agent produces rapid reduction of large popula-
tions of continuously dividing tubercle bacteria, such as in those present in the
cavern wall. Rifampicin and pyrazinamide have low activity at this site.
Rifampicin (1965) is bactericidal: it inhibits RNA polymerization, which
arrests bacterial protein synthesis. It kills persistent semidormant bacteria dur-
ing the short division phase. This chemotherapeutic agent is therefore essential
for sterilising the disease process and preventing relapse. Sterilising action
means the ability of the medication prescribed to render the disease process
germfree.
Pyrazinamide (1950) in high dosages with an unacceptably large number of
side-effects and since 1978 in therapeutically adequate dosages with an accept-
able level of side-effects) is only active in an acidic environment. The
chemotherapeutic agent is converted into pyrazine acid by the enzyme pyra-
zinamidase that comes from the tubercle bacteria. This lowers the pH value in
the macrophages and kills any intracellular bacteria (inside the macrophages)
and the bacteria in the acidic (caseous) inflammatory nidus [6]. Therefore,
pyrazinamide is of particular importance in the intensive phase of treatment. It
is only administered in the secondary phase in the case of multi-resistance.
The action of aminoglycocides (1941 streptomycin and amikacine) is based
on blocking ribosomal RNA. These agents are bactericidal under aerobic con-
ditions. The bactericidal action of streptomycin is limited to extracellular,
actively dividing bacteria (e.g. in caverns).
Ethambutol (1961) influences the RNA synthesis of the bacteria and inhibits
the incorporation of mycolic acid in the cell wall [7,8]. The agent is bacteriostat-
ic at a dosage of 15 mg/kg body weight and bactericidal at a dosage of 25 mg/kg
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body weight. At therapeutic dosages, it is far less effective than the above-
described agents.
(Multi)resistance
Soon after the introduction of the first chemotherapeutic agents it became clear
that monotherapy led to resistance formation. If streptomycin alone was
administered, 80% of the cases developed resistance within three months. With
isoniazid alone, 25% of the patients developed resistance after two weeks [9].
At the start of treatment, the bacteria population is large. To prevent resistance
forming, it is necessary to administer a combination of chemotherapeutic
agents in the intensive phase. In this way, one agent prevents the selection of
mutations against the other agent. Isoniazid and rifampicin contribute more to
the prevention of resistance formation than pyrazinamide and ethambutol. As
the volume of the bacteria population decreases, the risk of resistance forming
also decreases [10]. Multi-resistance develops through the step by step build-up
of resistance as a result of inadequate treatment, or as a consequence of primary
infection with a multi-resistant strain.
Treatment compliance
Insufficient treatment compliance leads to treatment failure and is partly
responsible for resistance forming.
Dosage
It is recommended to administer each chemotherapeutic agent once a day. The
effectiveness of chemotherapeutic agents does not depend on continuous blood
or tissue levels above the minimal bacterial growth inhibitory concentration
(MIC). Owing to the fact that tubercle bacteria only have a short division phase,
it is assumed that achieving a high serum concentration for a few hours is more
important than maintaining a low serum concentration for 24 hours. This has
actually been demonstrated for isoniazid [11]. High peak concentrations with a
once daily dosage inhibit mutations with a low grade of resistance [12]. The risk
is small that dividing bacteria are exposed to suboptimal chemotherapeutic lev-
els with once daily dosages. Moreover, most bactericidal agents have an after-
effect, or a postantibiotic effect: after the bacteria have been exposed to effec-
tive antibiotic concentrations, the bactericidal effect continues for some time.
This also explains why intermittent treatment regimens, in which chemother-
apeutics are administered two or three times per week, are also effective [13,14].
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Treatment duration and effectiveness
In the nineteen sixties, a combination of isoniazid, streptomycin, ethambutol or
para-aminosalicy acid (PAS, 1948) and a total treatment duration of 18-24
months led to relapse in 10% of the patients after the completion of treatment
[15]. With the introduction of rifampicin in addition to isoniazid, it became pos-
sible to shorten the duration of treatment to nine months. In human pulmonary
tuberculosis with normal sensitivity, nine months treatment with isoniazid and
rifampicin, whether or not in combination with ethambutol or streptomycin,
led to a relapse rate of 1% [16].
In the nineteen seventies, treatment with a (short) duration of six months that
comprised isoniazid, rifampicin, pyrazinamide and streptomycin for the first
two months and isoniazid and rifampicin for the following four months, proved
to be very effective. Pyrazinamide played a crucial role. When pyrazinamide
had been included in the treatment regimen, the relapse rates were 1.4% after
two years and 3.4% after five years, compared to 7.8% and 20.3%, respectively,
when it had been omitted [17]. At present, pyrazinamide is considered to be a
chemotherapeutic agent of first choice.
If treatment fails in the case of good treatment compliance, there may have been
insufficient biological availability of the chemotherapeutic agents. Pharmacoki-
netic tests are then indicated [18]. Determining serum chemotherapeutic levels
is possible in the Netherlands. However, it is difficult to interpret the results,
due to lack of experience. At this time, i.e. 2001, the pharmaceutical industry
has little interest in research into the action of the above-described chemothera-
peutic agents. These agents have proved to be effective and the incidence of
tuberculosis in developed countries is low.
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1 . 3  a i m s  of  t h e  s t u dy
The aims of the study were to gain greater insight into the treatment of tubercu-
losis with a combination of isoniazid, rifampicin and pyrazinamide and particu-
larly into treatment duration at a time when the circumstances surrounding
tuberculosis are changing dramatically. These aims were addressed by conduct-
ing a number of systematic literature studies. As far as possible, the results of
individual reports have been combined statistically. On the basis of the results
of this literature review, recommendations are made about the treatment dura-
tion for tuberculosis. These recommendations can form the basis of treatment
guidelines for tuberculosis physicians at Municpal Health Services (MHSs) and
hospital clinicians. Below, a description is given of the tuberculosis situation in
the Netherlands in the year 2000, with a low incidence, Dutch and non-Dutch
patients, pulmonary localisations and extra-pulmonary localisations.
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Ta bl e  1 . Frequency of localisation of tuberculosis in Dutch and non-Dutch patients, aver-
age per year, absolute and %. Period 1993-1997, data from the Netherlands Tuberculosis Reg-
ister (NTR) / Royal Dutch Tuberculosis Association (KNCV). Patients can have more than
one localisation
Dutch nationality non-Dutch nationality  
Total No. of patients with
tuberculosis average / year 743 893  
Primary tuberculosis 69 9.1% 42 4.7%
Pulmonary localisation 33 45.2% 445 49.8%
Other forms of tuberculosis of 
the respiratory tract 92 12.4% 114 12.8%
Oher organs, 60 8% 183 20.5%
incl. cervical lymph nodes 44 6% 149 17%
Meninges  and central 
nervous system 11 1.5% 10 1.2%  
Bones and joints 27 3.7% 41 4.6%  
Genitourinary tract 27 3.6% 16 1.8%  
Intestinal tract 11 1.5% 37 4.1%  
Miliary tuberculosis 22 3% 15 1.7%
Unknown / not mentioned 119 16.1% 112 13.6%
Tuberculosis incidence indicates the number of persons that are tuberculosis-
free at the beginning of a calendar year but develop tuberculosis in the course of
that year. The incidence of tuberculosis in the Netherlands is extremely low:
8.9/100,000 (data from the Netherlands Tuberculosis Register (NTR) 2000).
Among non-Dutch nationality subjects, the incidence of tuberculosis is
136.2/100,000. Among subjects with the Dutch nationality, the incidence is
3.4/100,000, comparable to Scandinavia. In the majority of West-European
countries, the incidence is three or four times higher, while in East-European
countries, it is 10 to 20 times higher. In the mid nineteen eighties, the number of
patients with tuberculosis stopped decreasing and started to increase. The
highest incidence was found among AIDS patients in regions with high endem-
ic tuberculosis. The incidence is especially high in sub-Sahara Africa and
South-East Asia: more than 100/100,000 per year (data from the World Health
Organisation). The number of patients with tuberculosis in the Netherlands is
directly related to the influx of migrants and asylum seekers, many of whom are
from regions with high endemic tuberculosis. The risk is even higher in the case
of comorbid HIV infection.
Other persons with an increased risk of tuberculosis are (a) persons returning
from a trip to countries where tuberculosis is common; (b) persons who may
have been exposed to infection and are therefore invited for source and contact
tracing; (c) persons addicted to drugs or alcohol; (d) elderly tuberculosis
patients who have never been treated or have not received adequate treatment;
(e) the homeless; (f) prison detainees; (g) health care workers; (h) seamen. The
Netherlands Tuberculosis Register shows that the annual number of patients
with tuberculosis varied from 1192 in 1987 to 1811 in 1994. In the period 1993-
1997, an average of 743 Dutch persons per year had active tuberculosis, com-
pared to 893 non-Dutch persons (55%) (Table 1).
About 70% of the patients with intact immunity and active tuberculosis had
pulmonary tuberculosis, while 30% had an extra-pulmonary form of tuberculo-
sis. The frequency of extra-pulmonary tuberculosis and the frequency per
organ localisation differ between population groups. Cervical tuberculous lym-
phadenitis is the most common extra-pulmonary localisation. In immune-com-
promised patients, such as HIV positive persons, tuberculous lymphadenitis
more commonly accompanies active tuberculosis in other organs [19]. It is also
important to take atypical mycobacteria into consideration, as these are more
common in AIDS patients [20].
If patients are from countries that do not have good tuberculosis programmes,
there is a risk of importing primary resistant tubercle strains. In addition, there
is a risk of inducing secondary resistance in the Netherlands, for example,
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through treatment errors. The risk of treatment errors is larger when there is no
uniform treatment policy and when there is no supervision of treatment.
Migrants and asylum seekers who enter the Netherlands are directly screened
for tuberculosis. Treatment is started by the MHSs and asylum seekers are
often transferred many times between shelters. Furthermore, the diagnosis of
tuberculosis can be made in patients with complaints. In this way, general prac-
titioners and hospital clinicians encounter tuberculosis. The absolute numbers
of tuberculosis patients that are treated by a general practitioner or hospital
clinician are small, which means that individual physicians can never gain suffi-
cient clinical experience with tuberculosis. The risk of treatment errors is
greater when the treating physicians do not have a uniform treatment policy
and the duration of treatment increases. Therefore, there is a clear need for uni-
form policies and guidelines.
1 . 4  s t ruc t u r e  of  t h e  t h e s i s
After the above description of the aims of the study, Chapter 2 gives an
overview of the literature studies on the treatment of pulmonary tuberculosis
caused by human tubercle bacteria with normal sensitivity; diagnoses and
relapses were bacteriologically proven. The question was: Can treatment for
pulmonary tuberculosis be shortened from 9 to 6 months?
In contrast with pulmonary tuberculosis, it is far more difficult to obtain bacte-
riological proof of the diagnosis of extrapulmonary forms of tuberculosis and
to make a bacteriological evaluation of the course of treatment. Chapter 3A
therefore addresses the diagnosis of cervical tuberculous lymphadenitis. The
question is: Can a diagnostic decision tree be developed for the Dutch situation
and what is the value of simple basic testing compared to advanced modern
techniques?
In Chapter 3B an overview is given of literature studies on the treatment of cer-
vical tuberculous lymphadenitis. The question is: Can the duration of treatment
be shortened to 6 months?
Chapter 4 gives an overview of the literature studies on the treatment of tuber-
culous meningitis. The question is: Is 6 months treatment equally as effective 
as longer treatment? An important point is whether during treatment, the
chemotherapeutics are able to adequately reach the focus of infection. In
patients with tuberculous meningitis, the diagnosis is often made after irre-
versible organ damage has occurred and the physician is confronted with a dra-
matic disease course. In children, chemotherapeutics, including isoniazid, are
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often administered in high dosages (10-20 mg/kg body weight per day). Very
few patient studies mention pharmacokinetic data on chemotherapeutics in
general, or on the central nervous system in particular. In the Netherlands, in
contrast with the American guidelines, it is recommended to administer isoni-
azid in a dosage of 4-8 mg/kg body weight/day, instead of 10-20 mg/kg body
weight/day. However, it is questionable whether in children with an active form
of tuberculosis, an isoniazid dosage of 5 mg/kg body weight is effective. There-
fore Chapter 5 discusses the treatment results for all forms of tuberculosis in
children in the Netherlands.
In Chapters 6 and 7, overviews are given of the chemotherapeutic treatment of
spinal and renal tuberculosis. The question is: Can treatment be shortened to 6
months?
It is necessary to prolong the duration of treatment if intake is inadequate.
Supervision of treatment compliance and source and contact tracing are car-
ried out by the MHS after the patient has been reported by the laboratory or
treating physician. In order to establish whether tuberculosis is under-reported,
Chapter 8 evaluates whether the amount of pyrazinamide dispensed by
chemists agreed with the number of days of pyrazinamide use noted per patient
by the Netherlands Tuberculosis Register.
Chapter 9A describes contact tracing around an asylum seeker, the source, as
performed by the MHS. Chapter 9B answers the question of whether after con-
tact tracing was closed, other patients were reported whose infection could
probably be attributed to the same source.
In the Netherlands, tuberculosis is fairly uncommon and the treating physicians
belong to various organisations. Chapter 10 evaluates which factors may have
played a role in the implementation of treatment advice that originated from
structured overviews and meta-analyses of the treatment of tuberculosis.
On the basis of all the above-mentioned studies, recommendations are made
about the duration of treatment with isoniazid, rifampicin and pyrazinamide in
patients with tuberculosis.
g e n e r a l  i n t roduc t ion  a n d  a i m s  of  t h e  s t u dy 19
1 . 5  r e f e r e nc e s
1 Fox W. Short-course chemotherapy for pulmonary tuberculosis and some
problems of its programme application with particular reference to India. Bull
Int Union Tuberc 1985;60:44-54.
2 American Thoracic Society (ATS). Treatment of tuberculosis and tuberculosis
infection in adults and children. Am Rev  Respir Dis 1986;134:355-63.
3 British Thoracic Society (BTS). Chemotherapy and management of tuberculo-
sis in the United Kingdom: recommendations of the Joint Tuberculosis Com-
mittee of the British Thoracic Society. Thorax 1990;45:403-8.
4 Fox HH. The chemical attack on tuberculosis. Trans NY Acad Sci 1953; 15:234-
42.
5 Takayama K, Schnoes JK, Armstrong EL, Boyle RW. Site of inhibitory action of
isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis. J
Lipid Res 1975;16:308-72.
6 Crowle AJ, Sbarbaro JA, May MH. Inhibition by pyrazinamide of tubercle
bacilli within cultured  human macrophages. Am Rev Respir Dis 1986;134:
1052-8.
7 Crowle AJ, Sbarbaro JA, Judson FN, May MH. The effect of ethambutol on
tubercle bacilli within cultured human macrophages. Am Rev Respir Dis
1985;132;742-5.
8 Takayama K, Armstrong EL, Kunugi KA, Kilburn JO. Inhibition by ethambu-
tol of mycolic acid transfer into the cell wall of Mycobacterium smegmatis.
Antimicrob Agents Chemother 1979;16:240-2.
9 Costello HD, Caras GJ, Snider DE jr. Drug resistance among previously treat-
ed tuberculosis patients, a brief report. Tubercle 1980;121:313-6.
10 Mitchison DA. Drug resistance in mycobacteria. Br Med Bull 1984;40:84-90.
11 Tuberculosis Chemotherapy Centre, Madras: A concurrent comparison of iso-
niazid plus PAS with regimens of isoniazid alone in the domiciliary treatment
of pulmonary tuberculosis in South India. Bull WHO 1960;23:535-85.
12 Mitchison DA. Plasma concentrations of isoniazid in the treatment of tubercu-
losis. In: Davies DS, Pritchard BNC (eds). Biological effects of drugs in relation
to their plasma concentrations. London: Macmillan, 1973:169-82.
13 Iseman MD. Curing and preventing tuberculosis. Presentation World Congress
on Tuberculosis. Bethesda USA:1992.
14 Crofton J, Horne N, Miller F. Clinical tuberculosis. London: Macmillan Edu-
cation Ltd, 1992.
c h a p t e r  120
15 Medical Research Council. Tuberculosis Chemotherapy Trials Committee.
Long term chemotherapy in the treatment of chronic pulmonary tuberculosis
with cavitation. Tubercle 1962;43:201-67.
16 Fox W. Whither short-course chemotherapy? Br J Dis Chest 1981;75:331-57.
17 Hong Kong Chest Service/British Medical Research Council. Five-year follow-
up of a controlled trial of five 6-months regimens of chemotherapy for pul-
monary tuberculosis. Am Rev Respir Dis 1987;136:1139-42.
18 Peloquin CA, Berning SE. Infection caused by Mycobacterium tuberculosis.
Ann Pharmacother 1994;28:72-84.
19 Perenboom RM, Richter C, Swai AB, Kitinya J, Mtoni I, Chande H, et al. Clini-
cal features of HIV seropositive and HIV seronegative patients with tubercu-
lous lymphadenitis in Dar es Salaam. Tuber Lung Dis 1995;76:401-6.
20 American Thoracic Society. Diagnosis and treatment of disease caused by non-
tuberculous mycobacteria. Am J Respir Crit Care Med 1997;156:S1-S25.
g e n e r a l  i n t roduc t ion  a n d  a i m s  of  t h e  s t u dy 21

Chapter 2
t r e at m e n t  du r at ion  f or  pat i e n t s  w i t h
pu l mona ry  t u be rc u l o s i s  c a n  be  s hort e n e d  f rom
9  t o  6  mon t h s  on  t h e  ba s i s  of  l i t e r at u r e  data
van Loenhout-Rooyackers JH, Veen J, Verbeek ALM
Verkorting van de therapieduur bij patiënten met longtuberculose van 9 naar 
6 maanden verdedigbaar op grond van gepubliceerde gegevens
Ned Tijdschr Geneeskd 1996;140:2181-7

2 . 1 a b s t r ac t
Aim: to determine whether in the Netherlands, as in other countries, the dura-
tion of treatment for pulmonary tuberculosis with normal bacterial sensitivity
can be shortened from 9 to 6 months.
Design: literature study.
Setting: Municipal Health Service Nijmegen, the Netherlands.
Method: relevant literature was analysed, in which the relapse rate was used as
criterion. Analysis was restricted to patients with bacteriologically confirmed
pulmonary tuberculosis, in whom human tubercle bacteria with normal sensi-
tivity had been isolated. Treatment had to include isoniazid, rifampicin and
pyrazinamide. There were no reports on a treatment duration of 9 months. Pre-
determined criteria were used in Medline to select studies with a treatment
duration of 6 months, published between 1980 and 1991.
Results: 25 publications containing 44 treatment regimens of 6 months dura-
tion were suitable for analysis. Six months treatment resulted in a relapse rate of
2.4% (95% CI 2.0-2.8) over a period of 12 to 94 months follow-up after the com-
pletion of treatment. These results were not affected by additional streptomycin
or ethambutol during the intensive phase, self-medication or treatment under
close supervision, daily or intermittent treatment. It was not possible to make
comparisons with the relapse rate of 1% reported in the literature after 9
months of treatment without pyrazinamide (1%, 0.2-2.9). Recent calculation of
the number of persons in the Netherlands with tuberculosis relapse resulted in
a relapse rate of 2.5% (1.8-3.2). The American Thoracic Society reported a
relapse rate of <5%, which was adopted as a guideline.
Conclusion: On the basis of relapse rates reported in the literature, it would be
justified to shorten the duration of treatment from 9 to 6 months in the Nether-
lands.
2 . 2 i n t roduc t ion
From time immemorial, chemotherapeutics have been distinguished according
to their so-called bactericidal and sterilant action. Swift bactericidal activity
rapidly interrupts the transmission of infection, while the sterilant action
destroys the total bacterial population and prevents the development of resis-
tant strains. Pyrazinamide is a chemotherapeutic with a strong sterilant effect.
In the Netherlands, it has been recommended to administer pyrazinamide in
the so-called intensive phase of tuberculosis treatment since 1978. The duration
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of treatment for an infection with a non-resistant human tubercle bacillus in the
Netherlands is 9 months; during the first 2 months (the intensive phase) isoni-
azid, rifampicin and pyrazinamide are administered daily. In the 7-month con-
tinuation phase, the daily administration of isoniazid and rifampicin is consid-
ered to be sufficient. This treatment regimen can be summarized as:
2HRZ/7HR (H = isoniazid; R = rifampicin; Z = pyrazinamide). No studies have
been performed on the relapse rate with this treatment regimen. The 9-month
treatment regimens that included isoniazid and rifampicin gave a relapse rate of
1% (95% CI: 0.2-2.9) [1].
It was expected that the strong sterilant action of pyrazinamide would make it
possible to shorten the duration of treatment. Owing to the fact that the effec-
tiveness of a treatment regimen is not only determined by the nature of the med-
ication, but also by the duration of administration, several international studies
have been performed since 1978 on the effectiveness of a treatment duration of
6 months or even shorter for pulmonary tuberculosis. These studies have
chiefly been performed in countries with a high tuberculosis prevalence. The
American Thoracic Society put forward a relapse rate of <5% as a criterion for
the effectiveness of a treatment regimen [2]. A shorter duration of treatment is
known to increase treatment compliance, reduce the risk of side-effects and
decrease the financial cost.
The question arises as to whether it is justified to shorten the continuation
phase by 3 months in patients with pulmonary tuberculosis (M.tuberculosis, 
normal sensitivity) in the Netherlands. To answer this question, a literature
study was performed to determine the bacteriologically confirmed relapse rate
after treatment with isoniazid, rifampicin and pyrazinamide.
2 . 3 m e t hod s  a n d  de f i n i t ion s
Relevant literature published in the period 1980 to 1991 was collected using
Medline. A total of 53 papers were analysed. The 6-month treatment regimens
which included isoniazid, rifampicin and pyrazinamide were selected on the
basis of the following inclusion criteria:
The treatment regimen must be clearly described and the medication dose must
be adequate, i.e. isoniazid 300 mg/day or 15 mg/kg body weight 3 times per
week; rifampicin 600 mg/day (body weight > 50 kg), 450 mg/day (body weight
< 50 kg) or 3 times per week; pyrazinamide 1.5 or 2 g/day or 2-2.5 g intermittent-
ly (i.e. several times per week).
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Two additional chemotherapeutics were permitted: streptomycin (S) 1 g i.m. or
ethambutol (E) 25 mg/kg daily for the first 2 months, 15 mg/kg in the continua-
tion phase or 30 mg/kg intermittently.
The chemotherapeutics must be taken daily or intermittently for a period of 6
months. Mention must be made of whether or not administration took place
under close monitoring. Studies with combination tablets were not taken into
consideration, unless the biological activity was documented [8,11].
Patients must not have received chemotherapeutics in the past, unless the
patient had been treated for less than 2 weeks in the past year, or prior to that,
for no longer than 4 months in total. Patients who had received the treatment
regimen 2HRZ/4HR for less than 30 days in the past half year were included in
the study [10]. Previous isoniazid prophylaxis was also permitted.
Patients had to be older than 14 years, without compromised resistance. Only
patients with a diagnosis of “pulmonary tuberculosis and/or pleuritis”, without
any extrapulmonary localisations, were included in the study.
Radiological abnormalities must be described and the diagnosis confirmed
bacteriologically. Ziehl-Neelsen staining could be negative, but the Löwenstein
culture had to be positive for Mycobacterium tuberculosis with normal sensitivi-
ty to the usual chemotherapeutics. A growth of > 20 colonies in at least one
culture was taken as the criterion for antibiotic resistance to the following or
higher antibiotic concentrations: isoniazid 0.2 mg/l; rifampicin 32 mg/l; pyrazi-
namide 50 mg/l (at the correct pH level); streptomycin > 32 mg/l.
After the start of treatment, (provoked) sputum must be tested at least once a
month. The date on which the first negative culture of two consecutive sputa
occurred was taken as the moment of so-called sputum conversion, provided
that the sputum remained negative during the subsequent 16 weeks of treat-
ment. 
If after 12 weeks of treatment, 2 or more positive cultures were found within an
interval of at least 1 month, then the treatment was considered to have failed.
Treatment was considered successful when sputum conversion occurred dur-
ing the first 16 weeks of treatment, provided that the sputum remained negative.
Treatment must not be interrupted for longer than 14 consecutive days. More-
over, at least 80% of the chemotherapeutics must have been taken by the
patient. After the completion of successful treatment, the patient must be fol-
lowed-up for at least 1 year and the sputum tested once or twice a month. Subse-
quently, sputum must be tested once every 3 to 6 months. “Bacteriologically
confirmed recurrence” was defined in the same way as that employed by the
author.
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Selected papers
Based on the above-described criteria, 25 papers were selected with a total of 44
treatment regimens [3-26]. In each paper, several combinations of chemothera-
peutics were compared. The selection procedure made it possible to draw con-
clusions, as though all the studies formed part of a larger study [27-30].
Relapse rates were classified according to (a) follow-up duration after the com-
pletion of treatment, (b) chemotherapeutic intake: self-medication or medica-
tion taken under close supervision; distinction was also between daily and
intermittent intake, (c) different treatment groups. Although all the treatment
regimens included isoniazid, rifampicin and pyrazinamide, there were differ-
ences between studies (Table 1).
Data analysis
The relapse rate reported for each treatment regimen or calculated from abso-
lute numbers was noted; 95% confidence intervals were taken from the papers
or calculated [31].
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Ta bl e  1 . Distribution of treatment regimens (n=44) used to treat patients with 
tuberculosis in 25 selected publications (3-27)
Group  Treatment  
I 2HRZ/4HR  
II 2HRZS/4HR  
III 2HRZE/4HR  
IV 2HRZ/4H3R3
V 2HRZ/4H2R2
VI 2HRZS/4H3R3
VII 2HRZS/4H2R2
VIII 2H3R3Z3S3/2H3R3S3/2H3R3
4H3R3Z3S3/2H3R3
IX Z for  6 months, monophasic regimen  
X Z for 6 months, biphasic regimen  
H = isoniazid    R = rifampicin    Z = pyrazinamide    S = streptomycin    E =ethambutol
The number in front of the letters is the number of months that the chemotherapeutics with
those letters were administered. The chemotherapeutics were taken daily. If the
chemotherapeutics were taken intermittently (a number of times per week), this is depicted
by a number in subscript after the letter of the chemotherapeutic. Example: 4H3R3 means 4
months of isoniazid and rifampicin 3 times per week
2 . 4 r e s u lt s
A total of 25 papers with 44 6-month treatment regimens were analysed (Table
2) [3-26]; we accepted that a number of papers did not fully comply with the cri-
teria described above. For example, it was not always reported whether the sen-
sitivity pattern had been determined [4-6,21]; and/or sputum had not been test-
ed once a month in the first year of follow-up, but every 3 months instead
[4,6,9,21]. One study had been conducted under primitive circumstances,
which meant that follow-up in the second year after the completion of treat-
ment did not take place every 3 to 6 months [7]. In 4 papers, the procedure was
not described [4,5,11,24].
The 44 treatment regimens were divided into 10 treatment groups (see Table 1)
and according to the duration of follow-up after the completion of treatment
(see Table 2). The 95% confidence intervals of the relapse rates of the 44 treat-
ment regimens overlapped (Fig. 1). The risk of relapse appeared to increase as
the duration of follow-up increased. Fifty per cent of the relapses occurred in
the first 6 months; the 75th percentile fell within 1 year after the completion of
treatment in the 4 studies with follow-up periods of 18, 24, 30 and 36 months,
respectively (Table 3).
After 6-months of treatment, relapse occurred in 116 out of the 4833 patients,
2.4% (2.0-2.8). Relapse rates after regimens conducted under close supervision
did not differ from those conducted under self-medication. The total number of
bacteriologically confirmed relapses after the completion of treatment in the 15
treatment regimens in which the medication had been taken daily was 28/1515
(1.8%; 1.1-5.5). The relapse rate of the 6 treatment regimens in which the medi-
cation had been taken daily under close supervision was 15/650 (2.3%; 1.3-3.7).
The relapse rate in the 23 regimens in which the medication had been taken
intermittently under close supervision was 71/2565 (2.8%; 2.2-3.5). There was
only one study of intermittent self-medication. These patients were followed-
up for 48 months after the completion of treatment. The recurrence rate was
2/103 (2%; 0.2-7.0).
2 . 5 di s c u s s ion
Since the introduction of pyrazinamide in 1978, no studies have been published
on the effectiveness of the treatment regimen 2HRZ/7HR. Therefore it was not
possible to compare 2HRZ/4HR to 2HRZ/7HR (a commonly used regimen in
the Netherlands) on the basis of a literature analysis. However, studies have
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Ta bl e  2 . Treatment for tuberculosis in the literature: treatment regimens including 
isoniazid (H), rifampicin (R) and pyrazinamide (Z)
1 stauthor treatment follow-up in relapse rate in patients 
regimen* months after after successfully 
completing completing 
treatment regimen treatment (%; 95%CI)
whether or not 
under close 
supervision (+/-)
Hong Kong Chest Service [3] 6HRZE 12 + 1/161 (1; 0.02- 3.46)
6H3R3Z3S3E3 12 1/150 (1; 0.02- 3.71)
6H3R3Z3E3 12 4/164 (2; 0.66- 6.25)
6H3R3Z3S3 12 2/150 (1; 0.16- 4.82)
Onadeko [4] 2HRZS/4HR 12 - 0/ 23 (0; 0.00-14.82)
2HRZS/4HRZ 12 0/ 20 (0; 0.00-16.84)
2HRZS/4HZ 12 0/ 22 (0; 0.00-15.44)
Fujiware † 2HRZ/4HR 12 - 1/ 95 (1; 0.03- 5.73)
2HRZE/4HR 12 1/ 95 (1; 0.03- 5.73)
Angel [5] 2HRZS/4HR  } 12 - 4/287 (1.4; 0.38- 3.57)2HRZE/4HR
Miles [6] 2HRZS/4HR 12 + 1/ 35 (3; 0.07-14.92)
Algerian Working Group [7] 2HRZE/4HR 18 - 4/131 (3; 0.83- 7.82)
Singapore Tuberculosis Service [8] 2HRZ/4H3R3 18 + 1/ 44 (2; 0.06-12.02)
1HRZS/5H3R3 18 1/ 46 (2; 0.06-11.53)
2HRZS/4H3R3 18 0/ 47 (0; 0.00- 7.55)
Combs  [9] 2HRZ/4HR 24 - 6/267 (2.6; 0.87- 5.18)
Brändli [10] 2HRZ/4HR 24 - 0/ 27 (0; 0.00-12.77)
Ormerod [11] 2HRZ/4HR 6-24 - 2/110 (2; 0.22- 6.57)
East and Central African/British 
Medical Research Council. [12] 2HRZS/4HR  } 24 + 4/166 (2.4; 0.66- 6.17)East and Central African/British 
Medical Research Council. [13] 2HRZS/4HR
Snider [14] 2HRZ/4H2R2 ‡ 24 + 4/110 (3.6; 0.99-9.31)
2HRZS/4H2R2$ 24 + 1/ 52 (1,9; 0.05-10.26)
Snider [15] 2HRZS/4H2R2$ 24 + 1/ 56 (2; 0.05-9.55)
2HRZ/4H2R2‡ 24 + 4/116 (3; 0.94-8.83)
2HRZS/4H2R2 30 + 0/ 85 (0; 0.00- 4.25)
Hong Kong Chest Service [16] 4H3R3Z3S3-2H3R3 30 8/133 (6; 2.60-11.85)
4H3R3Z3S3-2H3R3Z3 30 + 2/142 (1; 0.17-5.09)
2H3R3Z3S3-2H3R3S3-2H3R3 30 4/149 (3; 0.73-6.87)
6H3R3Z3 30 + 6/135 (4;1.63-9.67)
British Thoracic Society [17] 2HRZE/4HR 36 - 4/127 (3.1; 0.86-8.06)
2HRZS/4HR 36 2/119 (1.7; 0.20-6.07)
British Thoracic Association [18]
Cohn  [19] 2 weeks HRZS 36 + 2/ 88 (1.6; 0.28-7.97)
6 weeks H2R2Z2S2
18 weeks H2R2
Eule [20] 6H2R2Z2S2 48 - 2/103 (2; 0.20- 7.0)
Hong Kong Chest Service [21] 6HRZE 54 + 6/150 (3.8; 1.47-8.71)
6H3R3Z3S3E3 54 6/147 (4; 1.50-8.88)
6H3R3Z3E3 54 7/149 (4.4; 1.89-9.68)
6H3R3Z3S3 54 2/139 (1.3; 0.17-5.20)
Singapore Tuberculosis Service [22] 2HRZ/4H3R3 54 + 3/105 (3; 0.59-8.35)
2HRZS/4H3R3 54 2/ 96 (2; 0.25- 7.32)
1HRZS/5H3R3 54 2/ 96 (2; 0.25- 7.32)
Baba  [23] 2HRZS/4HRZ 60 - 3/108 (3; 0.57-8.12)
2HRZE/4HRZ 60- 1/ 84 (1; 0.03-6.46)
Hong Kong Chest Service [24] 6H3R3Z3S3 60 + 8/166 (5; 2.08-9.50)
Singapore Tuberculosis Service [25] 2HRZS/4HRZ 93.6 + 1/ 71 (1; 0.04-7.60)
Singapore Tuberculosis Service [26] 2HRZS/4HR 93.6 2/ 67 (3; 0.4 -10.4 )
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been performed on treatment regimens of 6 months or shorter. In view of the
strong sterilant effect of pyrazinamide, it should be possible to shorten the
duration of treatment. A 9-month treatment regimen without pyrazinamide,
but with isoniazid, rifampicin and possibly ethambutol or streptomycin, led to a
tuberculosis relapse rate of 3 out of 298 patients, with a bacteriologically con-
firmed relapse rate of 1% (0.2-2.9) (Table 4) [1]. Although in the literature, refer-
ence is often made to the studies reviewed by Fox, it was impossible to make
comparisons. They chiefly contained unpublished data on small numbers of
patients.
The American Thoracic Society put forward a relapse rate of <5% as a criterion
for the effectiveness of a treatment regimen [2]. Owing to the fact that a treat-
ment duration of 4 months with at least isoniazid, rifampicin and pyrazinamide
in patients with Ziehl-Neelsen-positive sputum and a positive Löwenstein cul-
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95% CI = 95% confidence interval;  H=isoniazid;  R=rifampicin; Z= pyrazinamide
* The number in front of the letters is the number of months that the chemotherapeutics with those letters were
administered. The chemotherapeutics were taken daily. If the chemotherapeutics were taken intermittently (a
number of times per week), this is depicted by a number in subscript after the letter of the chemotherapeutic.
Example: 4 H3R3 means 4 months of isoniazid and rifampicin 3 times per week.
† P.Fujiware and G. Schecter, written communication, 1991
‡ The same regimen, published twice
$ the same regimen, published twice
Ta bl e  3 . Relapse rates of tuberculosis after the completion of treatment reported in 
selected publications (3-27) grouped according to duration of follow-up in months
follow-up in No. of  No. of 
months after patients relapses months after completing of treatment
completing 
treatment         0-6 7-12 13-36 >36  
12 1312 17 13 3 1
18 268 6 4 2
24 794 20 11 3 6
30 644 20 12 5 3
36 334 8 5 0 1 2
48 103 2 0 0 2
54 882 28 2 7 10 9
60 358 12 6 0 1 5
94 138 3 1 1 1
Total 4833 116 54 21 24 17
ture led to a relapse rate of 12% (9-16%) [1], we only selected treatment regimens
with a duration of 6 months. Relapse occurred in a total of 116 out of the 4833
patients, a rate of 2.4% (2.0-2.8), which is less than 5%.
In the Netherlands, no norm has been established for the relapse rate. On the
basis of in vitro research by Grosset, it was decided to add pyrazinamide rou-
tinely to the treatment regimen in 1978 [32], on the assumption that the existing
low rate of relapse could be decreased even further. No prospective studies have
been performed in the Netherlands. Alternatively, it would be possible to per-
form a retrospective analysis on patient records, but the process would be very
time-consuming.
With the aid of tuberculosis registration cards on Dutch patients over the peri-
od 1984-1990 from the Inspectie voor de Gezondheidszorg van het Staats-
toezicht op de Volksgezondheid (IGZ), we calculated a relapse rate of 44/1792
(2.5%; 1.8-3.2) (M.tuberculosis) within 5 years after the completion of treatment
[31].
c h a p t e r  232
Ta bl e  4 . 9 month treatment regimens for tuberculosis, including isoniazid and 
rifampicin, but without pyrazinamide, based on an overview Fox [1]
Study treatment follow-up relapse rates in
regimen* In months patientsafter 
after  succesfully 
completing completing
treatment treatment (%)
First British Thoracic 2SHR/7HR 45 0/ 48 (0 ) 
Association Study (1978) 2EHR/7HR 45 0/ 51 (0)  
(unpublished data)
Second British Thoracic 2EHR/7HR 9 1/ 61 (2 )
Association Study (1981)
(unpublished data)
First French Study 3EHR/6HR 27 0/ 86
Brouet & Roussel 3SHR/6HR
(1977)
Seccond French Study 2EHR/7HR 12 2/ 52 (4 )
Pretet (1981)
(unpublished data)
Total 9-45 3/298 (1)
(95% CI: 0.2-2.9)
95% CI = 95% confidence interval;  S=streptomycin;  H = isoniazid;  R=rifampicin; 
E = ethambutol
* The number in front of the letters is the number of months that the chemotherapeutics
with those letters were administered. The chemotherapeutics were taken daily. Example:
2EHR / 7HR means: 2 months of ethambutol, isoniazid and rifampicin, followed by 7
months of isoniazid and rifampicin
It can never be totally excluded that relapse is the result of reinfection. The risk
is greatest in countries with a high tuberculosis prevalence. On the basis of cal-
culations, Styblo showed that in countries with a low tuberculosis prevalence,
such as the Netherlands, active tuberculosis can manifest itself for the first time
in elderly people as a result of an infection contracted in their youth [33]. This is
known as endogenous reactivation. The risk of exogenous reinfection being
diagnosed in countries with a high tuberculosis prevalence increases as the
length of follow-up after the completion of treatment increases. The majority of
papers analysed in this study were performed in countries with a high tubercu-
losis prevalence. Therefore the risk of exogenous reinfection can be expected to
be comparable in the various populations. The relapse rates observed were
probably higher than can be expected on the basis of endogenous reactivation
alone [34].
It was not possible to calculate a reliable regression curve for the majority of
studies, because not all the publications mentioned the month in which the
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Figure 1a. Relapse rates after various
treatment regimens for tuberculosis
(see regimens in Table 1) reported in the
literature: grouped according to follow
up period in months after completing
treatment
Figure 1b. Relapse rates after various
treatment regimens for tuberculosis
(see regimens in Table 1) reported in
the literature: mean percentages and
95% C.I. (white blocks)
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relapse occurred. In the studies with a follow-up period of 18 to 36 months, 75%
of the relapses occurred in the first year after the completion of treatment. Gen-
erally, a follow-up period of 24 to 30 months is considered to be sufficient for
prospective studies [35]. Nowadays further determination of M.tuberculosis is
possible using the restriction fragment length polymorphism (RFLP) method;
in some cases, distinction can be made between endogenous reactivation and
exogenous reinfection.
Isoniazid, rifampicin and pyrazinamide form the corner stones of tuberculosis
treatment. Various combination regimens can be administered. On the basis of
this study, we cannot state a preference for one particular treatment regimen. In
the patient populations analysed, the addition of streptomycin and/or ethambu-
tol was of no additional benefit (see Table 1 and Fig. 1). Self-medication did not
lead to a higher relapse rate than the administration of medication under close
supervision. This finding disagreed with general expectations. It should be
realised that the patients who took part in these studies underwent close super-
vision. No difference was found between daily and intermittent intake of medi-
cation.
Based on our findings, it seems justified to shorten the continuation phase of
treatment by 3 months in patients with pulmonary tuberculosis caused by non-
resistant M. tuberculosis in the Netherlands, on the condition that the patients
can be supervised closely. The latter is possible in the Netherlands due to the
extensive network of Municipal Health Services in which TB nurses can pro-
vide supervision at hospitals and at the patient’s home.  An advantage of shorter
treatment is that the willingness of patients to comply with taking medication,
increases as the duration of treatment decreases. The increase in tuberculosis
observed since 1987 in the Netherlands can be attributed to the increasing
influx of persons from countries with a high tuberculosis prevalence. Owing to
the fact that resistance to the usual chemotherapeutics is more common in
those countries than in the Netherlands, it may be necessary to administer more
than 3 antibiotics in the intensive phase. If sensitivity testing shows that M.
tuberculosis is sensitive to isoniazid, rifampicin and pyrazinamide, then we rec-
ommend limiting the treatment regimen to 2HRZ/4HR. A national guideline
has been published [36].
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Chapter 3
3.a
di ag no s i s  of  c e rv ic a l  t u be rc u l ou s  
ly m ph a de n i t i s
Based on: van Loenhout-Rooyackers JH, Richter C.
De diagnostiek en behandeling van halskliertuberculose.
Ned Tijdschr Geneeskd 2000;144:2243-7

3 a . 1 a b s t r ac t
The incidence of extrapulmonary forms of tuberculosis, which occur predomi-
nantly in immigrants and persons infected with HIV, is increasing. Cervical
tuberculous lymphadenitis is the most common form: about 200 patients in the
Netherlands per year. Fine needle aspiration is the diagnostic procedure of
choice. If no acid-fast rods or caseous granulomas are seen, then excision biop-
sy should be performed. Biopsy specimens must always be cultured for
mycobacteria. On the basis of anamnesis, physical examination, epidemiology,
laboratory results, acid-fast rods or cytological/histological evidence of caseous
granulomas, tuberculostatic treatment should be started while awaiting the cul-
ture results.
3 a . 2 i n t roduc t ion
Tuberculosis is a generalised infection that can be active in multiple organs
simultaneously. During active tuberculosis, lymph drainage from the primary
infection site, usually the lungs, spreads bacteria to the nearby lymph nodes:
this is referred to as the primary complex.
Below, we address the diagnosis of cervical tuberculous lymphadenitis. This
subject was chosen for several reasons. Firstly, cervical tuberculous lym-
phadenitis is the most common form of extra-pulmonary tuberculosis. Extra-
pulmonary forms of tuberculosis occur predominantly in immigrants and per-
sons infected with HIV. [1,2,3] Secondly, cervical lymph nodes often form part
of the primary complex, because M. tuberculosis enters the body via the oropha-
ryngeal mucosa. In many cases, an enlarged cervical lymph node is the chief or
only reason why a patient consults a physician. Many of these physicians only
have a rudimentary knowledge of tuberculosis. Thirdly, it is often difficult to
find bacteriological evidence and/or establish whether a patient has been cured.
Before starting tuberculostatic treatment, a diagnosis must be made. On the
basis of the literature, a diagnostic decision tree was developed for use in the
Dutch situation [4, figure 1].
3 a . 3 e p i de m iol o g y
World-wide, about 70% of the patients with tuberculosis and non-compro-
mised immunity have pulmonary tuberculosis and about 30% have an extra-
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pulmonary form. Risk groups for tuberculosis in the Netherlands are: a) per-
sons from a country or returning home from a country in which there is a high
incidence of tuberculosis (the risk is even greater in persons infected with HIV);
b) persons who may have been exposed to infection and are therefore invited to
take part in source and contact tracing; c) alcoholics and/or drug addicts; d)
elderly tuberculosis patients who have never received treatment or have never
been treated adequately; e) the homeless; f) detainees; g) health care workers; h)
seamen. The frequency of extra-pulmonary tuberculosis and the frequency of
organ localisation can vary per population group. Data from the Netherlands
Tuberculosis Register (NTR) show that in the period 1993-1997, the incidence
of extra-pulmonary tuberculosis increased in the non-Dutch population.
World-wide, cervical tuberculous lymphadenitis is the most common form of
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Fine needle aspiration 1
auramine/Ziehl-Neelsen staining
mycobacteria culture
cytology 
acid-fast rods or 
granuloma with caseous necrosis or 
positive culture: M.tuberculosis
Excision biopsy1
auramine/Ziehl-Neelsen staining
mycobacteria culture
histological examination
Begin tuberculostatic treatment2
granuloma without caseous necrosis 
and other disorders excluded
(e.g. toxoplasmosis, cat-scratch fever)
or
mycobacterial culture negative
1 Supply unfixed material; prior consultation with microbiologist and pathologist
2 If fine needle aspiration and biopsy only show granulomas and other causes have been
excluded, then the initiation of tuberculostatic treatment should be considered in persons
with risk factors for tuberculosis and in cases of persistent clinical suspicion, supported by a
positive Mantoux test
F igu r e  1 . Diagnosis of cervical tuberculous lymphadenitis in the Netherlands (Richter) 
extra-pulmonary tuberculosis; in the Netherlands, about 200 patients per year
are affected [1,2,3] (Table 1). In patients with compromised immunity, e.g. HIV-
positive, tuberculous lymphadenitis often accompanies active tuberculosis in
other organs [5]. In such cases, it is important to consider atypical mycobacteria
as the pathogen; this occurs commonly in AIDS patients.
3 a . 4 t h e  pat ho g e n
Mycobacterial infection of the cervical lymph nodes can be caused by typical or
atypical mycobacteria. Cervical tuberculous lymphadenitis only involves infec-
tion with members of the M. tuberculosis complex (M. tuberculosis, M. bovis, M.
bovis BCG, M. africanum). M. africanum cannot be distinguished clinically or
pathogenically from M. tuberculosis. M. bovis is resistant to pyrazinamide. Since
the pasteurization of milk in 1940, M. bovis has rarely been seen in the Nether-
lands and since 1956, Dutch livestock has been tuberculosis-free [6].
The atypical mycobacteria, e.g. M. avium and M. scrophulaceum, are encountered
in HIV-positive patients, but they can also occur in otherwise healthy young
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Ta bl e  1 .  Frequency of tuberculosis localisation in 1486 patients in 1997 
in The Netherlands*
Tuberculosis localisation Absolute numbers (%)** 
n= 1486
Primary tuberculosis 77  (  5.2 )  
Pulmonary localisation 762  (51.3 )  
Other forms of tuberculosis 
of the respiratory tract 229  (15.4 )  
Meninges and central 
nervous system 21  (  1.4 )  
Intestinal tract 59  (  4.0 )  
Bones and joints 76  (  5.1  )  
Urogenital tract 47   (  3.2 )  
Other organs 253  (17.0 )
Cervical tuberculous lymphadenitis 200  (13.5 )  
Miliairy tuberulosis 35  (  2.4 )  
Unknown / undetermined 133  (9.0 )
* Multiple localisations could be registered per patient
**Source: Netherlands Tuberculosis Register (NTR) and Royal Netherlands Tuberculosis
Association, The Hague
children in countries such as the Netherlands where tuberculosis is rare and
livestock is tuberculosis-free. The atypical mycobacteria fall outside the scope
of this paper.
3 a . 5 c l i n ic a l  pr e s e n tat ion
A patient consults a doctor because of an enlarged cervical lymph node that has
appeared gradually and is not painful. In some cases, there may also be other
long(er)-term complaints of fever, weight loss and fatigue. Night sweats and
coughing are fairly uncommon. General complaints are absent in 30% of the
patients. Children and adults up to the age of 30 years are more commonly
affected than other age groups. More women than men are affected. It is possi-
ble that women are more likely to consult a doctor for cosmetic reasons, but
endocrine factors may play a role.
3 a . 6 ph y s ic a l  e x a m i nat ion
In most cases, the cervical lymph nodes are affected, unilaterally or bilaterally.
Lymph nodes at other sites may also be affected (axillary, inguinal, mediasti-
nal). One single lymph node might be affected, or several smaller lymph nodes
in the vicinity. The lymph nodes can be friable, in which case they will feel soft
and be attached to the skin (cold abscesses) or they can be hard and mobile.
3 a . 7 di ag no s i s
Tuberculosis stands high on the list of differential diagnoses when a person has
enlarged lymph nodes and belongs to a risk group. Examination with fine nee-
dle aspiration is the diagnostic procedure of choice. If the result is inconclusive,
excision biopsy is recommended, because incision biopsy can give rise to fistu-
las. Physicians should always endeavour to obtain bacteriological evidence of
infection [7,8] (Figure 1). This means that fine needle aspiration and excision
biopsy specimens must be sent for auramine/Ziehl-Neelsen staining and
mycobacteria culture. The biopsy specimens should preferably be supplied
fresh and unfixed, after contacting the Departments of Microbiology and
Pathology. Cytological and histological examination may contribute to making
the diagnosis. Granuloma with caseation and necrosis is considered to be evi-
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dence of tuberculosis, even when the culture is negative. The value of the poly-
merase chain reaction (PCR) for demonstrating M. tuberculosis complex DNA
in extra-pulmonary material has not yet been fully validated. A negative PCR
result does not exclude tuberculosis, while a positive PCR result does not form
proof of active tuberculosis. Even after a patient has been cured, PCR DNA test
results in patient material can remain positive for a long period. Another disad-
vantage of PCR testing for mycobacteria is that it does not provide any insight
into the resistance pattern of the M.tuberculosis. If tuberculosis is not considered
in the initial stages and it is not possible to repeat fine needle aspiration, PCR on
M. tuberculosis complex DNA can be performed on fixed material. The geno-
type can sometimes be determined indirectly by PCR, eg with mixed linked
PCR spoligo-typing.
About 30-50% of the patients with cervical tuberculous lymphadenitis also have
pulmonary tuberculosis. A chest X-ray is always indicated, as well as sputum
collection for Ziehl-Neelsen and Löwenstein culture. Mantoux testing and the
skin test have limited value as diagnostic procedures for atypical mycobacteria.
Tuberculin conversion in patients with cervical tuberculous lymphadenitis is
often stronger than in patients with pulmonary tuberculosis [5,7]. If the direct
bacteriological result (auramine/Ziehl-Neelsen culture) of the cervical lymph
node is negative or if histological examination does not show caseous necrosis
or if the mycobacteria culture is negative, then consideration should be given to
other causes for the enlarged cervical lymph node(s), such as toxoplasmosis and
cat-scratch fever. If these other causes can be excluded, then the diagnosis of
“tuberculosis” should certainly not be dismissed in patients who belong to risk
groups for tuberculosis.
3 a . 8 di s c u s s ion
In the Netherlands, fine needle aspiration material and/or excision biopsy mate-
rial is often fixed before being sent to the microbiologist or pathologist, which
makes it impossible to culture mycobacteria. In view of the low number of
tuberculosis patients in the Netherlands, hospitals cannot be expected to
change their general policy of supplying unfixed biopsy material. The aim of
this paper is to indicate the value of macroscopic findings of caseation and gran-
ulomatous abscesses during histological examination, as has been observed in
countries with limited laboratory facilities and personnel [7,9]. Whether or not
a person is HIV-positive does not affect the diagnostic procedure [7]. Not being
able to find bacteriological evidence (Ziehl-Neelsen staining, mycobacteria cul-
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ture or PCR) must not form a reason for withholding tuberculostatic treatment
from patients who belong to risk groups for tuberculosis and have a granuloma-
tous abscess whether or not with caseation. In view of the different social and
cultural backgrounds of tuberculosis patients in the Netherlands, there is a high
risk that if treatment is postponed, the patient will present later elsewhere with
fulminant pulmonary tuberculosis or a disseminated form of tuberculosis.
3 a . 9 r e c om m e n dat ion s
In patients with enlarged cervical lymph nodes who belong to risk groups for
tuberculosis, the diagnosis of tuberculosis should be high on the list of differen-
tial diagnoses. Great effort should be made to obtain bacteriological evidence
of tuberculosis by means of fine needle aspiration or excision biopsy. Material
should be sent for examination in an unfixed state and cultured for mycobacte-
ria. If the material has unfortunately been supplied in a fixed state, PCR can be
considered, particularly if it is not possible to repeat the biopsies. On the basis
of granulomatous abscesses with caseation and necrosis, tuberculostatic treat-
ment can be started, even when the culture result is negative.
ac k now l e d g e m e n t
We would like to thank A.G.M. van de Zanden, MD, Gelre Hospital Apel-
doorn, for his valuable contribution and comments.
c h a p t e r  3 a46
3 a . 1 0 r e f e r e nc e s
1 Mehta JB, Dutt AC, Harvill L, Mathews KM. Epidemiology of extrapulmonary
tuberculosis. A comparative analysis with pre-AIDS era. Chest 1991;99:1134-
38.
2 Index Tuberculosis 1997. The Hague: KNCV;1999.
3 Rom WN, Garay SM. Tuberculosis. Boston: Little Brown;1996. 
4 van Loenhout-Rooyackers JH, Richter C. De diagnostiek en behandeling van
halskliertuberculose. Ned Tijdschr Geneeskd 2000;144:2243-7.
5 Perenboom RM, Richter C, Swai AB, Kitinya J, Mtoni I, Chande H et al. Clini-
cal features of HIV seropositive and HIV seronegative patients with tubercu-
lous lymphadenitis in Dar es Salaam. Tuber Lung Dis 1995;76:401-6.
6 Buf-Vereijken PWG du, Ven AJAM van der, Meis JFGM, Lemmens JAM, Meer
JWM van der. Swelling of hand and forearm caused by Mycobacterium bovis.
Neth J Med 1999;54:70-2.
7 Perenboom RM, Richter C, Swai ABM, Kitinya J, Mtoni I, Chande H, et al.
Diagnosis of tuberculous lymphadenitis in an area of HIV infection and limited
diagnostic facilities. Trop Geogr Med 1994;46:228-92.
8 Snow GB. Consensus diagnostiek van een verdachte halslymfklier. Ned Tijd-
schr Geneeskd 1988;132:114-9.
9 Bekedam HJ, Boeree M, Kamenya A, Liomba G, Ngwira B, Subramanyam VR,
et al. Tuberculous lymphadenitis, a diagnostic problem in areas of high preva-
lence of HIV and tuberculosis. Trans R Soc Trop Med Hyg 1997;91:294-7. 
t u be rc u l ou s  ly m ph a de n i t i s  a n d  di ag no s i s 47

Chapter 3
3.b
s hort e n i ng  t h e  du r at ion  of  t r e at m e n t
f or  c e rv ic a l  t u be rc u l ou s  ly m ph a de n i t i s
van Loenhout-Rooyackers JH, Laheij RJF, Richter C, Verbeek ALM
Eur Respir J 2000;15:192-5

3 b . 1 a b s t r ac t
The aim of the study was to determine the optimal duration of treatment for
patients with tuberculous lymphadenitis.
The Medline database was searched for relevant articles published  between
1978-1997.  Inclusion criteria were study populations of patients with predomi-
nantly cervical tuberculous lymphadenitis in whom the diagnosis had been con-
firmed bacteriologically and/or histologically, or was made probable by using
clinical and laboratory markers. Treatment management had to include at least
isoniazid, rifampicin and pyrazinamide and a follow-up of at least 12 months
after the end of treatment. Patients with resistance to rifampicin and pyrazi-
namide and previous treatment for tuberculosis were excluded.
The number of patients who relapsed after treatment was calculated.
The study population in eight out of the 35 articles retrieved were suitable for
analysis. Some concerned comparative studies. There were eight treatment
schedules of 6 months’ duration and three schedules of 9 months’ duration.
Treatment for 6 months resulted in a tuberculous lymphadenitis relapse rate of
13/422=3.3% (95% confidence interval: 1.7-5.5), with a mean follow-up of 31
months after completion of treatment. Treatment for 9 months resulted in a
relapse rate of 3/112= 2.7% (95% confidence interval: 0.6-7.8), with a mean fol-
low-up of 20 months. 
Despite the limitations of the literature available, 6 months of therapy is proba-
bly sufficient for patients with tuberculous lymphadenitis. 
3 b . 2  i n t roduc t ion
Lymph node tuberculosis, occurring predominantly in the cervical region, is
the most common manifestation of extrapulmonary tuberculosis [1].
In the Netherlands, the total number of tuberculous patients is about 1600 a
year, of whom 530 cases have extrapulmonary tuberculosis[2]. The case defini-
tion of extrapulmonary tuberculosis at several sites depends on the site with the
most severe disease. Cervical tuberculous lymphadenitis (n=200/year) and
pleuritis (n=200/year) are the most common localizations of extrapulmonary
tuberculosis [2]. Lymph node tuberculosis is classified as a less severe form of
extrapulmonary tuberculosis. Patients feel less ill and there is neither a signifi-
cant acute threat to life nor a risk of subsequent severe handicap. Considera-
tions for appropriate treatment are disease severity determined by bacillary
load, extent of the disease and anatomical site. In the Netherlands, recently the
51
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duration of treatment for pulmonary tuberculosis with sensitive tubercle bacilli
(M. tuberculosis) has been shortened from 9 to 6 months on the basis of litera-
ture data, using the percentage of bacteriologically proven relapses as the crite-
rion [3]. In contrast,  in some countries, like the Netherlands, the duration of
treatment for lymph node tuberculosis is still 9 months. The authors reviewed
the existing literature to determine whether 6 months of treatment for tubercu-
lous lymphadenitis is justifiable.
3 b . 3 m e t hod s  a n d  de f i n i t ion s
The Medline database was searched for relevant articles published from 1978-
1997 using the keywords: tuberculosis; lymph node; and drug therapy, with
restriction to the English language. In the 1950s pyrazinamide was used in high
doses, but it proved to be toxic. Nowadays it is routinely used in each combina-
tion of anti-tuberculosis drugs in the initial phase of treatment, because in  1978,
it was discovered that lower doses of pyrazinamide were also effective. All of the
retrieved publications were screened for the following six inclusion criteria: 1)
isoniazid, rifampicin and pyrazinamide had been included in the treatment
schedule, possibly with ethambutol and/or streptomycin in adequate doses [4];
2) treatment had been applied daily or intermittently, supervised or self-admin-
istered; 3) (combinations of) tablets of proven adequate bioavailability had been
used; 4) the diagnosis had been confirmed either by detection of acid-fast bacil-
li in direct smears from fine needle aspiration (FNA) or from biopsy and / or by
positive mycobacterial culture of biopsy and / or by histological evidence of
caseating or necrotizing granulomas  (clinical diagnosis with response to thera-
py, without bacteriological or histological evidence, was also included) [5]; 5)
cases were not resistant to rifampicin and pyrazinamide ; 6) follow-up after the
end of treatment had to be at least 12 months. Studies on patients with active
pulmonary parenchymal disease (but not isolated mediastinal lymphadenopa-
thy) or active tuberculosis at sites other than lymph nodes, were excluded. Fur-
thermore, patients with concomitant renal, hepatic or haematological disease
and patients who had previously received >1 month of treatment for tuberculo-
sis or who had missed > 14 consecutive or cumulative doses, were excluded from
the analysis.
Treatment  failures were also excluded from the analysis.
Failure was defined as a residual lymph node at the end of treatment, either
without any decrease in size or with a size of > 1 cm. Patients with suspicious
residual nodes were only excluded if they had been reassessed by FNA, biopsy
or had received additional treatment.
Relapse was defined as recurrence of a (residual) lymph node or the appearance
of a new node confirmed to be tuberculous after one full course of medication
with a period of initial clinical remission. To explore differences in treatment
duration, a stratified analysis was carried out. From each study, the authors cal-
culated the rate of relapse after the end of treatment, with a 95% confidence
interval (95% C.I.) [6].
3 b . 4 r e s u lt s
Eight out of the 35 articles met the criteria. As some concerned comparative
studies, there were eight treatment schedules of 6 month’s duration and three
schedules of 9 months’ duration [7-14]. Two articles used the same study popu-
lation; one  reported the preliminary results, the other the final results [10,11].
The total number of patients was 644 (table 1). In 229 patients FNA had been
performed, while in 291 a biopsy (excisional or incisional) had been taken. The
diagnosis had been bacteriologically proven by culture in 349 (54%) and histo-
logically proven in 315 (49%). In 259 patients Mycobacterium tuberculosis had
been susceptible to isoniazid, rifampicin and pyrazinamide; in 346 patients sen-
sitivity had not been tested or reported; 17 patients were resistant to isoniazid, 11
to streptomycin and 11 to isoniazid and streptomycin. Clinical and laboratory
parameters were not reported in detail and could therefore not be analysed. The
treatment outcome of patients with bacteriologically proven or suspected
tuberculosis was not given separately in the studies. The dose of anti-tubercu-
lous drugs used varied and was not reported in one study [14]. In adults, the
dose of isoniazid used was 300 mg daily or 10-15 mg/kg intermittently. In chil-
dren, the isoniazid dose was 15-30 mg/kg twice or thrice weekly [8,9]. The same
dose of rifampicin and ethambutol was given to adults and children (mg/kg
body weight): rifampicin:10-15 mg/kg, 450 mg < 50 kg and 600 mg > 50 kg;
ethambutol: 15 mg/kg. Adults received of pyrazinamide 1.5-2 g < 50 kg and 2-2.5
g > 50 kg while children received 45-60 mg/kg. Adults received streptomycin 1g
while children received 40 mg/kg, max. 750 mg. Side-effects were reported in 37
patients, 26 patients were not compliant and 27 were lost to follow-up for other
reasons. During treatment, new nodes or enlargement of existing lymph nodes
occurred in 79/468 =17% [7,8,10,11,13]. Nodes were present after treatment in
143/423= 34% of the patients [7,8,10,11,13]. The size of the nodes was not report-
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ed, or the nodes were not suspected of harbouring disease. If the diameter was 
> 1 cm and/or clinically suspicious, tissue was sent for culture before treatment
was restarted. In 5/9 patients with reported failure, the unfavourable outcome
was bacteriologically proven (9/553=1.6%) (Table 1) [8,12]. In one of these
patients, the residual lymph node resolved spontaneously within 3 months and
another patient with a residual node of 1 cm at the end of treatment was lost to
follow-up [13]. A total of 534 patients completed treatment and follow-up as
planned (Table 1). After a mean follow-up of 29 months, nodes were still present
in 41/378=11% [7,8,10,11]. However, the number of patients with a relapse on
clinical grounds after successful treatment of 6 months’duration was 13/422=
3.3% ( 95% C.I. 1.7-5.5, mean follow-up 31 months). After 9 months of therapy,
3/112 = 2.7% ( 95% C.I. 0.6-7.8, mean follow-up 20 months) relapsed. In three out
of these 16 patients, the relapse was bacteriologically confirmed, while in four it
was histologically proven [7,8]. Five patients relapsed during the first year
[7,8,13]; three patients relapsed later, and in eight patients there was no further
information [7-12].
3 b . 5 di s c u s s ion
The authors addressed the question of whether the duration of treatment for
tuberculous lymphadenitis can be safely reduced to 6 months. Most recent
national and international treatment guidelines also recommend a 6 month
therapy [4,15,16] The current meta-analysis supports these recommendations.
The relevant literature was analysed using the relapse rate as the criterion. Fol-
low-up was at least 12 months after the end of treatment. The shortage of litera-
ture with well-defined treatment results for tuberculous lymphadenitis made
analysis very difficult. Out of necessity, the authors limited the analysis to
patients with predominantly cervical tuberculosis. In general, cervical tubercu-
lous lymphadenitis is one of the less severe manifestations of tuberculosis.
Active tuberculous disease at other sites cannot always be ruled out completely.
It is important for the diagnosis to be bacteriologically confirmed, not only to
exclude other diagnoses, but also to obtain material for determination of the
organism and susceptibility tests.
In contrast with high-prevalence countries, tuberculosis in low-prevalence
countries is not the most frequent cause of lymphadenopathy. Persons infected
with human immunodeficiency virus (HIV) have an increased frequency of
mycobacterial infections in general, often affecting the lymph nodes. Care
providers should be aware that in these patients M.tuberculosis is not always the
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cause of lymphadenopathy. HIV-positive patients were not included in the pre-
sent analysis, because the authors could not find any literature with a follow-up
of at least 12 months after the end of treatment and no cases of infection were
restricted to the lymh nodes [17].
FNA is the diagnostic procedure of choice. If this fails to be conclusive, exci-
sional biopsy is the next step [5,18]. The diagnosis of tuberculosis was con-
firmed bacteriologically and histologically in 54% and 49% of the cases, respec-
tively. As a result, treatment outcomes in patients with bacteriologically or his-
tologically proven disease and in patients with suspected tuberculosis on clini-
cal grounds, were merged and could not be analysed separately. Rest nodes did
not always mean an unfavourable outcome. The latter was defined as treatment
failure or relapse not only proven bacteriologically or histologically, but also on
clinical grounds. The decision to perform a second diagnostic procedure or
start retreatment depended on clinical judgement. The bacteriologically proven
diagnosis depended on the bacillary load and the diagnostic approach. In con-
trast with smear-positive pulmonary tuberculosis, bacteriological confirma-
tion of a cure is not available. However an immunological response to the anti-
gens released from the dead bacilli may be reflected by the development of new
nodes, increases in diameter, or complications such as sinus and abscess forma-
tion during treatment or follow-up [11].
The recommendations of the World Health Organisation (WHO) for anti-
tuberculous drugs were not strictly adhered to [7-9]. Doses (mg/kg body
weight) of essential drugs for the treatment of tuberculosis should be the same
in adults and children [4]. Resistance may have been induced by human failure
(incompliance) when treatment was not supervised. Nevertheless the clinical
outcome was satisfactory in most cases. Such favourable outcomes may  be
explained by the small number of bacilli in such patients and the low resistance
rate. In the group of patients with tuberculous lymphadenitis treated for 6
months 3.3% relapsed, while those treated for 9 months had a relapse rate of
2.7%. Treatment for pulmonary tuberculosis for 6 months with a regimen
including isoniazid, rifampicin and pyrazinamide resulted in a relapse rate of
116/4833 =2.4% ( 95% C.I. 2.0-2.8, follow-up 12-94 months) [3]. Differences
were not statistically significant.
In studies on pulmonary tuberculosis, only patients with bacteriologically
proven, fully sensitive tuberculosis are analysed. Treatment failures and relaps-
es can be bacteriologically proven [3]. The suggestion that a low bacillary load
may justify an even shorter length of treatment, e.g. 4 months, needs to be
investigated [19]. However, sterilisation of lesions depends on the persistence
of (semi)dormant bacilli, but on theoretical grounds this may be unrelated to
the bacterial load. 
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In pulmonary tuberculosis, relapses mostly occur within 12 months after the
end of treatment. Therefore, for prospective studies, a follow-up of 24-30
months is generally enough [3]. The risk of relapse in lymph node tuberculosis
is unknown, but the small number of relapses during follow-up in the retrieved
articles confirms the advice given by the Joint Tuberculosis Committee of the
British Thoracic Society: after successful treatment, follow-up is not required
but patients should be re-referred if symptoms recur [15].
In conclusion, it seems justified to administer medication for 6 months, includ-
ing isoniazid, rifampicin and pyrazinamide, for tuberculous lymphadenitis (as
the individual authors of the retrieved articles suggested). A large proportion of
patients had rest nodes. Relapses occurred within 12 months after the end of
treatment, but later was also possible. The small number of patients described
in the literature makes consensus about diagnostic procedures and treatment
schedules important, because investigators have to depend on pooled data and
office-based analyses. Therefore data must be gathered in the same way to
enable sound clinical judgements and to formulate therapeutic guidelines.
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Chapter 4
t u be rc u l ou s  m e n i ngi t i s :
i s  a  6 - mon t h  t r e at m e n t  r e gi m e n  s u f f ic i e n t ?
van Loenhout-Rooyackers JH, Keyser A, Laheij RJF, 
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4 . 1 s u m m a ry
Background The British Thoracic Society and the American Thoracic Society
advise 12 months treatment for tuberculous meningitis, with at least isoniazid
(H), rifampicin (R) and pyrazinamide (Z).
Objective To establish whether 6 months treatment for tuberculous meningitis
is equally as effective as longer treatment.
Method Medline search for papers published between 1978 and 1999. Inclusion
criteria: study populations of patients with tuberculous meningitis, in whom
the diagnosis was confirmed with clinical, cerebrospinal fluid and epidemiolo-
gical findings; a treatment regimen with at least isoniazid, rifampicin and pyra-
zinamide and at least 12 months follow-up after the completion of treatment.
Outcome measure: the number of relapses.
Results There were four 6-month treatment regimens (G6) and seven longer tre-
atment regimens (G>6); 160/197 (81%) patients completed the 6-month treat-
ment regimens, while 577/675 (85%) completed the longer-term treatment regi-
mens. The clinical stage in G6 was poorer than in G>6. Relapse occurred in 2
out of 131 (1.5%) in G6 and in 0 out of 591 in G>6.
Conclusion Although no studies have compared 6-months treatment with lon-
ger treatment, it can be concluded on the basis of this literature review that 6-
months treatment is sufficient for tuberculous meningitis with fully susceptible
mycobacteria.
4 . 2 i n t roduc t ion
Tuberculosis is an infectious disease that can be active in many organs simulta-
neously. Recommended treatment duration differs from one organ site to anot-
her [1,2]. For tuberculous meningitis with fully susceptible mycobacteria, the
recommended treatment duration is 12 months, whereas the advised duration
for pulmonary tuberculosis is 6 months with at least isoniazid (H), rifampicin
(R) and pyrazinamide (Z) [1,2]. The following explanations can be put forward
for this difference: 1) tuberculous meningitis is difficult to diagnose; 2) morbidi-
ty and mortality are high; 3) reliable parameters to evaluate the effect of therapy
are lacking, such as bacteriology of cerebrospinal fluid (CSF); 4) it is unclear
whether rifampicin is effective in the central nervous system; 5) the penetration
of ethambutol and aminoglycosides is poor, particularly when the meninges are
non-inflamed; 6) there is a risk of relapse and cerebral damage if therapy is stop-
ped prematurely; and 7) the available studies are not considered to have reliable
methodology.
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The longer the duration of therapy, the greater the risk of non-compliance,
especially if the patient does not experience signs of clinical recovery. Moreo-
ver, if a shorter treatment duration is equally as effective, it will obviously be
cheaper.
We performed a literature review based on relapse rates of tuberculous menin-
gitis to evaluate the effectiveness of 6 months treatment with a regimen that
included at least isoniazid, rifampicin and pyrazinamide.
4 . 3 de f i n i t ion s  a n d  m e t hod
Medline was used to search for relevant papers in the English language that had
been published between 1978 and 1999. Reference lists were checked and aut-
hors contacted. Keywords were spinal tuberculosis, meningeal tuberculosis,
miliary tuberculosis, intracranial and spinal tuberculomas, tuberculous encep-
halitis and myelitis, tuberculous abscess of the brain and spinal cord, isoniazid,
rifampicin and pyrazinamide.
Inclusion criteria for the literature study were:
1) the diagnosis of tuberculous meningitis was based on clinical findings, CSF
analysis and epidemiological data;
2) treatment included at least isoniazid, rifampicin and pyrazinamide, pos-
sibly in combination with ethambutol and/or streptomycin in adequate
doses [3];
3) follow-up after treatment was at least 12 months.
The patients had to be classified into classes according to the clinical severity of
their disease, because this is of importance for the prognosis [4,5].
Stage I: the patient has non-specific complaints (headaches, nausea, vomiting)
without any changes in the level of consciousness.
Stage II: the patient shows changes in the level of consciousness, but there is no
coma or delirium. Physical examination reveals slight focal neurological symp-
toms.
Stage III: the patient is stuporous or comatose whether or not in combination
with severe neurological deficits; epileptic fits, extrapyramidal disturbances
and hemiplegia may be present.
The papers were also required to contain information about CSF analysis.
Lymphocytic pleocytosis, strongly elevated CSF protein and a decreased gluco-
se CSF:blood ratio were considered to correlate with tuberculosis.
Important epidemiological data to help confirm the final diagnosis were signs
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of direct contact with a patient with a contagious form of tuberculosis in the
anamnesis.
The diagnosis of tuberculous meningitis is "definite" when acid-fast rods are
found in the CSF, when the culture in Löwenstein-Jensen medium is positive,
or when autopsy findings are in line with tuberculosis.
The diagnosis is "probable" when M.tuberculosis is cultured from another
organ. The suspicion of tuberculous meningitis can be supported by: 1) cerebral
computed tomography (CT) findings that correlate with tuberculous meningi-
tis; 2) a chest radiograph with signs of tuberculosis; 3) a positive Mantoux test;
or 4) good response to tuberculous chemotherapy.
In this study, the following measures were employed to evaluate the effective-
ness of the treatment: number of patients who completed treatment and follow-
up according to the original treatment plan, the number of patients who died,
the number of patients who were cured, the number of patients who were cured
but still had residual neurological symptoms and the number of patients who
relapsed after completing treatment.
4 . 4 r e s u lt s
A total of 71 papers were found, but 60 could not be included in our review,
because the treatment regimen did not contain pyrazinamide, or it was not clear
how many patients had been treated with which drugs, or the follow-up period
was too short. One of the 11 remaining papers reported on tuberculomas [6],
while 10 reported on tuberculous meningitis [7-16]. Two papers described the
same study population, with short-term and longer-term follow-up periods.
Relevant details were extracted from both papers [15,16]. The studies included
in our analysis were published between 1961 and 1994. Three had been perfor-
med in Thailand, three in India, one in Ecuador, one in South Africa, one in
Turkey and one in China.
The paper on tuberculomas of the brain [6] reported on 108 patients, all aged
over 5 years, in whom the diagnosis had been made on the basis of clinical and
CT findings. Treatment duration was 9 months. A total of 105 patients comple-
ted treatment according to the original plan; 97 were cured and eight had resi-
dual neurological symptoms; all of them completed 15 months follow-up. At the
end of the follow-up period, 94 patients were cured, 11 had residual symptoms
and no relapses had occurred.
The papers on tuberculous meningitis described patients who had been treated
for 6 months (referred to as G6) or longer (G>6) [7-16]. The following informa-
tion was recorded (also see Table 1):
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Ta bl e  1 . Results on the basis of data from the literature on > 6 months treatment for
tuberculous meningitis. Treatment included at least isoniazid (H), rifampicin (R) and
pyrazinamide (Z). Numbers in so far as mentioned in the review studies (%)
6 months treatment > 6 months treatment
Population
Number of studies 4 5
Authors Cotmongkol [7] Dog˘anay [11]
Alarcon [8] Phuapradit [12]
Jacobs [9] Goel [13]
Donald [10] Humphries [14]
Ramachandran [15,16]
Number of patients 197 1176  
Analysed 197 675  
Age
< 16 years 147 515
≥ 16 years 50 160  
Diagnosis
Clinical  stage
I 27 (14%) 138 (18%)
II 95 (48%) 434 (58%)
III 75 (38%) 178 (24%)  
CSF testing
Ziehl-Neelsen 
Positive /number of 17/61    (28%) 36/103    (35%)
specimens
Löwenstein culture positive / 45/187   (24%) 105/330   (32%)
number of specimens 
Other diagnostic criteria
Contact with known TB patient 109/176  (62%) 84/180  (47%)
CT-scan positive 112/141  (79%) 35/45   (80%)
Hydrocephalus 89/113    (79%) 42
Tuberculoma 10 7
Chest X-Ray positive for TB 107/197  (54%) 243/479 (51%)
Miliary pattern 17 48
Mantoux > 10 mm 117/176  (66%) 90/180 (50%)
Treatment regimen 1 2HRZ/4HR
2HRZS/4HR 2HRZS/6-7HR
4-6HRZS/8-10HR
2HRZE/4HR 4-6HRZE/8-10HR
6HRZetionamide HRZS ethionamide, 
cycloserine, PAS
3HRZS/6HRE/15HE
2HRZS/10HE
2HR2ZS/10HE  
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6 months treatment > 6 months treatment
During treatment
Number of failures 2
Non-compliant 4 66
Side-effects 1 1
Died 32/197   (16%) 41/675   (6%)
Treatment completed 160/197  (81%) 577/675  (85%)
On completion of treatment:
cured 120/160  (75%) 91/148   (61%)
residual neurological deficits 40/160   (25%) 57/148    (39%)
During follow-up
Duration of follow-up mean 15 months mean 15 months
range 4-33 months range 4-36 months
85% at least 12 92% at least 12
months months
On completion of 
follow-up, absolute 131 5912
numbers and rates 
who completed 
treatment 82% ≥ 85%
Relapse3 2 0
Died 2 24
On completion of follow-up
cured 33/39    (85%) 188/307  (61%)
residual neurological  
deficits 6/39      (15%) 119/307  (39%)
1 isoniazid (H), rifampicin (R) pyrazinamide (Z) ethambutol (E) streptomycin (S)
2 including 100 patients [ref 15,16]: a maximum of 68 had received Z, while a minimum of 32
patients had not received Z
3 Goel et al. described 37 patients, who dropped out
(non-compliant); 25 children and 10 adults suffered 
relapse; 20 had received < 6 months treatment, 15 > 6 
months treatment [13]
Patient population
Numbers: Four studies reported on 197 G6 patients [7-10] and five studies
reported on 1176 G>6 patients; 675 G>6 patients were included in the analysis
[11-16], while 501 G>6 patients were excluded, because there was insufficient
information [13].
Age: in both the G6 and G>6 groups there were almost three times as many
children as adults.
Sero-positivity for the human immunodeficiency virus:
Human immunodeficiency virus (HIV) status was not mentioned.
Diagnosis: The distribution of G6 and G>6 patients over the clinical stages is
shown in Table 1. The clinical stage of G6 patients was poorer than that of G >6
patients. Distributions of children and adults over the clinical stages were equal.
CSF analysis: In the G6 group, 95% had undergone Löwenstein-Jensen culture
and 24% were positive. In the G>6 group, these percentages were 49% and 32%,
respectively.
Details about the diagnosis reported in the papers are listed in Table 1.
Resistance: the sensitivity of M.tuberculosis in vitro was reported in 42 G6
patients and in 56 G>6 patients [10,15]. Resistance to streptomycin, isoniazid,
ethambutol and a combination of isoniazid and streptomycin was found in one,
three, one and nine patients, respectively [15].
Treatment regimen: There were 4 G6 [7-10] and 7 G>6 regimens [11-16] 
(Table 1).
The treatment regimen mostly comprised an intensive phase of at least two
months with isoniazid, rifampicin and pyrazinamide, whether or not in combi-
nation with ethambutol or streptomycin, followed by at least four months of
isoniazid and rifampicin [7-9,11,12]. In two studies, ethionamide was also used
[10,14]. In the study by Humphries et al. it was administered in addition to cyclo-
serine and para-amino salicyl acid (PAS) [14]. Neither study made a distinction
between an intensive phase and a continuation phase [10,14]. Ramachandran et
al. did not administer rifampicin in the continuation phase, but ethambutol
[15,16]. After an intensive phase of 3 months, Goel et al. administered isoniazid,
rifampicin and ethambutol for 6 months and continued treatment with isonia-
zid and ethambutol for a further 15 months; their total treatment period was 2
years [13]. The medication was taken daily in all the treatment regimens except
for one, in which rifampicin was taken twice a week during an intensive phase
of 2 months duration [15,16].
Dosage: Isoniazid was administered in a dose of 300 mg/day, or the dose varied
between 5-12 mg/kg/day. Rifampicin was administered in a dose of 450 mg to
patients with a body weight of < 50 kg and 600 mg > 50 kg, or the dose varied
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between 10-15 mg/kg/day. Pyrazinamide was administered in a dose of 20-40
mg/kg/day. The only difference in dosage between G6 and G>6 patients was
that for 6 months, Jacobs et al. and Donald et al. gave a higher dose of isoniazid
(15 mg/kg) and a higher dose of rifampicin (20 mg/kg/day) to children [9,10].
Dosage was not mentioned in the study by Humphries et al. [14].
Medication under supervision
Patients were either hospitalized for the total treatment period of 6 months [10]
or for the first 2 to 3 months [8,15], or until they showed clinical improvement
[12,13]. Treatment was completed by 81% of the G6 patients and by 86% of the
G>6 patients.
Other medication
Prednisone (1-3 mg/kg or 30-60 mg/day) or dexamethasone (0.3-0.5 mg/kg)
were administered to patients with spinal arachnoiditis, high CSF protein level,
mental changes and focal neurological abnormalities. Donald et al. administe-
red steroids to 40 patients within the framework of their study [10], while
Ramachandran et al. administered steroids to all their patients [15,16]. The
paper by Goel et al. did not mention steroids [13]. Vitamin B6 was administered
in three studies in a dosage that varied between 10-100 mg/day [8,11,13].
Ramachandran et al. [15,16] reported that they had administered vitamins wit-
hout any further specification, whereas a number of other papers did not men-
tion vitamins at all [7,9,10,12,14].
Surgical intervention
All the authors reported that lumbar punctures were performed regularly in
patients with increased CSF pressure (>200 mm H2O). If this was insufficient,
ventriculostomy or a ventrico-peritoneal shunt was applied; 32/197 (16%) G6
patients received a ventrico-peritoneal shunt versus 126/674 (19%) G>6 patients
[7,8,10-16].
Parameters to monitor the course of recovery
After the completion of treatment, distinction was made between "cured" and
"cured but with residual neurological deficits" in all of the G6 patients and in
26% of the G>6 patients. In 429 G>6 patients, no distinction was made between
"cured" and "cured but with residual neurological deficits" [13,14]. None of the
papers mentioned criteria on which to base the decision of whether patients
should be treated for longer than 6 months. In the study by Alarcon et al., CSF
was normal in all 20 patients who completed treatment [8]; in the study by
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Chotmongkol, this was the case in nine out of the 15 patients tested [7]. The
remaining papers did not mention CSF analysis findings at the completion of
treatment.
Mortality was 16% (32/197) in G6 patients and 6% (41/675) in G>6 patients
(Table 1). More than 50% of all the cases died in the first three months; six
patients died in the seventh to fourteenth month of treatment [7-16]. The clini-
cal stage on admission of the 91 patients who died was: stage I 2%, stage II 43%
and stage III 55%.
Follow-up after the completion of treatment (Table 1)
Mean follow-up after the completion of treatment was 15 months in the G6 and
G>6 patients. Follow-up was at least 12 months in 85% of the patients who com-
pleted follow-up.
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Ta bl e  2 . Results in children with tuberculous meningitis after > 6 months treatment with
at least isoniazid (H), rifampicin (R) and pyrazinamide (Z) on completion of treatment and
on completion of > 12 months follow-up
Number (%) 6 months treatment > 6 months treatment 
Starters 147  515 
Completed treatment 127 447
(86%) (87%) 
Completed follow-up 99 4721
(78%) (≥ 83%) 
Relapse 1 0 
After treatment cured 93/127 32/68
(73%) (47%) 
After treatment 
residual neurological
deficits 34/127 36/68
(27%) (53%) 
After follow-up
cured 6/7 170/286
(86%) (59%) 
After follow-up
residual neurological
deficits 1/7 116 / 286
(14%) (41%) 
1 Including 100 patients [ref 15,16]: a maximum of 68 had received Z
It was not possible to indicate how many patients who received H, R and Z also
actually completed follow-up, because one study [15, 16] reported the results 
of 100 patients, but this group also included patients who had not received Z.
This means that a minimum of 85% (491/577) and a maximum of 97% (559/577)
of the patients who completed treatment also completed follow-up. Relapse
occurred in 2/131 (1.5%) in G 6 and in 0/591 in G >6. One G6 patient with 
stage III on admission suffered relapse and died 3 months after completing 
treatment [8]. The other G6 patient (stage I on admission) suffered relapse 
3 weeks after completing treatment and received a further 6 months treatment
[10]. The clinical stage on admission in G 6 patients was poorer than in G >6
patients.
Relapse was also reported by Goel et al. [13]. Their paper mentioned 37 drop-
outs; relapse occurred in 35 of them: 25 children and 10 adults; 20 of them had
received treatment for less than 6 months and 15 for more than 6 months.
During follow-up, two G6 patients and 24 G>6 patients died; 18 of these patients
had residual neurological deficits and eight died of other causes [10,16,14].
At least 82% of the G6 patients and at least 85% of the G>6 patients completed
follow-up after treatment. The percentage of patients who were cured or were
cured but had residual neurological deficits was not mentioned in all of the
papers: results were reported for 30% of the G6 patients and 52% of the G>6
patients. In the G6 group, 83% of the patients were cured and 15% had residual
neurological deficits [7,8]. No outcomes were mentioned in 87 patients [9,10].
In the G>6 group, 61% were cured and 39% had residual neurological deficits
[12-16]. Outcome was not mentioned for 260 patients [11,13].
Effectiveness in adults and children 
A young age is believed to be an unfavourable prognostic factor [14]. In the G6
group, treatment was completed by 86% of the children and by 66% of the
adults, while in the G>6 group, the completion rates were very similar at 83%
and 81%, respectively (Table 2 and 3). Mortality in the G6 children was lower
than in the adults ( 14% and 24%, respectively). In the G>6 group, mortality was
11% in the children and 2% in the adults. It should be noted that the clinical stage
on admission was poorer in G 6 than in G >6. 
In the G6 group, outcomes were mentioned for all the children and adults who
completed treatment; 73% of the children were cured, while 27% were cured but
had residual neurological deficits. In the adults, these rates were 82% and 18%,
respectively. In the G>6 group, the percentages of patients who were cured
and/or had residual neurological deficits after completing treatment were not
mentioned in all of the papers: outcomes were mentioned for only 15% of the
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children and in 62% of the adults. In the G>6 group, 47% of the children were
cured and 53% were cured but had residual neurological deficits. In the adults,
these rates were 73% and 27%, respectively. The large percentage of children
who were cured with residual neurological deficits is based solely on the studies
by Ramachandran et al.; This was the only study population in which rifampi-
cin was not administered in the continuation phase of treatment[15,16].
High percentages of children and adults completed follow-up in accordance
with the original treatment plan; completion did not depend on the duration of
treatment. In the G6 group, relapse occurred in one adult and one child. The
percentages of patients who were cured or were cured but had residual neurolo-
gical deficits at the end of follow-up were reported for all adults and for 7% of
the children. In the adult G6 patients, the results after follow-up were not diffe-
rent from the results at the end of treatment. In the G>6 group, outcomes at the
end of follow-up were mentioned for 18% of the adults and 61% of the children.
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Table 3. Results in adults with tuberculous meningitis after > 6 months treatment with at
least isoniazid (H), rifampicin (R) and pyrazinamide (Z) on completion of treatment and on
completion of > 12 months follow-up
Number (%) 6 months treatment > 6 months treatment 
Starters 50 160 
Completed treatment 33 130
(66%) (81%) 
Completed follow-up 32 119
(97%) (92%) 
Relapse 1 0 
After treatment 
cured 27/33 59/80
(82%) (73%)
After treatment 
residual neurological 
deficits 6/33 21/80
(18%) (27%)
After follow-up
cured 27/32 18/21
(84%) (86%) 
After follow-up
residual neurological
deficits 5/32 3/21 
(16%) (14%)
4 . 5 di s c u s s ion
In a literature study, we reviewed 10 papers that met our inclusion criteria regar-
ding the treatment of tuberculous meningitis, in order to analyse the risk of
relapse in relation to treatment duration. The patients had been treated for 6
months or longer. Although a 6-month treatment has never been compared to
longer treatment in one study, we could conclude that a treatment duration of 6
months for tuberculous meningitis with normal drug sensitivity was equally as
effective as longer treatment. However, for this conclusion to be valid, treat-
ment had to include a 2-month intensive phase consisting of isoniazid, rifampi-
cin and pyrazinamide and a further 4 months of isoniazid and rifampicin.
It was not possible to make a satisfactory comparison between the number of
patients in G6 and in G>6 who were cured or were cured but had residual neu-
rological symptoms at the time of completing treatment and at the time of com-
pleting follow-up, because not all of the papers reviewed reported the results
after completing treatment and after completing follow-up. Similary, it was not
possible to establish the degree of spontaneous recovery or deterioration of
neurological deficits after completion of treatment. Nevertheless the data
reported in the review studies and presented in Tables 1 and 2 seem to indicate
that in any case, a 6-month treatment regimen did not lead to poorer results
than one of more than 6 months, either at the time of completing treatment or at
the time of completing follow-up.
The treatment regimens applied in the review studies could be considered equi-
valent, except for Ramachandran et al. who discontinued rifampicin after the
intensive phase [15,16]. These authors suggested that the high rate of residual
neurological symptoms may have been caused by the extremely poor nutrition-
al state of their patients. Nothing was mentioned about nutritional state in the
other studies.
The treatment results as a whole show that tuberculous meningitis is a very dra-
matic form of tuberculosis. Between 10-50% of the patients were cured but had
residual neurological deficits, while mortality was between 10-30% [17]. At the
start of treatment, patients were commonly suffering from irreversible brain
damage. It may be possible to optimise treatment so that no further damage
occurs.
An important theoretical question regarding the regimens applied in the stu-
dies reviewed, is whether the drugs adequately reached the focus of infection. In
the literature as a whole, analyses on CSF concentrations of tuberculostatic
agents were performed in only a small number of patients. However, the outco-
me of treatment cannot be expected to be directly proportional to tuberculosta-
tic drug concentrations in the CSF.
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Owing to the fact that tuberculous meningitis also implies tuberculous menin-
go-encephalitis, the tuberculous infection can be focused in the CSF, meninge-
al tissue and/or cerebral parenchyma. Depending on the infection site, conside-
ration must be given to how and whether chemotherapy crosses the blood-CSF
barrier and/or the blood-brain barrier. The brain and CSF cannot be conside-
red as one pharmacokinetic compartment [18]. For example, active transport of
chemotherapy plays a role in crossing the blood-CSF barrier, while diffusion
plays a key role in the blood-brain barrier. Small molecular size, high lipophilia
and low binding to plasma proteins facilitate diffusion, but the influence of
these mechanisms on penetration into brain tissue and CSF decreases as the
severity of the TB infection increases.
Pyrazinamide and ethionamide have a low molecular weight, high lipophilia
and low protein binding in plasma. They easily cross the blood-CSF barrier in
the presence and absence of meningeal inflammation [9,13,17-21]. Rifampicin
binds to plasma proteins for 80%, but it has a very long half-life in CSF [18]. Iso-
niazid is hydrophilic, but easily crosses the blood-brain barrier in infected
meninges; the concentration also exceeds the minimum inhibitory concentra-
tion (MIC) value in non-infected meninges [18,22]. It is debatable whether
ethambutol is worthwhile in the continuation phase of treatment, because in
line with the aminoglycosides, its penetration is poor, especially when the
meninges are no longer infected [13-16,22]. Ofloxacin is the quinoline with the
best penetration of infected meninges [17,18].
In patients who are suspected of having tuberculous meningitis with drug resi-
stance, preference might be given to a highly penetrative chemotherapeutic
agent such as ethionamide as a fourth agent in the initial treatment phase, in-
stead of ethambutol and the aminoglycosides [10].
Another reason for administering a fourth tuberculostatic in the intensive tre-
atment phase is a high concentration of M.tuberculosis, because this involves an
increased risk of spontaneous mutation into a resistant strain. It is unclear
whether there is a high bacterial load in tuberculous meningo-encephalitis. Per-
sistently "dormant" bacteria require sterilisation therapy with rifampicin and
pyrazinamide. If these two agents cannot be administered, then long-term tre-
atment with isoniazid is necessary. It is unclear how many "dormant" bacteria
are present and how well they can be reached in the central nervous system.
In the studies reviewed, good results were achieved with 2 HRZ/4HR. The
majority of studies were performed during the period that there was little risk
of primary resistance.
Another factor that can affect treatment outcome is dosage. [23] In the treat-
ment of other bacterial infections, a great deal of data have recently become
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available on time-dependent and concentration-dependent bactericide of anti-
biotics [24]. High dosage alone does not appear to be a valid option in the case
of poor transport capacity. If a high peak concentration can be reached this
does not lead to more rapid bactericide or sterilisation owing to the long repli-
cation time of M.tuberculosis. It might be worthwhile to administer frequent
very high dosages, but this would increase the risk of side-effects and treatment
compliance is known to decrease with multiple daily intakes.
Another important issue is the potential interaction with other medication pre-
scribed for the patient. Remarkably, the penetration of tuberculostatics is not
impaired by the simultaneous use of corticosteroids [25,26]. Vitamins are often
given in high dosages. However, a dose of 10 mg vitamin B6 per day is sufficient
to counteract the neuropathy induced by isoniazid, while a high dose of vitamin
B6 might have an antagonistic effect on isoniazid [27,28,29]. It was not possible
to analyse the effect of vitamin B6 dosage on the outcomes of treatment in the
studies reviewed. In order for treatment to be effective, it is important that the
tuberculostatics are actually taken by the patient. More than 80% of the patients
in the review studies completed treatment irrespective of whether it was short-
term or longer-term. However, this does not mean that the tuberculostatics
were taken under supervision over the whole treatment period. Information
about supervision was scarce, except in the study by Donald et al. [10]. Longer-
term treatment will have little effect unless compliance can be guaranteed:
motivation is known to diminish if the patient does not experience steady clini-
cal improvement.
The aim of treatment is not only to cure the patients and avoid residual symp-
toms, but also to prevent relapse. Although a large number of children have
tuberculous meningitis, a disproportionately small number of studies have
addressed the relapse rate. A possible explanation is that follow-up is difficult in
tuberculosis endemic regions.
According to the literature, clinical and laboratory findings are the same in
HIV-infected and non-infected individuals [30,31]. Tuberculous meningitis in
HIV patients is treated in the same way. In HIV-infected children, the results
are poorer than in infected adults. The more severe clinical and neuroradiologi-
cal abnormalities in children are associated with HIV encephalopathy [31].
None of the review studies mentioned comorbid HIV seropositivity in their
tuberculous meningitis patients.
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4 . 6 c onc l u s ion s  a n d  r e c om m e n dat ion s
It can be concluded that 2HRZ/4HR is adequate treatment for tuberculous
meningitis with fully susceptible organism. If there is a suspicion of resistance,
four tuberculostatics should be administered; the fourth agent might comprise
ethambutol, an aminoglycoside, ethionamide or a quinoline. In patients with an
unknown resistance pattern or isoniazid resistance, pyrazinamide should be
administered during the total treatment period (2HRZE/4HRZ). In the case of
rifampicin resistance or multidrug-resistance, the treatment regimen should
include at least 2 tuberculostatics to which the bacteria are sensitive and the tre-
atment should be continued for longer than 6 months.
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Chapter 5
i s on i a z i d  d o sag e  i n  t h e  t r e at m e n t  
of  c h i l dr e n  w i t h  t u be rc u l o s i s
van Loenhout-Rooyackers JH
Dosering van isoniazide bij behandeling van kinderen met tuberculose.
Tijdschr Kindergeneeskd 1998;66:182-5

5 . 1  s u m m a ry
In 1997, a written survey was conducted among Municipal Health Service
tuberculosis physicians. Information was requested on the isoniazid dosage in
children with active tuberculosis treated in 1993, 1994 and 1995 and the relapse
rates after the completion of treatment. The period 1993 to 1995 was chosen
because a computer-based tuberculosis registration system was introduced
nationally in 1993. More than 75% of relapses occur within the first year after
the completion of treatment. In the period 1993 to 1995, 289 children aged 0 to
14 years were registered with active tuberculosis. Data on 176 children (61%)
could be analysed. Isoniazid dosage was 4-8 mg/kg body weight (mean 5 mg per
kg body weight) in 166/176 children (94%) and + 10 mg/kg body weight in 10
children. Clinical and radiological response to treatment was good in all the
children. The mean treatment duration was 9 months, in conformity with the
guidelines valid at that time. Mean follow-up duration after the completion of
treatment was approximately 24 months (12-36). None of the 176 children
relapsed after the completion of treatment. It can be concluded that the Dutch
policy of administering 4-8 mg/kg body weight of isoniazid was adequate.
5 . 2 i n t roduc t ion
Recently it has been recommended in this journal to administer 10-20 mg/kg
body weight of isoniazid per day to children, in conformity with the American
literature [1-3]. In the Netherlands, the National Tuberculosis Policy Commit-
tee (CPT) advises a mean isoniazid dosage for children and adults of 5 mg/kg
per day (4-8 mg/kg/day) to a maximum of 10 mg/kg, in accordance with the
guidelines of the International Union Against Tuberculosis and Lung Disease
(IUATLD). The maximum dose of isoniazid is 300 mg per day [4]. During treat-
ment, the dosage should be adjusted regularly to the child’ weight.
This study evaluated the INH dosage administered to children aged 0 to 14
years with active tuberculosis in the Netherlands in 1993, 1994 and 1995 and the
relapse rate after the completion of treatment.
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5 . 3 pat i e n t s  a n d  m e t hod s
In 1993, 1994 and 1995, 289 children were diagnosed for the first time with
active tuberculosis in the Netherlands (Table 1).
The dosage of anti-mycobacterial medication is not registered nationally.
Therefore, in April 1997, a questionnaire was sent to 29 tuberculosis physicians
working at Dutch Municipal Health Services, to obtain information on chil-
dren aged 0 to 14 years registered in 1993, 1994 and 1995 with active tuberculo-
sis.
Active tuberculosis was diagnosed when the diagnostic criteria of the Ameri-
can Thoracic Society (Table 2) were met, or when contact tracing in a child
without complaints revealed a positive Mantoux test and an abnormal chest X-
ray that improved after the start of treatment. Owing to the fact that the stan-
dard treatment duration for children with TB was 9 months, no information
was obtained about the duration of treatment.
5 . 4 r e s u lt s
A total of 22 out of the 29 physicians responded, which yielded information on
193 patients. In 17 patients, the data was not suitable for analysis: 14 patients did
not have active tuberculosis; one patient showed resistance to isoniazid and it
had been discontinued almost immediately; one patient had Mycobacterium
bovis; one patient had Mycobacterium avium.
Data were analysed on 176 out of the 289 (61%) children registered with active
tuberculosis for the first time. Age was 0-4 years in 54 children and 5-14 years in
122 children. Nationality was unknown in 34 children; 60 children had Dutch
parents and 82 had non-Dutch parents. Seventy-seven children were found by
contact tracing; they did not have any complaints, but they did have a positive
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Ta bl e  1 . Number of children with a first diagnosis of active tuberculosis in 1993, 1994 and
1995.  Netherlands Tuberculosis Registry data (NTR)
Localisation 0-4 yrs 5-14 yrs total  
Pulmonary 61 169 200 
Pulmonary and extrapulmonary 4 16 20 
Extrapulmonary 26 43 69 
Total 91 198 289
Mantoux test and radiological abnormalities on the chest X-ray that improved
with treatment.
In the group of 176 children, 114 had been treated by MHS physicians and 62 by
hospital specialists. In 34 out of these 62 children, the chief treating physician
had been a paediatrician. In 10 children, the hospital specialist had consulted a
pulmonologist.
In 94% of the children (166/176) the isoniazid dosage was 4-8 mg/kg body
weight per day (mean 5 mg/kg). In 10 children a higher dosage was administered
(mean 10.8 mg/kg body weight). In one patient with tuberculous meningitis, it
was decided to perform concentration of isoniazid in serum  on the basis of the
clinical reaction and to adjust the dosage accordingly. The mean treatment
duration of the 176 children was 9 months, in conformity with the guidelines
valid at that time. An intensive phase of 2 months with daily isoniazid,
rifampicin and pyrazinamide, if necessary supplemented by ethambutol, was
followed by 7 months of daily isoniazid and rifampicin. Treatment was success-
ful in all 176 children. None of the children suffered relapse after the completion
of treatment.
In 139 questionnaires, the year of starting treatment was mentioned. The esti-
mated follow-up period after the completion of treatment varied in 79% of the
patients from 12 to 36 months.
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Ta bl e  2 . Criteria for active tuberculosis according to the American Thoracic Society
Response to treatment for tuberculosis and at least 2 out of 
the following 3 criteria must be met:
1. One or more of the following clinical findings:
- fever > 380C for at least one week
- night sweats for longer than one week
- more than 20% weight loss
- coughing
- dyspnoea
- haemoptysis
- lymphadenopathy for longer than 4 weeks
2. One of the following microbiological criteria:
- acid-fast rods in sputum, pleural fluid or both
- positive Löwenstein culture
- histopathological findings correspond with tuberculosis
3. Radiological criterion
- chest X-ray findings correspond with tuberculosis (infiltrate, 
pleural fluid or hilar adenopathy
5 . 5 di s c u s s ion
The recommended isoniazid dosage for children varies. In the American litera-
ture, 10-20 mg/kg per day is advised. When isoniazid is combined with
rifampicin, isoniazid is administered in a dosage of 10 mg/kg per day to prevent
liver function disturbances [3,5]. The same dosage is prescribed in the UK [6].
In accordance with the IUATLD guidelines, an isoniazid dosage of 5 mg/kg per
day is advised in the Netherlands, the neighbouring countries and in the majori-
ty of countries with a high tuberculosis prevalence [7-9].
Arguments in favour of administering a higher isoniazid dosage to children
include: differences in pharmacokinetics compared to adults; poorer tissue pen-
etration; an assumed lower number of bacteria; the more frequent presence of
caseomas than cavernae; higher prevalence of extrapulmonary tuberculosis;
children tolerate high dosages and the limitations in the available means of
administration, so that one dose is often larger than 5 mg/kg body weight [10].
A study by the IUATLD on the serum concentration of isoniazid showed that in
children, a dosage of 5 mg/kg achieved a sufficiently high and therapeutic serum
concentration [11,12]. It was concluded that correspondingly, the dosage in chil-
dren does not need to be higher than that in adults.
The penetration of isoniazid through the blood-brain barrier is excellent, both
in healthy meninges and in meningitis. Therefore, it is not necessary to increase
the dosage for the treatment of tuberculous meningitis. An isoniazid serum
concentration analysis can be indicated in infants and young children in the case
of liver function disturbances, strong weight increase, decreased sensitivity of
mycobacteria to isoniazid, if there is no clinical improvement and in serious
forms of tuberculosis, such as miliary tuberculosis, meningitis and encephalitis
[13]. In the above-described survey, the dosage was adjusted on the basis of the
serum isoniazid concentration in one child with tuberculous meningitis.
The daily dose of isoniazid is taken in one go, preferably on an empty stomach.
In the case of gastrointestinal disturbances, it is recommended to take the isoni-
azid with a light breakfast. Although food delays the time until maximum serum
concentration is reached, this does not usually have any therapeutic conse-
quences. It is only worthwhile to perform serum concentration analysis if the
patient’s recovery does not follow the expected pattern. The questionnaires
showed than none of the 176 children suffered tuberculosis relapse. The mean
follow-up period was 24 months (12-36). The relapse rate is a gauge for the
effectiveness of treatment. In general, a follow-up period of 24 to 30 months
after the completion of treatment is considered to be adequate for a prospective
study.  More than 75% of recurrences occur within the first year after the com-
c h a p t e r  586
pletion of treatment [15]. Tuberculosis is a notifiable disease and the registra-
tion system is watertight. Therefore, if any cases of relapse occur, they will be
registered.
5 . 6 c onc l u s ion
The policy in the Netherlands of administering an isoniazid dose of 4-8 mg/kg
body weight per day in conformity with the guidelines of the IUATLD, did not
lead to treatment failure. At present, there do not appear to be any arguments in
favour of adopting the American policy of administering 10-20 mg/kg body
weight.
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Chapter 6
c h e mo t h e r a p e u t ic  t r e at m e n t  
f or  s p i na l  t u be rc u l o s i s  
van Loenhout-Rooyackers JH, Verbeek ALM, Jutte PC
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6 . 1 a b s t r ac t
Aim: to evaluate whether 6 months of chemotherapy for patients with spinal
tuberculosis prevents relapse as effectively as > 6 months of chemotherapy.
Method: literature review. Medline search including references, from January
1978 to November 2000. Inclusion criteria for publications: diagnosis of spinal
tuberculosis confirmed bacteriologically and/or histologically, or was probable
on the basis of clinical and radiological parameters; treatment regimen
(whether or not in combination with surgery) included isoniazid (H),
rifampicin (R) and pyrazinamide (Z); follow-up period after completion of
treatment of > 12 months. Exclusion criteria: patients with relapse who had pre-
viously been treated adequately for tuberculosis.
Outcome parameters: relapse rate.
Results: 4 publications were found with HRZ regimens of 6 months duration
and 10 publications with HRZ regimens of > 6 months duration. A number of
patients had received HRE (E=ethambutol) for > 9 months. In the results, no
distinction was made between treatment groups. HRZ for 6 months led to a
relapse rate of 0% (0/56)(95% C.I. 0.0-6.4); follow-up after surgical interven-
tion ranged from 6 to 108 months. HRZ for > 9 months (>119 patients) or HRE
for > 9 months (<71 patients) led to a relapse rate of 2% (4/218)(95% C.I. 0.6-
5.0); follow-up after surgical intervention was 6-168 months. Despite the small
number of studies 6 months of therapy is probably sufficient for patients with
spinal tuberculosis.
6 . 2 i n t roduc t ion
In the literature, there is no uniformity in the duration of chemotherapeutic
treatment for spinal tuberculosis. The American Thoracic Society (ATS) rec-
ommends 6 months treatment for spinal tuberculosis and osteoarticular tuber-
culosis in adults, but 12 months in children, because reliable data on shorter
treatment durations are lacking [1]. The British Thoracic Society (BTS) recom-
mends 6 months treatment, irrespective of the age of the patient [2]. The
Netherlands Tuberculosis Register (NTR) shows that in the period 1993-1998,
384 patients were treated for osteoarticular tuberculosis (55% had spinal tuber-
culosis); 22% (86/384) were treated for 6-9 months, 31% (119/384) were treated
for 10-12 months and 32% (123/384) were treated for > 13 months. The treatment
regimens included isoniazid (H), rifampicin (R) and pyrazinamide (Z).
In patients with spinal tuberculosis, surgical intervention is very important. It
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may comprise abscess drainage, debridement, laminectomy, anterior and/or
posterior stabilisation with bone grafts or metal implants. The following cir-
cumstances are generally considered to form indications for surgical interven-
tion: (1) neurological deficits (with an acute or non-acute onset) caused by com-
pression of the spinal cord, (2) spinal instability caused by collapse or destruc-
tion of vertebrae, or kyphosis of more than 300; (3) no response to chemothera-
peutic treatment; (4) non-diagnostic biopsy; (5) large paraspinal abscesses
[3,4,5].
The aim of this study was to investigate whether 6 months of chemotherapeutic
treatment with a regimen including isoniazid (H), rifampicin (R) and pyrazi-
namide (Z) (6HRZ), with or without surgery, was equally as effective as a
longer treatment regimen (> 6 months). Outcome was evaluated in terms of
relapse rates after successful treatment.
6 . 3 m e t hod s
A search was made of the English, German and French literature published
subsequent to 1978 (i.e. after the introduction of pyrazinamide) using Medline;
the references were checked for additional relevant publications. The most
recent search was performed in November 2000.
Keywords were osteoarticular, miliary, spinal tuberculosis, drug therapy;
searches were also made under Pott’s disease, vertebral tuberculosis, bone,
joint tuberculosis, treatment, antitubercular agents, isoniazid (H), rifampicin
(R) and pyrazinamide (Z).
Inclusion criteria were: study populations of patients with spinal tuberculosis
whose treatment had included isoniazid (H), rifampicin (R) and pyrazinamide
(Z) and in whom the follow-up period after the completion of treatment was at
least 12 months.
Exclusion criterion was: patients with tuberculosis relapse who had previously
received adequate treatment with chemotherapy.
Definitions
The diagnosis of spinal tuberculosis is certain when Löwenstein culture of
biopsy specimens obtained from the vertebrae are positive; the diagnosis is
almost certain in the case of a histological profile with caseating granulomas;
the diagnosis is probable when there is no bacteriological and/or histological
evidence of tuberculosis in the vertebral column, but active tuberculosis has
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been proven biologically in other body compartments (e.g. positive urine cul-
ture, positive sputum or positive stomach contents after fasting) in combina-
tion with clinical or radiological manifestations (X-ray, CT scan, MRI) that cor-
relate with spinal tuberculosis and a good reaction to chemotherapy.
Clinical symptoms vary widely, but usually comprise pain with an acute or
gradual onset, whether or not in combination with neurological deficits, fever
and elevated ESR. It is common for several vertebrae to be affected, including
the vertebral discs. Paraspinal and/or epidural abscesses may be present.
The diagnosis should be considered in patients who belong to the risk groups
for tuberculosis and have corresponding clinical and radiological symptoms
with a good reaction to chemotherapy.
Successful treatment
Treatment is considered to be successful when the symptoms have subsided or
the patient is complaint-free, the neurological deficits have improved or disap-
peared, there are no longer any clinical signs of abscesses or sinuses, the verte-
bral column is stable and the patient is able to resume full activities.
Radiological characteristics of successful treatment are: radiologically quies-
cent lesion, bony fusion with little or no deformity.
During (sufficiently long) follow-up, there must be no signs of progression of
the kyphosis and no relapse of the tuberculosis [6,7]. It should be realised that
the risk of kyphosis and paraplegia also depends on the surgical intervention at
an earlier stage [6,8,9]. There is a risk of kyphotic deterioration until bony
fusion has occurred, even when the clinical profile is stable [6]. In children in
the growth phase, the risk of kyphotic deterioration is greater than in adults.
Failure
Failure means that the complaints deteriorate during treatment and changes
have to be made to the chemotherapy regimen. Failure does not necessarily
have to be proven bacteriologically and/or histologically.
Relapse
Relapse refers to the situation in which the complaints recur after the comple-
tion of successful treatment and on the basis of the complaints, radiodiagnos-
tics, CT scan and MRI, whether or not in combination with biopsy, it is neces-
sary to start a new course of chemotherapy.
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6 . 4 r e s u lt s
Publications with a 6-month treatment regimen
There were 4 publications with a 6-month treatment regimen of isoniazid,
rifampicin and pyrazinamide (6 HRZ) (Tables 1 and 2) [10,11,12,13]. In each pub-
lication, a number of patients also received 18 months treatment with isoniazid,
rifampicin and ethambutol (18 HRE). When discussing the results, no distinc-
tion was made between the patients who had followed different treatment regi-
mens. In the publications, there was a total of 82 adult patients (68% men, 32%
women). There was no mention of whether HIV testing had been performed.
Chemotherapy was dosed according to the WHO guidelines [10,11,12,14].
Nothing was mentioned about administering the chemotherapy under supervi-
sion. All the patients had undergone surgical intervention, usually within 3-4
weeks of starting chemotherapy. The interval between the onset of complaints
and intervention varied from 1-12 months in 67% of the patients [12,13] and from
6-12 months in 33% [10,11].
The localisation of the affected vertebrae was as follows: cervical 23%; thoracic
21%; thoracolumbar 17%; lumbar 40% and lumbosacral 1/82; there were double
localisations in 3 patients [12]. In 48% of the patients, 1 vertebra was affected; in
34% of the patients, 2 vertebrae were affected and in 18% of the patients, 3 verte-
brae were affected.
Neurological deficits were present in 60% of the patients; 18% were known to
have an abscess preoperatively and 6 had a fistula [13]. The diagnosis had not
been proven bacteriologically in any of the patients, but the histological profile
corresponded with tuberculosis in 55%.
After the completion of treatment, all the patients were declared cured. The
neurological deficits had improved in 48/49 patients, but 8 patients had not
recovered completely. In 3/6 patients the fistula persisted; surgical intervention
was necessary in 2 of them [13]. The interval until radiological consolidation
was 3-5 months in all the patients. All 82 patients completed postoperative fol-
low-up (duration: 6-108 months). The relapse rate was 0%.
Publications with a > 6-month treatment regimen
There were 10 publications with a > 6-month treatment regimen of isoniazid,
rifampicin and pyrazinamide (> 9 HRZ) (Tables 1 and 2) [4,5,15-22]. Three pub-
lications also reported on patients who had not received Z [16,21,22]. When pre-
senting the results, no distinction had been made between the patients who had
received Z and those who had not.
The results of these 10 studies were as follows.
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In a total of 344 patients (56% men, 44% women), 274 had spinal tuberculosis.
Only one publication mentioned HIV testing: none of the 7 patients tested were
found to be HIV-positive [18]. Age distribution was as follows: 79% (216/274)
were adults [4,16,17,20,21,22]; 2% (6/274) were < 12 years [15]; 19% (52/274) com-
prised adults and children [5,18,19]. In 4/10 publications, chemotherapy was
dosed according to the WHO guidelines [14,4,17,18,20]. The actual treatment
regimen was not mentioned in 2/10 [5,18]. Nothing was mentioned about
administering the chemotherapy under supervision. A proportion of the
patients had undergone surgical intervention (162/274) and a proportion had
not (112/274). The interval between the onset of symptoms and chemotherapy
and/or surgery varied from 2 weeks to 39 months; in 60% (165/274), the average
duration was 6 months [4,5,20,16,22]. The time of surgery in relation with the
start of chemotherapy was not always mentioned [4,5,15,16,18,19,21].
The localisation of the affected vertebrae was as follows: cervical 4% (7/199);
cervicothoracic 1 patient (1/199); thoracic 51% (102/199); thoracolumbar 14%
(27/199); lumbar 29% (57/199); lumbosacral in 1 patient; double localisations
were present (thoracic and cervical) in 4 patients. In one publication on 75
patients with spondylitis, the precise localisations were not mentioned [22].
The number of affected vertebrae was not mentioned in 64 patients [5,16,18].
One vertebra was affected in 24% of the 210 patients, while more than one was
affected in 76%. Neurological deficits were reported in 53% (144/274); paraver-
tebral abscesses were present in 102 patients and epidural abscesses in 41
[4,5,15,17,18,21,22].
On the basis of the vertebral biopsy specimens, the diagnosis was confirmed
bacteriologically in 62% (114/183), histologically in 72% (87/121) [19,21,22] and
bacteriologically and/or histologically in 50/58 patients [4,17]. The diagnosis
was confirmed bacteriologically and histologically from a biopsy specimen
obtained from a different location in 26 and 3 patients, respectively [5,16,20,21].
Isoniazid resistance was present in 5/70 patients [4,22]. Failures occurred in
10/42 patients, whether or not they received Z and whether or not they received
surgery [21]. Nussbaum stated that a treatment duration of < 6 months led to
relapse. [5]. His patients received varying combinations of H,R,Z,E,S for at
least 3 months. Progression of the symptoms was observed in a total of 13/29
patients 2 months to 14 years after diagnosis; no distinction was made between
failures and relapse and it was not mentioned whether a new course of
chemotherapy had been started. One patient died within one month of starting
treatment. The average follow-up period in the 28 remaining patients was 7.4
years (1-20 years); one patient died, 17 patients had mild or no residual neurolog-
ical deficits and 10 patients had severe residual neurological deficits [5].
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When the 29 patients who had received ≥ 3 HRZSE in the study by Nussbaum
were omitted from the analyses, the results were as follows: 3% of the patients
died before completing treatment (8/245); 7 out of these 8 patients died of other
causes [4,17,21,22]. A total of 93% were cured (227/245). After the completion of
treatment, 9% had residual neurological deficits [4,15,19,21]. Bony fusion had
occurred in all the cases (16/16) [15,20], in 36/57 within 3 months and in 56/57
within 6 months [17,19].
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Ta bl e  1 .  Publications with study populations of patients with spinal tuberculosis,
whether or not in combination with surgery, treated for 6 months or ≥ 9 months with
isoniazid (H), rifampicin (R) and pyrazinamide (Z), whether or not in combination with
ethambutol (E) and/or streptomycin (S). The number preceding the treatment regimen is
the treatment duration in months. The cure rate in the patients who started treatment and
the relapse rate are shown. Postoperative follow-up period is given in months.
Author Regimen Surgery No. of Cure rate Follow-up Relapse
patients months 
mean 
(range)
Loembe [10] 6HRZE + 3 100% 32 (8-96) 0/3
18 HRE + 2 100% 0/2
Loembe [11] 6HRZE + 14 100% 23.7 (8-96) 0/14
18 HRE + 8 100% 0/8
Loembe [12] 6HRZE + 18 100% 6-108 0/18
18HRE + 8 100% 0/8
Ghadouane [13] 6HRZS + 21 100% 15.6 (8-60) 0/21
12-18HRE + 8 100% 0/8
Rezai [4] ≥18HRZE - 9 100% 12 (12-60) 0/18
12HRZE + 9 78%, 2
RZE (H + 2 deaths tb-
resistant)
Nussbaum [5] ≥3 months + 25 29 1 death 7.4 yrs 13 patients
HRZES - 4 < 1 months (1-20) readmitted
combina- treatment 2 months
tions -14 year
after initial 
diagnosis
Journeau [15] 3HRZE/ + 6 100% 12-168 0/6
2HRE/7HR
Follow-up duration after surgical intervention varied from 6-168 months.
Relapse occurred in 2% (4/218). It is unclear whether they had received pyrazi-
namide and/or surgery [21,22]. Colmenero [21] reported relapse in 3 patients
(3/29=10%); follow-up duration was 6 months after the completion of treat-
ment. Pertuiset reported relapse in 1 patient (1/73=1%); follow-up duration was
12.3 months + 21 months. The patient was treated for 9 months [22].
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Author Regimen Surgery No. of Cure rate Follow-up Relapse
patients months 
mean 
(range)
Peronne [16] 3HRZE/HR +1 23 100% >12 0/22
-22 (9/31 lost)
3HRE/HR -8 8 100%
(9-18HR 
median 
12HR)
Yilmaz [17] 2HRZS/ + 38 97% 29 (24-76) 0/37
7HR 1 death tb-
Vohra [18] >9HRZE +19 4/25 spinal 100% 41 (13-96) 0/4 (0/25)
-6 tbc
Louw [19] 12HRZE + 19 100% 25.5 (6-47) 0/19
Güven [20] HRZ + 10 100% 24.2 (17-36) 0/10
mean 11 
months
Colmenero [21] 2HR(Z) +32 42 69% 6 months, 3/29
(E)/7-10HR -10 10 failures, after com-
3 deaths tb- pletion of
treatment
Pertuiset [22] 3HRZE/& +20 52 97% 12.3 ± 21 1/73
-55 2 deaths,
3HRE/& 21 1tb+ and
mean 14.7 1 tb-
± 3.4 months
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Ta bl e  2 . Spinal tuberculosis patient characteristics and treatment regimens with
isoniazid (H), rifampicin (R) and pyrazinamide (Z), whether or not in combination with
ethambutol (E) and/or streptomycin (S) [4,5,10-22]
6HRZ ≥9HRZ  
No. of patients 56/82 274/344  
Age
Adults 82 79% (216/274)
Children < 12 yrs 2% (6/274)
Adults and children 19% (52/274)
Male:female 68%:32% 56%:44% 
(56:26,  n=82) (192:152, n=344)  
Delay
1-12 months 67% (55/82)
6-12 months 33% (27/82)
mean 6 months 60% (165/274)
Localisation of affected vertebra
Cervical 23% (19/82) 4% (7/199)
Cervico-thoracic 1 patient
Thoracic 21% (17/82) 51% (102/199)
Thoracic-lumbar 17% (14/82) 14% (27/199)
Lumbar 40% (32/82) 29% (57/199)
Lumbosacral 1 patient        1 patient
4 patients cervical
and thoracic
unknown 75
No. of affected vertebrae
1 vertebra 48% (39/820) 24% (51/210)
> 1 76% (159/210)
2 vertebrae 34% (28/82)
3 vertebrae 18% (15/82) 
unknown 64 patients (n=274)
Neurological deficits 60% (49/82) 53% (144/274)
Abscess paravertebral/epidural 18% (15/82) 62% (143/229)
fistula 6 patients 
6 . 5 di s c u s s ion
Very few reports have been published on the results of 6 months treatment with
HRZ in spinal tuberculosis patients [10-13]. This might be because surgical
intervention forms an essential part of treatment and the literature has focused
more attention on this aspect [4-9]. It is unclear whether there is overlap in the
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6HRZ ≥9HRZ  
No. of patients 56/82 274/344  
Diagnosis tuberculosis vertebra
Bacteriological 0/82 62% (114/183)
Histological 55% (45/82) 72% (87/121)
Bacteriological and/or histological 50 patients (n=58)  
Tuberculosis elsewhere 10% (8/82) 27% (81/295)  
Treatment
Surgery 100% (82/82) 61% (181/295)
chemotherapeutic
HRZ 10 patients 
HRZE 35 patients 122 
HRZS 21 38 
HRE 26 29 
RZE 2 
HR(Z)(E) 42
Different combinations of HRZES 29
No. of deaths 0% 3% (8/245)
Reason tbc 1
Radiological consolidation 
after 3-6 months 100% (82/82) 99% (72/73)  
Treatment completed as planned 100% (82/82) 93% (227/245)
Cure rate No. of patients 
treatment completed 100% 100%
Follow-up in months after 
surgery, range 6-108 6-168  
Follow-up completed as planned 100% (82/82)  96%  (218/227)  
Relapse 0% (0/56) 2% (4/218)
95% C.I. 0.0-6.4 95% C.I. 0.6-5.0
patients described by Loembe [11,12]. In most cases, the follow-up duration
after surgical intervention is mentioned, not the duration after the completion
of chemotherapy. It was not possible to establish how many patients had com-
pleted a follow-up of > 12 months after chemotherapy. All the patients who
received 6 months chemotherapy had also received surgery. Relapse only
occurred in the group that had been treated for longer than 6 months. It was
unclear whether the patients with relapse had received pyrazinamide, whether
they had undergone surgery or had an indication for surgery. On the other hand,
the relapse rate of 2% (95% C.I. 0.6-5.0) is so low that this does not justify 
treatment for a period longer than 6 months, especially in view of the good
result in the group of patients who were treated during 6 months. HRZ for 6
months led to a relapse rate of 0% (95% C.I. 0.0-6.4). In as far as data are avail-
able, the penetration of chemotherapy in spinal tuberculosis lesions is good
[23]. Surgery accelerates the resolution of sinuses and abscesses and reduces the
risk of their development [24]. In the case of progression or persistence of
abscesses and/or neurological deficits during chemotherapy, surgical interven-
tion should be considered [4,25]. Not only the risk of relapse, but also the risk of
kyphotic deterioration and late neurological complications justify a long fol-
low-up period. [6,9].
Another explanation for the small number of studies might be that even after
treatment with 6 HR and a follow-up of > 3 years, the relapse rate was low
[26,27].
The question arises as to why patients are treated for longer than 6 months. A
possible explanation is that there is doubt about the parameters for declaring a
patient “cured”. There might be doubt about the radiological quiescence of the
affected vertebra. The clinical profile can be stable even when bony fusion is
incomplete [6].
The BMRC studies have shown that further improvement of the radiological
profile occurs even after the chemotherapy has stopped, but the kyphosis can
still deteriorate [26,28]. The risk of kyphotic deterioration is greatest (i) in chil-
dren of younger than 15 years, in whom > 3 thoracic vertebrae are affected, (ii) in
patients in whom the disease spreads from 1-2 vertebrae to 3-4 vertebrae and
(iii) in patients with an initial angle of > 300 [9]. Chemotherapy in patients with
spinal tuberculosis is obligatory, but careful monitoring is necessary in order to
perform surgery as soon as there is an indication [4,6,9,24]. It may be possible
to administer fewer chemotherapeutics to patients with spinal tuberculosis,
because the bacterial load is much lower than that in lung tuberculosis [26,29].
The risk of primary resistance developing through spontaneous mutation is
lower in the case of low bacterial concentration. However, tuberculosis can be
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active in several organs simultaneously, which necessitates an intensive phase
with 3 chemotherapeutics (HRZ) for M. tuberculosis with normal sensitivity.
Moreover, in contrast with the period in which the BMRC studies were per-
formed, there is a greater risk nowadays of becoming infected with a primary
resistant strain. An intensive phase with 4 chemotherapeutics (HRZE) is neces-
sary if the resistance pattern is unknown.
It is very unlikely that this literature analysis included patients known to be
HIV-positive. The clinical profile and chemotherapeutic regimen would be the
same as that in HIV-negative patients [30].
6 . 6 c onc l u s ion s  a n d  r e c om m e n dat ion s
On the basis of this literature analysis, it can be concluded that the treatment for
spinal tuberculosis does not differ from that for lung tuberculosis. The treat-
ment regimen comprised 2HRZ/4HR for M. tuberculosis with normal sensitivi-
ty. If there are indications of resistance, 4 chemotherapeutics (HRZE) should
be administered while awaiting the result of the resistance pattern. If the resis-
tance pattern remains unknown, then ethambutol should be continued
throughout treatment (2HRZE/4HRE). The necessity for surgical intervention
should be considered per individual [3]. A separate study on the effectiveness of
surgical intervention in combination with chemotherapeutics is planned.
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Chapter 7
c h e mo t h e r a p e u t ic  t r e at m e n t  f or  r e na l  
a n d  u r i na ry  t r ac t  t u be rc u l o s i s

7 . 1  s u m m a ry
Aim: to evaluate whether 6 months treatment for patients with renal tuberculo-
sis prevents relapse as effectively as >6 months treatment.
Method: literature study. Medline search and relevant publications in the peri-
od 1978 to November 2000.
Inclusion criteria: studies on patients whose chief diagnosis was genitourinary
tuberculosis, in whom the diagnosis was confirmed bacteriologically and/or
histologically or was probable on the grounds of clinical and/or radiological
findings and who responded well to chemotherapeutic treatment. The treat-
ment regimen had to include isoniazid, rifampicin and pyrazinamide (whether
or not in combination with surgery). Follow-up after the completion of treat-
ment had to be at least 12 months.
Exclusion criteria: patients with tuberculosis relapse who had been treated ade-
quately with chemotherapy in the past and studies that only described genital
tuberculosis.
Outcome parameter: patients with tuberculosis relapse.
Results: five publications were found with a total of 334 adult patients who had
been treated with isoniazid, rifampicin and pyrazinamide. Fifty-four patients
(16%) had been treated for four months; 187 patients (56%) had been treated for
six months and 93 patients (28%) had been treated for eight to eleven months.
Follow-up after concluding treatment varied from six to 120 months and had
been completed by more than 90% of the 334 patients. There was one relapse in
the group who had been treated for six months (0.6%, 95% CI: 0.0-3.2), but no
relapses in the group who had been treated for >6 months (0%; 95% CI: 0.0-
4.5). It can be concluded that six months treatment for patients with renal tuber-
culosis caused by M. tuberculosis with normal sensitivity is sufficient.
7 . 2  i n t roduc t ion
Renal tuberculosis is a late complication of tuberculosis. In general, it can still
occur 20 to 50 years after primary infection. Renal tuberculosis is registered
under tuberculosis of the genitourinary tract, together with tuberculosis of the
bladder, ureter, epididymis, other male genital organs, ovary, fallopian tube,
cervix and endometrium. In the period 1993 to and including 1999, a total of
11059 patients were registered with tuberculosis in the Netherlands, including
6205 (56%) non-Dutch patients (data from the Netherlands Tuberculosis
Register (NTR), Royal Netherlands Tuberculosis Association (KNCV). In 267
patients (2.4%) a diagnosis of genitourinary tuberculosis was made; 103 of them
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had renal tuberculosis (63 Dutch and 40 non-Dutch patients). The male:female
ratio among the Dutch patients and non-Dutch patients was about 1:1 for geni-
tourinary tuberculosis and renal tuberculosis. The age peak among the Dutch
patients lay between 45 and 84 years; in the non-Dutch patients, the peak lay
between 25 and 44 years. In the period 1993 to and including 1999, the diagnosis
of renal tuberculosis was made in only one child (non-Dutch nationality; age
category 5 to 14 years). Genitourinary tuberculosis and renal tuberculosis in
combination with active tuberculosis in other organs was present in 33%
(88/267) and 42% (43/103) of the patients, respectively. Genitourinary tubercu-
losis and renal tuberculosis in combination with bacteriologically proven pul-
monary tuberculosis was present in 17% (45/267) and 14% (14/103) of the
patients, respectively. In 15% (40/267) of the patients with genitourinary tuber-
culosis, the diagnosis of tuberculosis had also been made in the past (NTR). In
the Netherlands, the diagnosis of renal tuberculosis was bacteriologically con-
firmed in 76% to 80% of the patients. Chemotherapeutic treatment was admin-
istered to 38% of the Dutch renal tuberculosis patients and to 43% of the non-
Dutch renal tuberculosis patients for a duration of six to nine months and to the
same percentages for ten to twelve months (NTR).
The literature showed that the most common complaints in genitourinary
tuberculosis are unexplained micturition disorders, haematuria and sterile
pyuria. These complaints were present in 50%, 21-30% and 15% of the patients,
respectively [1,2,3]. Bacterial super-infection can occur: E. coli infection was
found in 30% of the patients [2]. The percentage of patients with renal calcifica-
tion varied from 13-52% [1,3]. At the time that genitourinary tuberculosis was
diagnosed, only 2% (2/87) and 6.3% (10/160) of the patients also had active pul-
monary tuberculosis [1,3]. The suspicion of tuberculosis in the past varied from
30%-49.3% [2,3,4].
The clinical symptoms of this rare disorder are vague; physicians are unlikely to
consider tuberculosis and the diagnosis is often made after severe renal damage
has occurred. This means that besides chemotherapeutic treatment, surgical
intervention might be necessary to resolve the excretory impairment or to try to
improve renal function.
We determined whether on the basis of the literature, judgement could be made
about the efficacy of six months treatment with at least isoniazid (H),
rifampicin (R) and pyrazinamide (Z) for renal tuberculosis.
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7 . 3  m e t hod  a n d  de f i n i t ion s
Using Medline, the literature was searched for relevant publications in the peri-
od 1978 to 2000. Keywords were genitourinary tuberculosis, drug therapy, anti-
tubercular agents. No restrictions were made regarding language.
Inclusion criteria: populations of patients with the chief diagnosis of genitouri-
nary tuberculosis whose diagnosis was confirmed bacteriologically and/or his-
tologically or was considered probable on the basis of clinical and/or radiologi-
cal findings and who responded well to chemotherapeutic treatment. The treat-
ment regimen, whether or not in combination with surgical intervention, had to
include at least isoniazid (H) rifampicin (R) and pyrazinamide (Z), possibly in
combination with ethambutol and/or streptomycin. Follow-up after the com-
pletion of treatment had to be at least 12 months.
Exclusion criteria: patients with tuberculosis relapse who had been treated ade-
quately in the past with chemotherapy and studies which only described
patients with genital tuberculosis.
Outcome parameter was the number of patients with tuberculosis relapse.
Definitions: Treatment was considered to have failed if after 12 weeks of treat-
ment, 2 or more positive cultures were found within an interval of at least 1
month. Treatment was considered to be successful if the patient was complaint-
free and the urine did not contain M. tuberculosis. Genitourinary tuberculosis
relapse was defined as symptom recurrence after the completion of treatment
and the presence of M. tuberculosis in the urine.
7 . 4  r e s u lt s
A total of five publications were found, containing 1586 adult patients with gen-
itourinary tuberculosis. It was not possible to distinguish patients with renal
tuberculosis in combination with genital tuberculosis from patients with renal
tuberculosis alone on the basis of the data presented in the publications. There
were two prospective studies [5,6] and three retrospective studies [3,4,7]. In
21% (334/1580), treatment had comprised at least isoniazid (H), rifampicin (R)
and pyrazinamide (Z) [3-7]. Treatment regimens without rifampicin or pyrazi-
namide were not included in the analyses [3,4,7]. The study by Benchekroun et
al. which described 40 patients who had received isoniazid and rifampicin dur-
ing six months with pyrazinamide during the first two months (2HRZ/4HR)
and 16 patients who had received isoniazid, rifampicin, pyrazinamide and strep-
tomycin for the first two months and isoniazid and rifampicin during the next
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seven months (2HRZS/7HR), was not included in the analyses because no fol-
low-up data were presented [2]. The diagnosis had been confirmed bacterio-
logically or histologically in 1431 patients [3-6]. M. tuberculosis had normal sensi-
tivity, in as far as this detail was mentioned [4]. Chemotherapy dosage had been
administered according to the World Health Organisation (WHO) guidelines,
with the exception of the low dosage of pyrazinamide (1000 mg/day) adminis-
tered by πkutil et al. [6]. Poulios and Malovrounas did not mention anything
about dosage [3]. Gow and Barbosa reported that the dosage had been adjusted
according to renal function and that a creatinine clearance of 100 ml/minute
was considered to be normal, but they did not mention the specific chemothera-
peutic agent. If clearance fell below this level, the dosage was adjusted in terms
of percentage [4]. The medication was administered under full supervision by
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Ta bl e  1 . Treatment for genitourinary tuberculosis in the literature with treatment
regimens comprising at least isoniazid (H), rifampicin (R) and pyrazinamide (Z)
Author Gow [4] Wong [5] πkutil [6] Bennani [7] Poulios [3] Total No. of
period 1961-1981 1975-1983 1979-1980 1976-1993 1976-1986 patients (pts)  
No. of pts 1117 110 113 86 160 1586
Age (yrs)  7-8 19-79 23-72 14-82 18-82
(20-50) (mean 34) (mean 50)
Male: 2:1 2:1 2:1 1.4:1 2:1
female 
Diagnosis 100% 100% 100% ? 57%
bacterio-
logically 
and/or 
histolo-
gically 
confirmed    
Surgery:
Radical 58% 43% 22% 36% 39%
Recon- 13% 32% 1% 20% 4%
structive 
Drug therapy 29% 25% 77% 44% 57%
alone    
Pts with HRZ 74 110 113 31 6 334
(+/- surgery)
4 months 48 6 54
6 months 26 27 113 21 187
8-11 months 83 10 93
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Ta bl e  2 . Studies in the literature that mention relapse rates after treatment for
genitourinary tuberculosis with treatment regimens comprising at least isoniazid (H),
rifampicin (R) and pyrazinamide (Z), possibly in combination with ethambutol (E) and
streptomycin (S). The figure in front of the letter is the number of months that the agent was
administered. Medication was administered daily. When the medication was administered
intermittently (a number of times per week), the number of times is given in subscript after
the agent
Author Regimen No. of patients No. of patients, Follow-up No. of patients
who started who discontinued duration in who completed
treatment treatment months follow-up /
(because of side- after started treatment
effects) completing (no. of patients 
treatment with relapse)
Gow 2HRZ/ 48 1(1) >12 130/135
[4] 2H3R3 (0)
2HRZS/
2H3R3
2HRZ/4RZ 26
3HRE/6HR 4
3HRE 57
3HRE/3HR
Wong 2HRZE/ 27 5(3) mean 35 22/27
[5] 4H3R3Z3 months (0)
no surgery
2HRZE mean 49
before and (6-82)
after 
surgery/
after 
ablative 48 6(6) 42/48 (0)
surgery
4H3R3Z3 
and 
after  recon-
structive 35 7(5) 28/35 (0)
surgery
7H3R3Z3
πkutil [6] 2HRZ/4HR 113 7(7) 45-63 106/113 (1)  
Bennani [7] 2HRZ/4HR 21 12-120 31/31 (0)
2HRZS/ 10
7HR
Poulios [3] 4HRZ 6  18 6/6 (0)
πkutil et al. during the first two months [6]. The percentage of patients who had
to discontinue treatment because of side-effects varied from 2-14% (Table 2).
Ethambutol had to be stopped in 8% (5/61) [1]. There were no treatment failures
[3-7]. After two months of treatment, M. tuberculosis could no longer be demon-
strated in the urine [4,6]. After one to two months of chemotherapeutic treat-
ment, Wong et al. demonstrated M. tuberculosis in 17.9% of the patients who had
undergone ablative surgery. In some of the patients who underwent reconstruc-
tive surgery, the urine was still positive one month after surgery, i.e. three
months after the start of chemotherapeutic treatment [5]. In general, surgery
was performed four to six weeks after the start of chemotherapeutic treatment
[4,5].
More than 90% (304/334) of the patients who had received HRZ completed the
follow-up period, which varied from 6 to 120 months after concluding
chemotherapeutic treatment (Table 2). Only one bacteriologically confirmed
relapse occurred six months after the completion of six months treatment
(1/170=0.6%; 95% C.I. 0.0-3.2). The patient had M. tuberculosis with normal sen-
sitivity [6]. In the groups that were treated for four months and for 8-11 months,
the relapse rates were 0/54=0% (95% C.I. 0.0-6.6) and 0/80=0% (95% C.I. 0.0-
4.5), respectively.
7 . 5  di s c u s s ion
On the basis of the perhaps limited literature data, we can conclude that in gen-
eral, a treatment duration of six months was sufficient for patients with renal
and urinary tract tuberculosis. In such cases, adequate surgical intervention is
necessary. The low number of publications on the treatment of urinogenital
tuberculosis since the introduction of pyrazinamide can probably be explained
by the good results of even four months treatment [4,9]. As explanations for the
effectiveness of four to six month treatment regimens, the following arguments
have been put forward [1,10]: (1) the number of M.tuberculosis in the kidneys is
probably low in comparison with the bacterial load in patients with pulmonary
tuberculosis; (2) owing to the rich blood supply, concentrations of isoniazid,
rifampicin and pyrazinamide in the kidneys are much higher than the minimum
inhibitory concentrations. In a non-functional kidney, chemotherapeutics will
not be able to reach the focus of infection and renal resection might be consid-
ered. Only Wong et al. based the duration of chemotherapeutic treatment on
the degree of organ damage and the type of surgical intervention (Table 2) [5].
The clinical symptoms of this rare disorder are vague, which means that many
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patients present with severe and very advanced disease. The studies included in
our analyses did not mention the severity of renal dysfunction or how often this
required treatment adjustment. It was not possible to evaluate the relation
between the dosage of ethambutol, pyrazinamide, the severity of renal dysfunc-
tion and the occurrence of side-effects [4,5].
The dosage of ethambutol and pyrazinamide must be adjusted in the case of
impaired renal function [8,11-13]. Ethambutol is administered as the fourth
chemotherapeutic agent in the intensive phase, while awaiting the resistance
pattern of the M. tuberculosis. The studies included in the analyses were per-
formed in the period that resistance to M. tuberculosis seldom occurred. Etham-
butol had been administered to 33% (110/334) of the patients. A total of 13%
(14/110) of the patients suffered from side-effects, but no mention was made of
the specific chemotherapeutic agent(s) [5]. Close ophthalmological monitoring
has been recommended in patients with renal dysfunction while they are receiv-
ing ethambutol [14]. Although it is possible to determine serum chemothera-
peutic levels in the Netherlands, there is insufficient experience to interpret the
data adequately. A rapid test to determine rifampicin resistance might reduce
the need to include ethambutol at the start of treatment. M. tuberculosis can eas-
ily be detected in the urine. In experienced hands, Ziehl-Neelsen staining of
morning urine can produce reliable results [15]. However, it is important to take
into consideration that the antibiotics used for common bacterial super-infec-
tions, such as aminoglycosides, rifampicin and ciproxin, must be stopped for
the Löwenstein culture to be reliable.
The percentage of patients in the studies included in our analyses who received
chemotherapeutic treatment alone varied from 25% to 77%. In patients with an
abnormal IVP, the investigation was repeated every three months, combined
with isotope renography, in order to detect the earliest possible indications for
surgical intervention. A proportion of the cases of stricture were caused by
oedema, which responded well to chemotherapeutic treatment. Corticos-
teroids are only worthwhile in the acute phase and are not the medication of
first choice [4]. There are two types of surgery: radical and reconstructive. Rad-
ical operations included (partial) nephrectomy, cavernectomy and epididymec-
tomy. Reconstructive operations included resolution of the ureter-urethral
stricture and bladder enlargement. After the completion of chemotherapeutic
treatment, it has been recommended to send morning urine for Löwenstein cul-
ture on three separate occasions and to repeat this procedure every three
months up to a total follow-up of 12 months after the completion of treatment.
The IVP should be repeated after the completion of treatment and at follow-up
visits if the previous investigation showed abnormalities [4]. Patients with large
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renal calcifications should be follow-up once a year, in order to monitor indica-
tions for surgery [4].
7 . 6  c onc l u s ion
On the basis of this literature study, it can be concluded that treatment for renal
and urinary tract tuberculosis need not differ from that for pulmonary tubercu-
losis. Treatment should comprise 2HRZ/4HR in patients who have M. tubercu-
losis with normal sensitivity. On the suspicion of resistance, four chemothera-
peutic agents must be administered while awaiting the resistance pattern
(HRZE).
Surgical intervention may be necessary in combination with chemotherapeutic
treatment.
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Chapter 8
pyrazinamide use as a method to estimate 
under-reporting of tuberculosis
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8 . 1  s u m m a ry
Objective: to develop a method of validating the notification of active tuber-
culosis by physicians in the Netherlands.
Method: the chemotherapeutic agent pyrazinamide was used as a “marker” for
the occurrence of tuberculosis. On the basis of Defined Daily Doses (DDD) of
pyrazinamide dispensed to out-patients, an estimate was made of the number
of patients with tuberculosis in the Netherlands in the period 1994-1998. DDD
is a technical unit of measurement and does not necessarily reflect the recom-
mended or actual dose used. Usually it is based on the average dosage per day
for the main indication in adults with normal organ function. The Dutch Drug
Information Project (GIP) of the Health Care Insurance Board (CVZ) provided
the DDD data. Based on the notification of tuberculosis patients to the Nether-
lands Tuberculosis Register (NTR) we calculated how much pyrazinamide
(measured in DDDs) these patients would have used depending on their body
weight.
Results: the number of DDDs prescribed according to the GIP pharmacy
records differed by only 8% from the number of DDDs calculated on the basis
of notification to the NTR; 6889 patients should have been registered instead of
6349.
Conclusion: the close correlation between the use of pyrazinamide measured
by means of the GIP and NTR provides strong evidence that in the Netherlands,
tuberculosis is reported in conformity with the guidelines for notifiable dis-
eases. The method was simple to apply and may deserve following-up in other
countries.
8 . 2  i n t roduc t ion
In the Netherlands, tuberculosis is a notifiable disease [1,2]. A case is notifiable
when M.tuberculosis complex is present in patient material, or when a physician
makes the diagnosis of tuberculosis on the basis of symptoms, clinical and radi-
ological signs and decides to start curative treatment with anti-tuberculosis
drugs. A medical microbiology laboratory or a treating physician is obliged by
law to notify the Municipal Health Service in the region where the patient lives.
After receiving notification, the staff at the Municipal Health Service fill in reg-
istration forms for the Inspectie voor de Gezondheidszorg (IGZ) and for the
Royal Netherlands Tuberculosis Association (KNCV). The KNCV keeps the
Netherlands Tuberculosis Register (NTR). The register holds anonymous
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detailed information on every tuberculosis patient reported to the Municipal
Health Service. After notification, the staff at the Municipal Health Service
record the data for epidemiological purposes and also start source and/or con-
tact tracing. In addition, the patient is monitored by a TB nurse from the Munic-
ipal Health Service to prevent resistance induction from treatment errors.
The number of patients with tuberculosis in the Netherlands is closely associat-
ed with the influx of persons from countries where tuberculosis is highly
endemic. More of these persons have extra-pulmonary forms of tuberculosis
than Dutch tuberculosis patients. In the case of non-infectious forms of tuber-
culosis, there is a greater risk of under-reporting by the treating physician,
because there is no need for contact tracing. In addition, if the diagnosis has not
been confirmed bacteriologically, the laboratory cannot notify the Municipal
Health Service.
To estimate under-reporting, this study compared the number of days of pyraz-
inamide use registered by the NTR, to the number of days of pyrazinamide use
measured on the basis of data from the Dutch Drug Information Project (GIP)
of the Health Insurance Board (CVZ) in the period 1994-1998.
Pyrazinamide was chosen as a “marker” for tuberculosis, because this medica-
tion is used solely for the treatment of tuberculosis and moreover, it usually
forms part of the treatment [3-5].
8 . 3  m at e r i a l  a n d  m e t hod s
The use of pyrazinamide derived from notification to the NTR was compared
to the quantity of pyrazinamide supplied on prescription by Dutch pharmacies.
Since 1993, the NTR has been computer automated. Therefore, we chose the
period 1994 to and including 1998 for this study.
In the NTR the following patients data are included: age, number of days that
the patient was hospitalized and number of days that the patient took medica-
tion, including isoniazid, rifampin, pyrazinamide or alternatively other anti-
tuberculosis drugs.
The standard treatment of tuberculosis is a six-month regimen consisting of
daily isoniazid, rifampin, pyrazinamide and ethambutol given for two months
followed by isoniazid and rifampin for four months. Pyrazinamide is always
given for at least 2 months, but administration of pyrazinamide is continued
after this period if no sputum conversion has occurred. Pyrazinamide treat-
ment can also be continued after 2 months if the final typing and the resistance
pattern have not been determined yet, pending the results of the cultures.
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In the Netherlands the advised dosage pyrazinamide is 30 mg/kg body weight
per day, with a maximum of 2 grams per day for 2 months.
Data on the out-patient use of pyrazinamide were made available by the GIP
over this period. Pyrazinamide use was calculated as the number of DDDs per
year. Defined Daily Doses (DDD) is a technical unit of measurement and does
not necessarily reflect the recommended or actual dose used. Usually it is based
on the average dosage per day for the main indication in adults with normal
organ function [6-9]. On the basis of population data from the GIP and the
total Dutch population, an estimate was made of the number of patients with
tuberculosis in the whole of the Netherlands.
According to the World Health Organisation (WHO), the DDD of pyrazi-
namide is 1500 mg per day [5]. The actual dosage prescribed (Prescribed Daily
Dose = PDD) may deviate, for example on the basis of the patient’s weight.
Therefore, a correction factor was determined.
Distinction was made between patients < 16 years and > 16 years, because chil-
dren < 16 years usually weigh ≤ 50 kg. That means that for children < 16 year 1
DDD = 1500 mg pyrazinamide per day is prescribed and that for patients ≥ 16
years 2000 mg pyrazinamide per day is prescribed. In the Netherlands tubercu-
losis patients > 16 years usually weigh more than 60 kg. A survey held by the first
author among 36 tuberculosis physicians at Municipal Health Services revealed
that a dose of 2 gram of pyrazinamide is prescribed for the majority of patients.
A survey of tuberculosis patients’ medical files in the Municipal Health Service
Nijmegen showed that in the period 1994-1998, 60% (100/163) of the patients
received prescriptions for 2 gram of pyrazinamide. It was assumed that in at
least 60% of the adult patients, the PDD = 1.3333 DDD and that for 40% of the
adults and for children younger than 16 years the PDD = 1 DDD.
In the NTR, selection was made of days of pyrazinamide use, excluding the
number of days that the patient was hospitalized.
8 . 4  r e s u lt s
The following data were extracted from the NTR: in the period 1994-1998,
6349 patients were registered with tuberculosis in the Netherlands; 58% were
not of Dutch origin. Pulmonary tuberculosis was present in 60%, extra-
pulmonary tuberculosis in 33% and a combination of pulmonary and extra-
pulmonary tuberculosis in 7%. Diagnosis of the pulmonary form of tuberculo-
sis was confirmed bacteriologically in 77% of the patients using Löwenstein
Jensen medium for culture; Ziehl-Neelsen stain was positive in 21%. 
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Ta bl e  1 . Number of tuberculosis patients treated with anti-tuberculosis drugs including
pyrazinamide (Z) with duration in days according to 1994-1998 Netherlands Tuberculosis
Register (NTR) data and calculated Defined Daily Doses (DDD), compared to data on Z
use of the Dutch Drug Information Project (GIP) of the Health Care Insurance Board
(CVZ)
Year of diagnosis Total 
1994 1995 1996 1997 1998 
No. of tuberculosis patients 1396 1258 1404 1256 1035 6349 
Age and days of Z use 
< 16 years 8070 8805 8905 8908 6162 40850 
>= 16 years 141497 120345 121888 111784 86706 582220 
Treatment duration of 
Z in days (all ages) 149567 129150 130793 120692 92868 623070 
Percentage of completed 
Part 3 of the NTR form 96.2 92.5 97.6 96.5 86.5 93.9 
No.of days of Z after 
correction for 100% 663546 
Part 3 completion
Corrected DDD based 
on body weight
< 16 year x 1 DDD 8070 8805 8905 8908 6162 40850 
>= 16 year 
x 1.3333DDD (60%) 113195 96274 97508 89425 69363 465765 
>= 16 year
x 1 DDD (40%) 56599 48138 48755 44714 34682 232888
Total DDD corrected
for body weight 177864 153217 155168 143047 110207 739503
DDD corrected for body
weight and after correction 184889 165640 158984 148235 127407 787543
for 100% Part 3 (NTR)
completion
Total No. of DDDs
pyrazinamide (GIP) 200837 191496 187579 140136 134240 854288
108.6% 115.6% 118.0% 94.5% 105.4% 108.4%
No. of prescriptions 4789 4521 4484 3520 3394 20708
DDD per prescription 41.9 42.4 41.8 39.8 39.6 41.3
Extra-pulmonary forms were confirmed bacteriologically in 74%, while ZN
was positive in 2%. A combination of pulmonary and extra-pulmonary forms
was confirmed bacteriologically in 82%, while ZN was positive in 16%.
The number of days of pyrazinamide use is reported in Part 3 of the NTR form.
Part 3 had been filled in for 93.3% of the cases: the 6349 tuberculosis patients
had been treated with pyrazinamide (Z) for 623070 days (Table 1). Correction
for 100% completion of Part 3 led to 663546 days of Z in the 6349 patients.
According to the GIP, 854288 DDDs had been supplied (Table 1). According to
Dutch regulations, drugs for chronic diseases, like pyrazinamide, can only be
prescribed for a maximum period of one month. By dividing the number of
DDDs by the number of prescriptions, we found that on average, the patients
had received a one month supply of Z per prescription and that the PDD was
equal to 1.3333 DDD (Table 1). This means that according to the GIP, Z was dis-
pensed for 640732 days (854288÷1.3333). The difference between the number of
days of Z use according to the NTR and number of days according to the GIP
was 4%.
If we assume that all the patients aged < 16 years and 40% of the patients > 16
years used 1 DDD Z per day, and that 60% of the patients aged > 16 years used
1.3333 DDD Z per day, then on the basis of the NTR data, the 6349 patients used
739503 DDDs of Z. After correction for 100% completion of Part 3, this means
787543 DDDs. In this case, the difference between the number of days of Z use
according to the NTR and the number of days according to the GIP (854288
DDDs) was 8%. According to the NTR, a patient used an average of 124 DDDs
(787543÷6349), while according to the GIP, 854288 DDDs were dispensed
(Table 1). This means that notification should have been received by the NTR
for 6889 patients (854288 DDDs ÷ 124 DDDs per patient). Thus, under-report-
ing was 8.5%.
By dividing the number of days of Z use according to the NTR by the number of
tuberculosis patients, we found that each tuberculosis patient used Z for an
average of 105 days (663546 days of Z ÷ 6349 tuberculosis patients).
8 . 5  di s c u s s ion
Our study showed that pyrazinamide as a “marker” for tuberculosis made a
valid estimate of the number of patients with tuberculosis in the Nether-
lands [6-9]. In this way, it was possible to investigate under-reporting of a noti-
fiable disease by Dutch physicians. Choosing a period of several years auto-
matically corrected for the patients who were diagnosed in the last few days of
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one year and actually started treatment on anti-tuberculosis drugs in the fol-
lowing year. In addition, the wide time frame covered any doses of pyrazi-
namide that might have been obtained but not used, and later given to patients
without health insurance by tuberculosis physicians from Municipal Health
Services.
Our calculations showed that the patients had used pyrazinamide for an average
of 3.5 months, instead of the minimum of 2 months advised by protocol. The
NTR data from 1998 show that 53% (582/1090) of the patients used pyrazi-
namide for 2 months, 19% (208/1090) for 3 months and 20% (218/1090) for a
period longer than 3 months. No information on the use of pyrazinamide is
available from 19% (251/1341) of the patients.
A possible explanation for the longer treatment period is that the resistance pat-
tern would still have been unknown at 2 months, so pyrazinamide was contin-
ued while awaiting the result of the resistance pattern.
Although only a very small proportion of patients take their medication under
the supervision of a TB nurse in the Netherlands, so-called Direct Observed
Therapy (DOT), treatment compliance is monitored very thoroughly. A TB
nurse visits the patients regularly at home, checks the medication prescribed by
the doctor and checks that the correct medication has been dispensed by the
pharmacy. The same TB nurse fills in the number of days of pyrazinamide use
on the registration forms.
It is possible that the GIP gave an under-estimation of pyrazinamide use among
asylum seekers in the Netherlands, because these persons fall under the care of
the agency for the reception of asylum seekers (COA). In the period 1994-1998,
asylum seekers spent an average of 15 months under the care of the COA [10]. It
is not clear whether asylum seekers have an increased tuberculosis risk com-
pared to the other tuberculosis risk groups. In the period 1994-1998, 21%
(1335/6349) of the tuberculosis patients were asylum seekers; 54% (723/1335) of
them had been in the Netherlands for less than 2 years (NTR/KNCV).
Underestimation of pyrazinamide use in relation with discharge from hospital
and the patients taking a supply with them was considered to be negligible,
because hospitals in the Netherlands are budgeted. Patients probably only
received sufficient medication for the first day. In the period 1994-1998, it was
not yet customary to use pyrazinamide as a prophylactic. Pyrazinamide use on
the basis of the GIP data may have led to overestimation of the number of
patients with active tuberculosis, because treatment is also started on the suspi-
cion of tuberculosis, although later, culture might show that the tuberculosis is
caused by non-tuberculous mycobacteria.
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8 . 6  c onc l u s ion  a n d  r e c om m e n dat ion s
On the basis of the number of days of pyrazinamide use by patients with active
tuberculosis as reported on Part 3 of the NTR forms in the period 1994-1998
and on the basis of data from the GIP of the CVZ on the number of DDD of
pyrazinamide supplied to out-patients, it can be concluded that in the Nether-
lands, there is only a small amount of under-reporting of the number of patients
with tuberculosis. In addition, it can be concluded that TB nurses  generally
monitor and record treatment accurately. From an epidemiological point of
view, employing data on pyrazinamide use proved to be a good and simple
method of validating notification of tuberculosis patients. The method may
also be suitable for validation purposes in other countries.
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9 a . 1 a b s t r ac t
Objective: descriptive study on tuberculosis screening at a temporary shelter
for aspirant asylum seekers and contact tracing around infected patients.
Design: descriptive.
Setting: Municipal Health Service Nijmegen.
Method: 3 River Rhine cruisers (with inadequate ventilation facilities) served as
a temporary shelter for aspirant asylum seekers in the winter months from
November 1993 to April 1994. Residents were screened for tuberculosis by
means of chest X-ray after an average of 10 days. In the case of radiological
abnormalities, sputum was tested (Ziehl-Neelsen staining and Löwenstein cul-
ture). Mantoux testing was performed on the shelter staff.
Results: 4 out of the 834 screened persons had open tuberculosis. Contact trac-
ing yielded 3 infected cases in the first ring (n=5) and 11 infected cases and two
other patients with infiltrative and cavernous lung tuberculosis in the second
ring (n=215); 14 of these cases were shelter staff. The bacteria were not resistant
to tuberculostatics.
Conclusion: Rapid transmission of tuberculosis occurred due to inadequate
ventilation facilities and delayed screening. Tuberculosis among aspirant asy-
lum seekers is a major problem that requires serious attention.
9 a . 2 i n t roduc t ion
Since 1987, there has been an increase in the number of patients with tuberculo-
sis in the Netherlands. This increase can largely be attributed to the increasing
influx of asylum seekers from countries with a high tuberculosis prevalence
(S.T. Keizer, Royal Netherlands Tuberculosis Association, written statement,
1994). The incidence of tuberculosis in the Dutch population is 10 per 100,000
per year. The prevalence of tuberculosis among immigrants is about 300 per
100,000, whereas the prevalence among asylum seekers is 400 per 100,000. In
view of the large influx of asylum seekers, the number of patients with tubercu-
losis can be expected to increase sharply. In 1994, 50,000 asylum seekers were
expected, which means about 200 tuberculosis patients. An extra problem is
the possible import of tuberculosis strains that are resistant to current tubercu-
lostatics.
Tuberculosis surveillance among aspirant asylum seekers at the so-called River
Waal Harbour Temporary Shelter (Dutch abbreviation: POC) by the Municipal
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Health Service Nijmegen in the period November 1993 to April 1994, revealed
that there is a real danger of infection transmission to the Dutch population.
The POC comprised 3 River Rhine cruisers. Insufficient ventilation led to the
infection of persons in the direct vicinity. The authorities responsible for
receiving the asylum seekers neglected to obtain advice from the Municipal
Health Service.
This study wishes to draw attention to the problem of tuberculosis among asy-
lum seekers and to demonstrate how inadequate (temporary) shelter facilities
and poor execution of policy can lead to secondary cases of infection.
Reception of aspirant asylum seekers and tuberculosis screening
In the Netherlands, the reception of aspirant asylum seekers is organised
nationally by the Agency for the Reception of Asylum Seekers (COA). While
awaiting accommodation at an official Reception Centre where the first legal
hearing will take place, it is sometimes necessary for asylum seekers to be
placed in temporary shelter facilities for several weeks. National policy is to
screen asylum seekers for tuberculosis directly on arrival in the Netherlands
and to continue screening for 2 years at 6-monthly intervals. Municipal Health
Services (MHSs) are responsible for carrying out this policy. Screening can
take place at the MHS building or a mobile X-ray unit can be placed at the shel-
ter facilities once a week. The MHS in Tilburg and Lelystad coordinate screen-
ing for tuberculosis with the aid of mobile X-ray units.
9 a . 3 m e t hod
The POC Waal Harbour procedure was as follows:
Reception of aspirant asylum seekers During the period November 1993 to April
1994, a total of 928 aspirant asylum seekers were accommodated aboard 3 River
Rhine cruisers moored in the Waal Harbour. Each had accommodation for 100
persons. These cruisers were not suitable for permanent residence. The Inspec-
tion of Shipping Inland Waters does not have ventilation norms for hotel ships /
river cruisers. In view of the fact that these river cruisers were used in the winter
months, it could be expected that the asylum seekers would spend most of their
time indoors aboard the cruisers. On inspection of the quarters, the MHS
found that the cabins were small and only suitable for sleeping in. A number of
cabins did not admit daylight, while 14 cabins did not have any ventilation facili-
ties at all. Aboard all the cruisers, the height of the ceilings was less than 2
metres and the ventilation facilities were inadequate. The dining rooms (nor-
c h a p t e r  9 a130
mal capacity: 100 persons) each had to accommodate 300 asylum seekers and
the shelter staff. In the cold winter months, these dining rooms were not venti-
lated at all; but even if the ventilation facilities had been in operation, they
would not have been sufficient to prevent aerogenic infection by a patient with
undiagnosed open tuberculosis.
Accommodation for the shelter staff, ship’s crew and medical team Although the
shelter staff and asylum seekers made communal use of the dining rooms, the
ship’s crew had separate recreation rooms. Smoking was only permitted in the
dining rooms or recreation rooms. The medical team (doctors, nurses and
administration staff) had offices and care facilities in barracks on the quay.
At the POC, the first medical examination comprised triage. The asylum seek-
ers received a written call-up notice. During the triage, the anamnesis list was
checked that the residents had received and filled-in beforehand. A nurse went
through the list with the residents and if necessary, made an appointment with
the doctor. The doctor could then refer residents to a general practitioner or
medical specialist.
Owing to the unexpectedly high water level in the River Waal, the medical team
had to abandon the barracks on the quay and create medical care facilities on
the lower deck of one of the river cruisers. Therefore, intake and examination of
newly arrived asylum seekers took place below deck, where there was no day-
light or ventilation. Despite serious complaints from the shelter staff and the
MHS, these conditions had to be endured from December 1993 to April 1994.
Tuberculosis examination procedures
Before opening the Waal Harbour shelter, the following agreements were made
between the MHS and the medical team regarding the tuberculosis examina-
tion procedure:
- Procedure for aspirant asylum seekers: each asylum seeker will be called-up
for chest X-ray by the medical team within one week of arrival aboard a river
cruiser. The X-ray will be taken in the mobile X-ray unit. Use of the mobile X-
ray unit will be coordinated by Tilburg MHS.
The mobile X-ray unit will be parked on the Waal Harbour quay every Wednes-
day, provided that there are at least 15 new arrivals. The X-rays will be developed
on the same day at Tilburg MHS and be read on the following day by the Com-
munity Health Officer for TB & Infectious Diseases at the MHS Tilburg. In the
case of abnormalities, the shelter will be informed immediately by telephone, so
that the patient can attend the tuberculosis out-patient clinic at the Nijmegen
MHS on the same day. In the case of open tuberculosis, the patient can immedi-
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ately be admitted to the Chest Clinic Dekkerswald of the University Hospital
Nijmegen, which has an isolation ward. In the case of suspected tuberculosis,
the patient should be accommodated in a single cabin that can be ventilated.
The importance of good coughing hygiene should be emphasized.
Second reading of the chest X-rays will be performed by the Community
Health Officer for TB & Infectious Diseases at the Nijmegen MHS within 7
days. The doctor on the medical team could also send residents to the MHS for
chest X-ray in the intervening period.
- Procedure for shelter staff: the shelter staff will be advised to undergo screen-
ing for tuberculosis (Mantoux test) before starting work at the shelter in
November 1993 and to repeat the screening 2 months after the last contact (in
view of the incubation period) in June 1994. In addition, contact tracing will be
performed if one of the residents is diagnosed with an infectious form of tuber-
culosis. Information sessions about tuberculosis will be provided by the MHS
for the shelter staff and ship’s crew.
9 a . 4 r e s u lt s
Results of the first screening
A total of 834 aspirant asylum seekers (90% of all the shelter residents) were
screened for tuberculosis (Figure 1). The estimated response rate after one writ-
ten call-up was 70%. Mean interval between arrival aboard a river cruiser and
the first chest X-ray was 10 days according to the medical team. Ninety-four
persons (10%) were not screened: 48 (5%) left with destination unknown and 46
(4%) were transferred prematurely.
Radiological abnormalities possibly associated with tuberculosis were present
in 13 (1.5%) of the aspirant asylum seekers. A sputum test was performed in 11 of
them. In 7 persons, Ziehl-Neelsen staining and Löwenstein culture were nega-
tive; 5 of these persons nevertheless started extramural tuberculostatic treat-
ment on the grounds of the radiological abnormalities. One of them left with
destination unknown.
Four asylum seekers had open tuberculosis. Löwenstein culture showed human
tubercle bacillus growth with good sensitivity to the usual tuberculostatics.
One of these 4 patients with open tuberculosis had visited the doctor on the
medical team directly on arrival because of health complaints; the doctor
immediately referred him to the MHS. Another of these 4 patients with open
tuberculosis had been transferred from a different shelter to the Waal POC by
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F igu r e  1 . Results of the first screening for tuberculosis in 928 asylum seekers at the River
Waal Harbour Temporary Shelter (POC) in Nijmegen
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the COA without any form of prior consultation. The intervals between arrival
aboard a cruiser and the first chest X-ray in the 4 patients with an infectious
form of tuberculosis were 2, 1, 9 and 19 days, respectively. Due to circum-
stances, the chest X-ray of the first patient was not read on the day after it was
taken, but 4 days later. The 4 patients were admitted to the Nijmegen University
Chest Clinic Dekkerswald. The first patient arrived at the POC Waal Harbour
in mid-November. Contact tracing around this patient was performed 2
months after the last contact (in mid-February) in view of the incubation peri-
od. The remaining 3 patients with open tuberculosis arrived in mid-February. It
was decided that contact tracing in their case would coincide with the screening
examinations planned at shelter closure in June 1994.
Contact tracing around the first patient with open tuberculosis
First ring: Contact tracing around the patients with an infectious form of tuber-
culosis was performed in the usual way according to the ring principle [1]. Con-
tact tracing around the first patient was performed in February 1994 (Table 1).
In this patient the first ring comprised the cabinmate and 5 shelter staff. In 3 out
of these 5 shelter staff, a positive Mantoux reaction was found, i.e. an increase in
tuberculin conversion of at least 10 mm (baseline value 0-2 mm) within a period
of one year. This indicated an infection rate of 60% among the shelter staff in
the first ring. Therefore, contact tracing was extended to the second ring.
Second ring: The second ring comprised 105 shelter employees/ visitors and 110
asylum seekers residing aboard the same river cruiser.
- Shelter employees/visitors included shelter staff from the Agency for the
Reception of Asylum Seekers, ship’s crew, security personnel, Refugee Work-
ers Nijmegen, Alien Registration Officers, drivers from a taxi company, family
members of the shelter staff who visited the cruisers and lawyers. The work
force had been changing constantly since the shelter opened; the Agency for the
Reception of Asylum Seekers did not have a complete list of employees. In a
number of cases, this contact tracing formed the first screening test, because
medical examinations had not been performed before they started work at the
shelter.
In the group of 105 employees/visitors, 29 were considered to have an indication
for chest X-ray and 76 underwent Mantoux testing (the rule employed was: per-
sons born prior to 1945 and persons with a history of positive tuberculin con-
version or BCG vaccination were screened with a chest X-ray, while the others
were screened with a Mantoux test). Eleven employees / visitors had a positive
Mantoux test. This meant an infection rate of 10.5% in the second ring. Five out
of the 11 Mantoux-positive persons showed positive tuberculin conversion; in
the other 6 persons, recent infection and therefore actual tuberculin conversion
could be assumed in view of their young age [1].
The group of 14 infected employees/visitors (the total number from the first
and second ring) comprised 5 ship’s crew and one person from security; 5 out of
these 6 persons had a positive Mantoux test; they had not had any direct contact
with the residents, but they had used the communal dining room. The remain-
ing 8 persons were all employees from the Agency for the Reception of Asylum
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Seekers. The 14 persons with a positive Mantoux reaction had a normal chest X-
ray. They were advised to take 300 mg of isoniazid per day for 6 months as pro-
phylactic treatment. Later, 2 of them had to stop the medication prematurely
owing to liver function disturbances. In addition, one person withdrew from
the control visits, which made therapy compliance doubtful.
- Residents. The 110 fellow-residents in the second ring of the first patient had
been transferred to other shelters for asylum seekers in the meantime. With the
aid of 16 different MHSs, these persons were traced and approached personally.
Two of them had consulted a doctor in March and April 1994, respectively. One
had infiltrative lung tuberculosis and the other had cavernous tuberculosis.
Human tubercle bacillus were found with good sensitivity. The first screening
of the patient with cavernous tuberculosis in November 1993 had revealed radi-
ological abnormalities that may have been caused by a previous tuberculosis
infection. The patient had never received treatment. Further determination of
M.tuberculosis with restriction fragmentation polymorphism by the National
Institute of Public Health and the Environment (RIVM) showed that the
M.tuberculosis of both these patients matched that of the first patient. Before
tuberculostatic could be started, the asylum seeker with cavernous tuberculosis
left with destination unknown.
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Ta bl e  1 . Results of contact tracing around the first of 4 patients diagnosed with open
tuberculosis at the temporary shelter for aspirant asylum seekers (Waal Harbour POC,
Nijmegen) in mid-February 1994
No. of persons No. of persons No. of persons Tuberculosis
total with positive with open infection
Mantoux test tuberculosis rate (%)
Direct employees* 5 3 - 60  
Other employees** 105 11 - 10.5  
Aspirant asylum 
seekers 110 - 2† 1.8  
*   Staff at the temporary shelter
**Personnel from the Agency for the reception of Asylum Seekers, ship’s crew, security per-
sonnel, Refugee Workers Nijmegen, Alien Registration Officers, drivers from a taxi com-
pany, family members of the shelter staff who visited the cruiserd, lawyers
† One person left with destination unknown
9 a . 5 di s c u s s ion
During the reception of aspirant asylum seekers at the Waal Harbour POC, a
great deal went wrong with prevention and control of tuberculosis in the initial
stages. There was a high rate of infections in the first and second ring, because
of delayed diagnosis of patients with open tuberculosis. This was caused by
inadequate accommodation facilities and sluggish surveillance. In view of this
high infection rate, we feel it worthwhile to briefly summarize the transmission
mode of tuberculosis and the preventive measures.
Infection Infection with tuberculosis occurs by means of aerogenic transmis-
sion. Droplet nuclei with a diameter of 1-5 µm can reach the lower airways after
inhalation. In the case of equal immunological resistance, the risk of actual
infection is directly proportional to the concentration of airway particles and
the duration of exposure. One out of every 25-30 patients with cavernous lung
tuberculosis is highly infectious.
Prior to World War II, before adequate tuberculostatics became available, good
coughing hygiene and ventilation were considered to be the most effective
means of preventing tuberculosis infection. Studies at sanatoria showed that it
took an average of 6 to 18 months for the staff to become infected. One study on
an outbreak of tuberculosis that might have been related with the air circulation
system within a building, showed that being inside the building for > 40 hours
per week was the largest only risk factor [2,3]. After adequate tuberculostatics
became available, less attention was paid to good coughing hygiene and ventila-
tion. However, the current threat of imported tubercle bacillus that is resistant
to medication has reawakened the need to prevent droplet infection. It is gener-
ally accepted that if bodily odours can be dispelled by the ventilation system,
then the ventilation is adequate. The degree to which aerogenic transmission
can be prevented by ventilation is limited. Natural ventilation varies with the
weather conditions, the construction of the building and the behaviour of the
people inside. Ventilation must be compatible with the work situation and be
regarded as acceptable by the users of the building. Many people suffer from
respiratory infections during the winter months. Coughing contributes to the
spread of bacteria and viruses through a building. Exogenic reinfection with
tuberculosis can lead to an active form of tuberculosis in persons who have suf-
fered from tuberculosis is the past. The risk is greater in the case of decreased
psychological or physical resistance [4].
It is certain that the poor ventilation in the Waal Harbour POC and the fact that
the asylum seekers were not screened for an infectious form of tuberculosis
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before being permitted to board the river cruisers led to an unnecessarily high
number of tuberculosis infections. In view of the risk of asylum seekers intro-
ducing resistant tuberculosis, conscious exposure of staff and fellow-residents
to potential patients with open tuberculosis is irresponsible. Moreover, it is a
spine-chilling thought that potentially infectious patients are able to “disap-
pear”. In the meantime, the MHS Nijmegen has alerted the Agency for the
Reception of Asylum Seekers, the Inspectorate of Health, the Royal Nether-
lands Tuberculosis Association and the municipality.
Prevention Based on the above-described experience, the MHS gave the follow-
ing advice to the Agency for the Reception of Asylum Seekers:
- Accommodation facilities of limited size with poor ventilation and little day-
light can only be used for asylum seekers in whom active pulmonary tuberculo-
sis has been excluded. Obviously, it would be better never to use such facilities.
- Consideration must be given to whether a sanction policy should be intro-
duced for asylum seekers who ignore the first written call-up for compulsory
tuberculosis screening.
- Asylum seekers cannot be transferred to other shelter accommodation by the
Agency for the Reception of Asylum Seekers until it has been established that
they do not have open tuberculosis. This is necessary to prevent infections at
multiple shelters.
- To promote treatment compliance, it is important for asylum seekers who are
taking tuberculostatics to remain at the same shelter for the total duration of
treatment. In this way, the patient can be monitored by one and the same MHS.
- Isolation facilities should be available at shelters for asylum seekers.
- Personnel and volunteers who apply for work at shelters for asylum seekers
should be approached personally and/or provided with written information by
the Industrial Health Authority. Screening for tuberculosis directly after work
acceptance and every 6 months thereafter must be made compulsory.
Furthermore, the MHS emphasizes that tuberculosis in asylum seekers is a
major problem that requires serious attention.
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9 b . 1  a b s t r ac t
Background: in asylum seekers with open tuberculosis, contact tracing is
always performed by the Municipal Health Service (MHS). We investigated
whether any further patients had been registered after regular contact tracing
around an asylum seeker with open tuberculosis had closed.
Methods: data from the Fingerprinting Surveillance Project after regular con-
tact tracing had closed.
Results: there were four further contacts. They all had bacteriologically con-
firmed Mycobacterium tuberculosis, whose DNA fingerprint was identical to
that of the index patient and they all manifested active tuberculosis after regular
MHS contact tracing had closed. No further contacts with a bacteriologically
confirmed form of tuberculosis were found around these four new patients.
Conclusion: DNA fingerprinting contributed to tracing further patients after
regular contact tracing had closed.
9 b . 2  i n t roduc t ion
In the period 1993-1998, an average of 32986 asylum seekers per year entered
the Netherlands [1]. The annual percentage of people screened for tuberculosis
by means of a chest X-ray on entry varied from 90-98%. Pulmonary tuberculo-
sis was diagnosed in an average of 93 asylum seekers per year, a prevalence of
300 per 100,000; in 37 persons, the diagnosis was confirmed bacteriologically,
an average prevalence of 124 per 100,000 [1]. Since 1993, all M. tuberculosis cul-
tures have been sent to the National Institute of Public Health and the Environ-
ment (RIVM) for DNA fingerprinting [2]. A specific characteristic of the bac-
teria is revealed by DNA fingerprinting. This technique provides a routine
means of monitoring which tuberculosis patients in the Netherlands have been
infected with the same M. tuberculosis. This is of importance for source and con-
tact tracing. It has also led to new insights into the epidemiology of tuberculosis
in broader terms [2]. Patients with 100% identical DNA fingerprints belong to
one cluster [2].
This article presents an example from clinical practice.
Firstly, the results of the regular contact tracing performed in 1993/1994 by the
MHS are summarized [3].
In November 1993, an infectious form of pulmonary tuberculosis was diag-
nosed in an aspirant asylum seeker from Algeria who was staying at the Tem-
pory Shelter (POC) Waalhaven. Examination took place within the framework
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of the compulsory screening for tuberculosis, valid for asylum seekers after
entering the Netherlands. The ventilation facilities at the POC Waalhaven were
totally inadequate [3]. Contact tracing was performed by the MHS according to
the usual ring principle [4].
Contact tracing around the persons who belonged to the first ring of the asylum
seeker, revealed an infection rate of 60%. Therefore, it was decided to extend
the contact tracing to the second ring. The second ring comprised 110 other co-
tenants at the POC Waalhaven, all aspirant asylum seekers [3]. In the meantime,
these asylum seekers had been transferred to other shelters. With the coopera-
tion of 16 different MHSs, these persons could be approached personally. Spe-
cial care was taken to ensure their participation in the voluntary half-yearly fol-
low-up screening for tuberculosis during the first two years of their stay in the
Netherlands, as recommended for persons from countries with high rates of
endemic tuberculosis. The asylum seekers had received BCG vaccination in
their countries of origin, which made detection of a latent tuberculosis infec-
tion impossible with a Mantoux test. Screening for tuberculosis was only possi-
ble by means of a chest X-ray and on the basis of symptoms. After regular con-
tact tracing by the MHS had closed in February 1994, but before the first half-
yearly follow-up screening in May 1994, two asylum seekers (one from
Afghanistan and one from Bosnia) consulted a physician because of symptoms.
In contrast with the results of screening performed on entry to the Netherlands
in November 1993 and the results of contact tracing, active pulmonary tubercu-
losis was diagnosed in these two asylum seekers. Determination of the
mycobacterium by the RIVM revealed that both patients had tuberculous bac-
teria with normal sensitivity and 100% identical DNA fingerprints to the index
patient who came from Algeria and had been a co-tenant at the POC Waal-
haven in November 1993.
Below we discuss how with the aid of data from the DNA Fingerprinting
Surveillance Project over the period 1994 to January 2001, patients were identi-
fied with bacteriologically proven tuberculosis, whose M. tuberculosis had an
identical DNA fingerprint to that of the index patient.
9 b . 3  m e t hod s
DNA typing of the M. tuberculosis was performed by means of the Restriction
Fragment Length Polymorphism (RFLP) technique. Different M. tuberculosis
stems contain a varying number of IS6110 insertion elements. In addition, there
is wide variation in the position in the genome of the bacteria where the ele-
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ments are inserted. During RFLP typing, DNA fragments are identified that
contain IS6110 DNA.
In order to establish whether patients with an identical M. tuberculosis (100%
identical DNA fingerprints) had indeed been in contact with each other, a nurse
from the Royal Netherlands Tuberculosis Association (KNCV) contacted a 
TB nurse at the MHS where the patients with 100% identical DNA fingerprints
had been found, in the framework of the DNA Fingerprinting Surveillance Pro-
ject [5].
In order to make an epidemiological link, consultation took place between the
TB nurse from the MHS and the individual patients, while observing the priva-
cy regulations.
9 b . 4  r e s u lt s
The asylum seeker from Algeria who was diagnosed with an infectious form of
pulmonary tuberculosis in November 1993 during his stay at the POC Waal-
haven, belonged to a cluster of 14 persons whose M. tuberculosis DNA finger-
prints were identical. Within this cluster, three groups of patients could be dis-
tinguished, containing five, three and six persons each. No epidemiological
links could be established between the three different groups, or between the
six patients in group 3, which makes cross-contamination unlikely. Below, we
briefly discuss the countries of origin and the possibility of cross-contamina-
tion in the countries of origin or in the Netherlands of the different persons in
this cluster.
Group 1 of the cluster comprised five persons: the asylum seeker from Algeria
who was diagnosed with an infectious form of pulmonary tuberculosis at the
POC Waalhaven and four asylum seekers from Afghanistan (n=1), Bosnia (n=1)
and Somalia (n=2). The latter four asylum seekers were staying at the POC
Waalhaven in November 1993 and belonged to the second ring of the patient
from Algeria. In these four asylum seekers, there were no signs of active tuber-
culosis in November 1993 or in February 1994. After the regular contact tracing
had closed, an infectious form of pulmonary tuberculosis was diagnosed in
three of them after they had contacted a physician of their own accord, because
of symptoms; this occurred in March 1994, April 1994 and September 1996,
respectively. In the remaining asylum seeker, infectious tuberculosis was diag-
nosed in April 1994 during the recommended half-yearly screening programme
for tuberculosis that applies to asylum seekers and immigrants during their first
two years in the Netherlands [6]. Screening was performed by means of a chest
X-ray.
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In group 2 of the cluster, three patients had been in contact with each other: two
were members of a family from Somalia and the remaining person was a Dutch
nurse. The link between the nurse and her index patient (from Somalia) was
made after it became known that the DNA fingerprints were identical; this was
later confirmed by anamnesis.
Group 3 of the cluster comprised six patients who had not shared accommoda-
tion or shelter facilities. They indicated that they had never met any of the other
persons in the group or any of the other 8 patients in the cluster with an identical
DNA fingerprint. One came from Algeria, 2 from Iran, 1 from the Netherlands,
1 from Somalia and 1 from Syria.
9 b . 5  di s c u s s ion
In the Netherlands, the IS6110 RFLP patterns of M. tuberculosis stems are
extremely polymorphic. An identical fingerprint does not form indisputable
evidence that contact has taken place between patients in the same cluster,
because there can be a non-identified index patient or an external source. The
finding of identical DNA fingerprints in immigrants means that the patients
must have had a common source in the Netherlands or in their country of ori-
gin, or that they infected each other in their country of origin or in the Nether-
lands.
Regular contact tracing by the MHS is conducted according to the ring princi-
ple [4]. If infections are found, for example, in co-tenants, i.e. the first ring, then
contact tracing is extended to the next ring and so on until no more cases of
infection are found.
On the basis of contact tracing by TB nurses from MHSs ( period 1997-1999),
an epidemiological link was suspected in 22% of the patients in the same
clusters. Using unpublished data from the DNA Fingerprinting Surveillance
Project (M. πebek) over the period 1997-1999 on 1673 patients, a definite epi-
demiological link was made in 26% of the patients and a suspected link in 21%
with the aid of the RFLP technique and supplementary anamnesis. Therefore
RFLP typing contributed to demonstrating links that were not found by means
of regular contact tracing.
These findings support the results of the present study. None of the four con-
tacts with the index patient at the POC Waalhaven were detected by means of
regular contact tracing in February 1994. Three out of these four patients con-
sulted a physical because of symptoms. Patients who might have been exposed
to infection and have therefore been invited for contact tracing belong to risk
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groups for tuberculosis. In persons known to have a positive Mantoux test and
in persons who have received a BCG vaccination in the past, it is no longer pos-
sible to make a diagnosis of latent tuberculosis by means of a Mantoux test. A
Mantoux test can also give a false-negative result. Three out of the four contacts
became ill within two years of infection. This rate agrees with data in the litera-
ture. Although the incubation period for tuberculosis is lifelong, the majority of
patients manifest active tuberculosis within two years of infection [7]. Endeav-
ouring to achieve optimal compliance with the voluntary half-yearly screening
for tuberculosis by means of a chest X-ray during the first two years of an asy-
lum seeker’s stay in the Netherlands is therefore extremely desirable [6]: on the
one hand because the risk of developing active tuberculosis is greatest in the
first two to five years after immigration and on the other hand because it is pos-
sible for a person to become infected while staying at a shelter for asylum seek-
ers [8]. The risk of infection is greatest when the ventilation facilities at a shelter
are deficient and a (too) large group of people who have not been screened for
tuberculosis are sharing such accommodation. Regular contact tracing every
three months after the last contact cannot always be performed, because it is
common practice for asylum seekers to be transferred from one shelter to
another.
9 b . 6  s u m m a ry  a n d  c onc l u s ion
On the basis of 100% identical DNA fingerprints and anamnestic findings, it is
very likely that one patient caused bacteriologically proven active tuberculosis
in four other persons. At the time of regular contact tracing, none of these four
asylum seekers had any signs of active tuberculosis. Three out of these four per-
sons became ill within two years of infection and one became ill within three
years. Three out of the four patients were detected as a result of symptoms and
one was detected by screening. No further patients with a bacteriologically
proven form of tuberculosis were found around these four new patients. DNA
fingerprinting contributed to making links that were not made using regular
contact tracing.
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1 0 . 1  c onc l u s ion s  a n d  di s c u s s ion
A 6 months treatment of tuberculosis in which isoniazid, rifampicin and pyraz-
inamide are administered during the first two months, followed by 4 months on
isoniazid and rifampicin, suffices irrespective of the organ in which the disease
is most active. M.tuberculosis has to be normally sensitive in this case, i.e. it
should not be a resistant bacterium.
After 6 months the patient is cured, and the chance of relapse is less than 3.3%.
This is the most important conclusion to be drawn from this study of the litera-
ture, which systematically charts the results of a 6 months treatment of non-
immunocompromised patients primarily diagnosed with lung-, cervical lymph
node-, meningitis-,  bone- or kidney tuberculosis.
These findings do not imply that the duration of treatment cannot be shortened
still further. Some knowledge of the history is needed to understand why the
effectiveness of therapy plans shorter than 6 months has not been considered
here. Tuberculosis is a severe infectious disease, which may be contagious. The
condition may be contracted unwillingly and unwittingly. Even before
chemotherapeutics became available after World War II, the number of patients
in the Netherlands decreased as a result of better food and housing. The tuber-
culostatics that became available in the period 1940-1945 turned ambulatory
treatment into an option to replace (several) year’s hospitalisation in a sanatori-
um. Since treatment with a single remedy soon led to resistance, and short-term
treatment led to an unacceptably high relapse percentage, patient compliance
was stressed for protracted ambulatory treatment. Depending on the availabili-
ty and right combination of tuberculostatics, therapy duration could be reduced
from 18-24 to 9 months. As a result of this, and of the effective network of
Dutch organisations fighting tuberculosis, the number of patients with tuber-
culosis in the Netherlands has decreased annually, ranking the Netherlands
among the countries with the lowest incidence of tuberculosis and a low level 
of resistance. This result, together with the lack of a truly effective remedy,
explains why in the early 90s in the Netherlands, research was limited to the
effectiveness of a 6 months treatment. The treatment duration is arbitrary.
What relapse percentage is still acceptable is debateable. Treatment with 
isoniazid, rifampicin, pyrazinamide and streptomycin for 4.5-5 months, of
patients with tuberculosis of the lungs (M.tuberculosis, normal sensitivity)
resulted in a 4% relapse (95% C.I. 3-6), 4 months therapy in a 12% relapse 
(95% C.I. 9-16) and 3 months therapy in a 16% relapse (95% C.I. 12-20) [1,2].
This actually means that 80% of the patients were cured within 3 months. After
3 months of successful therapy, it is impossible to determine which of the
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patients should receive continued treatment up to a total treatment duration of
6 months [1].
At present, the increasing migration is the determining factor for the number of
tuberculosis patients in the Netherlands. Worldwide the increase of tuberculo-
sis is related to the population growth and the high incidence of HIV in areas
highly endemic to tuberculosis. For the Dutch situation, in which more than
half of the tuberculosis patients are foreigners, this means that screening for
tuberculosis should take place as soon as possible after entry. The risk of impor-
tation resistance is realistic with persons from countries that had no adequate
tuberculosis programmes. The reception of these persons should be such that
spreading of the disease is prevented and intensive therapy monitoring is safe-
guarded, especially during the first 2-3 months of treatment. Concentration of
patients and concentration of tuberculosis experts is necessary if sufficient
experience is to be gained in the Netherlands. Only a combination of research
results from areas that are highly endemic to tuberculosis with sufficient in-
country clinical experience will promote a correct interpretation of the guide-
lines regarding treatment. 
There is no longer any space for guidelines specific to the Dutch endemic form
of tuberculosis, e.g. a low incidence of tuberculosis and no resistance. This is a
challenge for the future.
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1 0 . 2  i n t roduc t ion
From 1978, international research has shown that a 6 months treatment of lung
tuberculosis will suffice on condition that medication is taken faithfully [3]. In
the late 80s, based on studies of patients with lung tuberculosis (normal sensi-
tive M.tuberculosis) both the American Thoracic Society (ATS) and the British
Thoracic Society (BTS) advised a 6 months treatment [4,5]. The common
treatment duration in the Netherlands was 9 months. Possible missed doses of
tuberculostatics in the first 6 months were to be compensated by the longer
therapy, so that the number of patients with relapse caused by non-compliance
would be low. Particularly in the Netherlands, where the 44 well-functioning
tuberculosis units of the Municipal Health Service (MHS) safeguard proper
care for tuberculosis patients, shorter treatment duration of tuberculosis
should be possible. The shorter the treatment, the bigger the chance that
patients would comply fully with the therapy.
The immediate cause for the study into the treatment duration of tuberculosis
was the difference between the treatment duration of lung tuberculosis in the
Netherlands and in other countries [4,5]. In view of the good treatment results
of tuberculosis in the Netherlands there was an unwillingness to simply adopt
the advice of the ATS and BTS. A systematic survey of the clinical trials about
the treatment duration of tuberculosis might provide basis for therapy advice
[6]. Not only for lung tuberculosis, but also for the extra-pulmonary forms of
tuberculosis, a need for such a systematic survey of clinical trials was felt. An
organ specialist may be called for in the case of extra-pulmonary forms like
bone- and kidney tuberculosis. Beside the obligatory medicinal treatment, sur-
gical intervention may be necessary.
The diagnosis for extra-pulmonary tuberculosis is harder to prove bacteriologi-
cally, moreover, the effect of the therapy is more difficult to evaluate bacterio-
logically. In addition to this, extra-pulmonary forms of tuberculosis occur far
less often than lung tuberculosis, so that there is less clinical experience as well.
In 1992, at the start of the study of the literature about the treatment duration of
tuberculosis, the aims were: 1) to develop guidelines about treatment duration,
based on reliable scientific publications. 2) to contribute to the implementation
of these guidelines, which should also be used in practice by the doctors that
treat tuberculosis patients. 3) to evaluate progress as regards the implementa-
tion of the guidelines. This might take place on the basis of the data in the
Netherlands Tuberculosis Register (NTR).
In this chapter, a description will be given of the way in which, at the start and
during the study of the literature about the treatment duration of tuberculosis,
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based on literature and practical experience, consideration was given to any fac-
tors that could possibly play a part in the implementation of the guidelines
resulting from this research [7-10].
1 0 . 3  prof e s s iona l s ,  org a n i sat ion s  
a n d  pat i e n t  g rou p s  i n volv e d
Professionals involved
The annual number of patients with tuberculosis varies, from 1192 in 1987 to
1811 in 1994 [11]. In the period 1993-1998, 6511 patients in the Netherlands were
registered as having been diagnosed with lung tuberculosis. In 37% of these
cases, the diagnosis was made by a tuberculosis doctor working for the MHS.
There are 35 such doctors, which amounts to 11.3 patients a year per MHS doc-
tor. Most patients go to a clinical lung specialist with their symptoms; there are
344 of such specialists in the Netherlands, who diagnosed 53% of the patients
with lung tuberculosis. On average, therefore, a clinical lung specialist treats 1.7
tuberculosis patients a year. For 6% of the patients the diagnosis was made by
an internist-infectiologist. There are 40 such doctors in the Netherlands, which
amounts to 1.6 patients with lung tuberculosis each a year. Other specialists
made the diagnosis lung tuberculosis for 3% of the other patients; of the remain-
ing 1% this was unknown (data NTR/KNCV 2000).
Organisations involved
The tuberculosis doctors working for the MHS are lung specialists or medical
officers. All tuberculosis doctors working for the MHS are members of the
National Tuberculosis Policy Committee (CPT). This Committee is part of the
KNCV. The KNCV was founded as a private initiative in 1903 and has devel-
oped into an international organisation, partly because of its successful pro-
grammes to combat tuberculosis. This organisation wants to organise the fight
against tuberculosis taken up by the MHS as a coherent national programme; in
order to achieve this, it functions as a data bank and coordination centre. The
KNCV safeguards and supports the national consensus consultation inside the
CPT. Not only the doctors working at the tuberculosis units of the MHS are
members of this Committee, but also a representative of the nurses that work at
these tuberculosis units, as well as a representative of the clinical lung special-
ists (nominated by the Nederlandse Vereniging van Artsen voor Longziekten en
Tuberculose, NVALT), the clinical consultant for tuberculosis (a clinical lung
specialist appointed by the KNCV), a representative of the National Institute of
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Public Health and the Environment (RIVM) and a representative of the Inspec-
tie voor de Gezondheidszorg van het Staatstoezicht op de Volksgezondheid
(IGZ). Topics regarding both prevention and cure are discussed in the CPT.
Apart from its representative in the CPT, the NVALT has its own tuberculosis
committee, whose members include members of the CPT. In this way, an effort
is made to reach consensus about therapy policy between the tuberculosis doc-
tors working for the MHS and the clinical lung specialists.
Patient groups involved
The population of tuberculosis patients in the Netherlands has changed gradu-
ally. From 1992, more than half of the patients have come from abroad. These
tuberculosis patients are migrants and asylum seekers. Patients who reside ille-
gally in the Netherlands, as well as uninsured homeless people, are treated by
the MHS. The language barrier and the different socio-cultural backgrounds
may have their influence on the therapy compliance of these patients. More-
over, asylum seekers frequently move during treatment, which means that they
encounter several different doctors for treatment. This makes it difficult to pro-
vide optimum care, the more so if the therapy advice is not unequivocal. Thera-
py mistakes may induce resistance. A normally sensitive M.tuberculosis is easy to
treat, but the treatment of resistant strains is more complex. Also in patients
who have contracted HIV and tuberculosis at the same time, the treatment of
tuberculosis, but also of HIV, is more difficult.
The risk of importation of resistance is realistic with persons from countries
that have no adequate tuberculosis programmes. Simultaneous infection with
HIV and tuberculosis is seen particularly in persons from countries where
tuberculosis occurs frequently. In the Netherlands, the more complex tubercu-
losis problems clearly occur in the patient groups that are hard to reach.
1 0 . 4  c u r r e n t  pr ac t ic e  a n d  prof e s s iona l  
c o n duc t
In the Netherlands, there is an obligation to notify the authorities of any case of
tuberculosis [12]. The hospital laboratories and/or the clinical doctors contact
the MHS as soon as there is proof of the diagnosis tuberculosis or as soon as
symptoms and radiological findings seem to indicate tuberculosis and treat-
ment is started. The MHS passes such reports on to the IGZ. In addition to this,
the MHS records the tuberculosis data for each patient as part of the NTR [11].
This register is administered by the KNCV. After a tuberculosis patient is regis-
i m pl e m e n tat ion 155
tered, the MHS will do any source- and contact studies necessary, and in con-
sultation with the doctor the patient will be monitored to safeguard therapy
compliance. The diagnosis tuberculosis may also be made at the MHS unit,
after which treatment will take place from there. In this way, the tuberculosis
doctors of the MHS have an overview of all the patients with tuberculosis in
their working area. Since they are in such close contact with the NTR, they can
follow the epidemiological development of the tuberculosis [11]. The tuberculo-
sis doctors of the MHS are specialised in the treatment and monitoring of
patients with tuberculosis. Unlike that of the individual clinical lung specialist
or internist-infectiologist, this is their principal task. 
1 0 . 5  fac t or s  i m p e di ng  a n d  promo t i ng  c h a ng e
Impediments to the implementation of new treatment guidelines
In view of the very limited numbers of tuberculosis patients in the Netherlands,
it is hard for the individual doctor to gain sufficient experience with tuberculo-
sis. This makes it impossible to experience the necessity and advantage of
change first-hand. Chances are that treatment remains based on familiar but
outdated knowledge. As a result of the decreasing number of tuberculosis
patients after World War II, the lung specialist working in the hospitals stood
out less clearly as tuberculosis specialists. It became less natural for doctors to
be knowledgeable about the organisation of the fight against tuberculosis in the
Netherlands, about the methods of the KNCV and the operating procedures in
the tuberculosis units of the MHS.
If it is impossible to gain experience first-hand, proposals for change will have
to be made by persons or organisations well known and well trusted [9,10]. The
initiative to issue guidelines for the treatment of tuberculosis on the basis of a
systematic study of clinical trials was initiated by the CPT, a committee not well
known by the clinicians. The CPT has taken into account the fact that founda-
tions that underlie a proposition for change have to be transparent; the advan-
tages must be visible.
Favourable factors for the implementation of the advice to shorten the treatment
duration of lung tuberculosis by 3 months
In the same period that the research into the treatment duration in the Nether-
lands took place, worldwide an increase of tuberculosis was seen in patients
with simultaneous infections of HIV and M.tuberculosis. In addition to this, in
countries without adequate tuberculosis programmes M.tuberculosis turned out
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to have become resistant to the commonly used tuberculostatics. In the Nether-
lands, the number of patients with tuberculosis increased as a result of migra-
tion of persons from areas highly endemic to tuberculosis. This meant that the
importation of resistant tuberculosis strains into the Netherlands became a
realistic risk. In the same period that the study into the optimum treatment
duration of lung tuberculosis was finished, the committee “Multiresistente
Tuberculose” (Lambrechts-van Weezenbeek CSB) [13] issued a report entitled
“Richtlijnen met betrekking tot de behandeling en preventie van multi-
resistente tuberculose in Nederland”. Instead of starting treatment with the 3
medicines commonly used up to that point, if resistance was suspected treat-
ment would have to begin with four types of medication.
In the Netherlands, much more attention was bestowed on the report about
multi-resistant tuberculosis than on the results of the study into shorter treat-
ment duration [13,14]. The chance of infection with a multi-resistant strain of
M.tuberculosis in hospitals led to discussions inside these hospitals. The medical
microbiologist in a hospital is often in charge of the department for hygiene and
infection prevention. Besides the lung specialists and the internist-infectiolo-
gists, he is involved in the tuberculosis policy of the hospital. The influx of asy-
lum seekers grew rapidly and their inadequate reception led to heated political
discussion, in which the risk of importation of tuberculosis was pointed out
[15].
Tuberculosis occurs early in the course of an HIV infection. Patients with HIV
infections come to the surgery of the internist-infectiologist. The latter treats
AIDS patients with tuberculosis. Interaction of anti-retroviral therapy with
tuberculostatics complicates the treatment of even a normally sensitive
M.tuberculosis, so that internist-infectiologists and lung specialist will need to
know about the treatment of tuberculosis.
In spite of the small numbers of patients, the combination of AIDS and tuber-
culosis, the threat of multi- resistance and the attention paid by the media to the
issue of tuberculosis in asylum seekers and the interest in HIV in general, have
put tuberculosis back on the lung specialist’s agenda.
Who wanted shorter treatment and for whom was this relevant?
The need to change the treatment duration of tuberculosis was increasingly felt
in the Netherlands by the tuberculosis doctors working for the MHS, though
not by clinical specialists. If, on the basis of research, a decision was to be taken
to shorten the duration of treatment with three months also in the Netherlands,
this would facilitate monitoring of the tuberculosis patients, decrease the
chance of side effects, increase patient compliance, and be cheaper as well.
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Clearly, establishing a new treatment protocol, supported by tuberculosis spe-
cialists working for the MHS and clinical specialists alike, was of the highest
priority.
1 0 . 6  t h e  way  t h e  k nc v  h a s  dr aw n  t h e  at t e n t ion
of  t h e  t r e at m e n t  prov i de r s  f or  t h e
r e s u lt s  of  t h e  s t u dy  i n t o  t h e  op t i m u m
t r e at m e n t  du r at ion  of  t u be rc u l o s i s
All during the study, the issue at stake was brought to the attention of clinical
specialists at local and national referee evenings. In this way, both the topic and
the methods were elucidated. Most studies about treatment duration were done
on patients with lung tuberculosis, the most common form of tuberculosis. The
diagnosis for this has been bacteriologically proven more often than with extra-
pulmonary forms of tuberculosis. This means that, due to sufficiently large
numbers of patients with bacteriologically proven lung tuberculosis, convinc-
ing statements could be made. The systematic reviews of the treatment of the
extra-pulmonary forms of tuberculosis did not clarify why a 6 months therapy
was effective, but did show that a 6 months therapy was certainly no worse than
a longer therapy. The result of the first study was that the treatment of lung
tuberculosis (normal sensitive M.tuberculosis) could be shortened by three
months [14].
The results of the first literature study about shorter treatment duration of lung
tuberculosis and the report about multi-resistant tuberculosis prompted the
CPT to set up the study group “Therapiebeleid” [13,14]. This study group was
assigned to advise on the treatment of lung tuberculosis in the Netherlands: in
short, a guideline for the treatment of lung tuberculosis.
A conscious effort was made to include in this study group representatives of
the MHS as well as clinical chest-physicians and internist-infectiologists. The
concept advice, i.e. to start with 4 types of medication if resistance was suspect-
ed, and to treat for 6 instead of 9 months in case of a normally sensitive M.tuber-
culosis, was discussed both within the CPT (June 1995) and at an open meeting
of the tuberculosis study group (the later committee) of the NVALT. After the
treatment advice of the CPT had been established (November 1995) it was pub-
lished as a report of the KNCV  [16]. Distribution took place from the KNCV
among all the tuberculosis doctors and lung specialists in the Netherlands
(February 1996).
In close consultation with the NVALT, the KNCV decided to pay extensive
c h a p t e r  1 0158
attention to the new treatment advice in the Nederlands Tijdschift voor
Geneeskunde [17,3,18,19]. Subsequently, the new therapy policy was consis-
tently brought to the attention of the specialists [20,21].
1 0 . 7  i m pl e m e n tat ion  of  s hort e r  t r e at m e n t
du r at ion
Evaluation of the implementation of the advice of the study group Thera-
piebeleid has now taken place (inspection study results; data are being pub-
lished, J.Veen, KNCV. Data from the NTR show that as early as June 1995,
patients with bacteriologically proven tuberculosis, normally sensitive M.tuber-
culosis, were treated for 6 instead of 9 months by the tuberculosis doctors; from
the beginning of 1997 also by the clinical lung specialists (data J. Veen). The
advice about shorter treatment duration for the extra-pulmonary forms of
tuberculosis was issued only recently; evaluation based on data from the NTR
is not yet possible, therefore.
1 0 . 8  p o s s i bl e  f u t u r e  i m pl e m e n tat ion  s t r at e gi e s  
Establishing the safety and effectivity of a specific treatment is a necessary step.
Establishing guidelines and protocols is the next step. After these steps, the
actual implementation process takes place. Tuberculosis is an issue several dis-
ciplines are confronted, but have little to do with. This sets clear limits to the
amount of time they can devote to this issue. A questionnaire in which clinical
lung specialists were asked about their involvement with tuberculosis revealed
that their interest in tuberculosis is considerable [22]. The Kwaliteitswet Zor-
ginstellingen makes specific demands of responsible medical conduct [23]. The
treatment advice a patient gets should not depend on the doctor he consults
[23]. Guidelines help doctors to give the correct advice. If they want to divert
from the guidelines, they have to substantiate their reasons. During the general
meeting on 9 October 1998, within the NVALT a decision was made to set up a
Commissie Richtlijnen Longziekten (CRL). In 2001, the Tuberculosis Com-
mittee of the NVALT (the earlier tuberculosis study group of the NVALT)
decided to develop guidelines for tuberculosis policy. Clinical conduct based on
evidence, the treatment and the correct implementation of the guidelines are
topics for discussion [24,8,9,10]. It is to be expected that, apart from those
regarding the treatment of lung tuberculosis, guidelines will also be defined for
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the treatment of the extra-pulmonary forms of tuberculosis. The quality guide-
lines and the CRL should safeguard a qualitatively responsible tuberculosis pol-
icy in the future.
During the study into and the definition of the advice regarding the optimum
treatment duration of (lung) tuberculosis, the CPT and the KNCV have taken
into account the implementation, and the realisation that the target group of
tuberculosis doctors of the MHS would have to be approached in a different
manner from the target group of clinical specialists. Refresher courses, written
information and involvement of the target groups in developing the advice and
guidelines were emphasised. The lung specialists, for their part, structurally put
the topic tuberculosis on the agenda of the NVALT meetings. The involvement
with tuberculosis of clinical lung specialists was increased during the study,
since the HIV- and tuberculosis resistance problems that result from the grow-
ing migration of people from countries with a high incidence of tuberculosis
have turned tuberculosis into a problem inside the Dutch hospitals as well. This
factor has contributed to making the implementation of the advice concerning
the treatment duration of lung tuberculosis possible.
Permanent refresher courses or an individual refresher course with reference to
a specific patient is an implementation strategy. On the other hand, tuberculo-
sis care should perhaps be concentrated more with specific specialists. The var-
ious parties involved see the problem from different perspectives, related to
their backgrounds and patient populations, which makes regional multi-disci-
plinary cooperation another issue that needs work. Since segments of the
patient population, such as migrants, asylum seekers and HIV-positive persons,
have specific characteristics, these will have to be taken into account in order to
optimalise therapy compliance.
In the Netherlands tuberculosis has become an import disease that is difficult
to treat. Its incidence may be expected to remain low, if the organisation of the
care for tuberculosis is adjusted. Sufficient own clinical experience is necessary
if every individual patient is to be treated optimally and in accordance with
guidelines. This pleads for transmural tuberculosis centres that provide inte-
grated care.
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Tuberculosis is an infectious disease caused by the Mycobacterium tuberculosis,
which can induce symptoms of the disease in all organs. Of all forms of tubercu-
losis, pulmonary tuberculosis is the most common form. It accounts for 70% of
all cases of tuberculosis. The pulmonary form is also the best known form of
tuberculosis, since patients can infect other people in the environment by
coughing. Treatment aims at patients to be cured as soon as possible without
having relapses of the disease later on. Chemotherapeutic treatment for tuber-
culosis was developed during the 1940s and 1950s: streptomycin (1941), PAS
(1948), isoniazid (1952), ethambutol (1961), rifampicin (1965) en pyrazinamide
(1978). In the fifties, pyrazinamide was applied in high doses, which led to unac-
ceptable side effects. Since 1978 therapeutically adequate doses have been
applied. It is not possible to eliminate all tubercle bacteria at once, i.e. in one
treatment. The reason for this is that tubercle bacteria in a patient with tubercu-
losis are present at various levels of metabolic activity. The duration of the treat-
ment does depend on the types of tuberculostatics that are used. A treatment
regimen of 9 months duration with isoniazid and rifampicin resulted in a
relapse rate of 1%. Soon after the use of pyrazinamide had been reintroduced in
1978, it became clear that the 9 months treatment including only isoniazid and
rifampicin could be shortened, if pyrazinamide was given in addition during the
first two months. Considering the working mechanism of the tuberculostatics,
administration of pyrazinamide can be stopped after two months, but the ques-
tion remains for how long administration of isoniazid en rifampicin should be
continued after those two months. A shorter therapy is obviously cheaper and
easier for the patient to go through with it. In the eighties several studies have
been performed on treatment regimens of 6 months or even shorter, in coun-
tries where tuberculosis is endemic. At that time AIDS and resistance to antibi-
otics were no issues yet. Most studies were performed on patients with pul-
monary tuberculosis. Based on the results of these studies, a treatment duration
of 6 months for patients with pulmonary tuberculosis was recommended inter-
nationally at the end of the eighties. For extrapulmonary forms of tuberculosis a
longer duration of the treatment used to be advised, due to the fact that for these
forms less research data were available. In the Netherlands patients with pul-
monary tuberculosis continued to be treated with isoniazid en rifampicin for 9
months as before, while pyrazinamide was added to the medication during the
first two months. 
Since 1987 a worldwide increase in the number of patients with tuberculosis has
been observed. These patients with tuberculosis are mostly AIDS patients
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from countries where tuberculosis already was endemic. The increase in tuber-
culosis observed since 1987 in the Netherlands can be attributed to the increas-
ing influx of persons from countries where tuberculosis is endemic and highly
prevalent. In the Netherlands there are yearly about 1500 newly diagnosed
patients with tuberculosis. Social and cultural differences as well as increased
mobility especially of asylum seekers in the Netherlands hamper optimal super-
vision of the therapy. Therefore the question has arisen whether also in the
Netherlands the treatment duration should be shortened from 9 to 6 months. 
If the treating physicians at the Municipal Health Services and in hospitals
employ unambiguous and short treatment regimens, treatment compliance will
increase. The importance of treatment compliance with regard to the preven-
tion of resistance induction, combined with the fact that internationally a 
6 months treatment regimen had been employed for a long time already, led 
to the decision to perform a methodical study on the effectiveness of regimens
with a duration of 6 months or longer for the treatment of tuberculosis. Treat-
ment regimens had to include isoniazid, rifampicin and pyrazinamide. The
results of the methodical literature studies have been described in chapters 2,
3b, 4, 6 and 7. 
In all studies the same method was applied. A comprehensive literature search
was performed using the Medline database, collecting only studies published
after 1978 (when pyrazinamide was introduced). References were investigated.
Publications were selected and retrieved on the basis of the abstracts, without
any language restriction. Because a 9 months treatment regimen with isoniazid
and rifampicin was known to give good results, no comparative studies have
been performed internationally on the effectiveness of 9 months and 6 months
treatment regimens including isoniazid, rifampicin and pyrazinamide, for
patients with lung-, meningitis-, bone- and kidney tuberculosis. Only for
patients with cervical lymph node tuberculosis one study has been performed
in which treatment effectiveness was compared of 66 patients who had received
treatment during 6 months and 70 patients who had received treatment during
9 months. Since it appeared impossible to compare the effectiveness of 9 and 6
months treatments on the basis of randomised controlled studies we choose to
compare groups of patients who met some predetermined inclusion- and exclu-
sion criteria. With the help of a checklist we only included those studies in our
analysis in which patients data as well as therapy regimens and treatment results
had been described accurately. Only in those cases it was possible to make an
accurate description and comparison of the results for patient groups from dif-
ferent studies. This method is called a meta-analysis and it enables one to draw
conclusions just as if all studies were part of one big study. Most papers that
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could be included in the analysis were written in English. Only for one paper on
meningitis tuberculosis the authors have been contacted, because it was not
clearly understood from the paper on which grounds the authors had recom-
mended a treatment regimen of longer than 6 months. As a measure for treat-
ment effectiveness we determined the number of patients with tuberculosis
relapse during a follow-up period of at least 12 months after completion of a suc-
cessful treatment. The relapse rate as well as the 95% confidence interval has
been calculated. An absolute norm for the relapse rate has not been established.
Although children as well as adults were included in the studies, for pulmonary
and kidney tuberculosis only adults were involved. To the extent that it was test-
ed, no patients were found to be infected with HIV (human immunodeficiency
virus). For pulmonary and kidney tuberculosis, we were able to make a compar-
ison between groups of patients who all had bacteriologically confirmed diag-
noses, while treatment results were evaluated bacteriologically as well. For
patients with lymph node, meningitis and bone tuberculosis the diagnoses were
confirmed bacteriologically in 50%, 28% and 31% respectively. To the extent
that it was tested no resistant strains were found. When the diagnosis had not
been confirmed bacteriologically, it was made on the basis of histological, 
epidemiological, clinical, laboratory and radiological data. 
After a 6 months treatment, tuberculosis relapse occurred in 116/4833 (2.4%;
95% C.I. 2.0-2.8) of the patients with pulmonary tuberculosis, 13/422 (3.3%; 
95% C.I. 1.7-5.5) of the patients with cervical lymph node tuberculosis, 2/131
(1.5%; 95% C.I. 0.2-5.5) of the patients with meningitis tuberculosis, 0/56 (0%;
95% C.I. 0.0-6.4) of the patients with bone tuberculosis and 1/170 (0.6%; 
95% C.I. 0.0-3.2) of the patients with kidney tuberculosis. In the studies of
patients with pulmonary tuberculosis with a follow-up period of 18-36 months
after completion of the treatment, 75% of the relapses occurred in the first year
after completion of the treatment. Irrespective of the main diagnosis, no patient
group with a 6 months treatment regimen had lower treatment results than the
patient group with treatment regimens of longer than 6 months duration. In all
studies the importance of bacteriological confirmation was emphasized. After
having performed the final typing of the tubercle bacteria, the sensitivity for the
usual tuberculostatics can be tested. To the extent that those tests have been
performed for patients with tuberculosis relapses, a normal sensitivity of the
tubercle bacteria was found in all cases. Most studies have been performed in
countries where tuberculosis is endemic and highly prevalent, and where the
laboratory facilities are far from similar to those in the Netherlands. Neverthe-
less, in those countries it was of equally great importance for an adequate diag-
nosis to give tuberculosis a high ranking in the differential diagnosis. The
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occurrence of a granulomatous infection with caseous necrosis in a puncture or
biopsy always led to starting treatment with tuberculostatics. Postponing the
start of the treatment, pending the results of the bacterial cultures, can cause a
progression of the clinical picture and possibly irreversible damage to the
organs. Continuing the administration of tuberculostatics for a longer period
after a late start can never undo the sustained damage. For this reason the
importance of macroscopical and histological observations of the puncture or
biopsy, also valid for the situation in the Netherlands, has been pointed out in
chapter 3a. 
Medicinal treatment of tuberculosis is obligatory for all forms of the disease,
but serious remaining damage might make surgery necessary, especially in the
case of bone and kidney tuberculosis. This fact probably explains why in papers
on bone tuberculosis the emphasis is mainly put on technologies of surgical
interventions. Existing doubts about the tuberculostatics reaching the foci of
infection were reason for mapping the treatment results per organ. The same
doubts explain the fact that especially for meningitis tuberculosis higher doses
of medication were given than for other forms of tuberculosis.  The treatment
results of Dutch children with tuberculosis, as described in chapter 5, show that
isoniazid dosages of  4-8 mg/kg bodyweight are sufficient.  The results of the
studies give indeed no answer on the question why the treatment is effective,
however they do answer the question whether it is effective or not. 
The studies have been performed in countries with high tuberculosis preva-
lence. That means that there is a chance that after successful treatment a patient
is reinfected by the environment and thus develops active tuberculosis. This
disease will be erroneously classified as relapse tuberculosis, which means a
failure of previous treatment. DNA fingerprinting techniques, as described in
chapter 9b, can be used to determine whether a patient is reinfected with the
same or with different tubercle bacteria. By this method a tuberculosis relapse
caused by endogenous reactivation can be distinguished from one caused by
exogenous reinfection. In addition, these techniques can help to gain an insight
into the import and distribution of tubercle bacteria in the Netherlands. This
appeared not only to be an indicator for the quality of treatment effectiveness
for patients with tuberculosis, it could also reveal relations between patients
that had not been found by traditional source and contact tracing made by the
Municipal Health Service. Conventional source and contact tracing has been
described in chapter 9a. This study concentrated on one asylum seeker who had
been diagnosed to have pulmonary tuberculosis as he entered the country. The
absolutely inadequate reception of a group of asylum seekers, including this
patient, in poorly ventilated rooms led to the infection of some fellow asylum
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seekers and some Dutch social workers. This reception policy is irresponsible,
even more considering the present chances on the import of resistant tubercle
bacteria. 
Apart from the patient’s own interest, in tuberculosis there is also the general
interest of public health. Therefore in the Netherlands tuberculosis is a notifi-
able disease. Every case of tuberculosis has to be reported to the Municipal
Health Service (GGD) that will then start source and contact tracing. In addi-
tion, the patient gets support from the GGD during the treatment period. In the
analysed studies on treatment results of patients with tuberculosis, medication
was generally given without close supervision. However, patients were thor-
oughly informed and monitored. 
In chapter 8 it is described how a comparison of data from the Netherlands
Tuberculosis Register (NTR) and data from the Dutch Drug Information Pro-
ject (GIP) of the Health Care Insurance Board (CVZ) showed that a close corre-
lation exists between the number of days of pyrazinamide use as registered in
the NTR and the daily dosage of pyrazinamide supplied on prescription by
Dutch pharmacies. On the basis of this close correlation it was concluded that
in the Netherlands patients with tuberculosis are indeed reported and thus
known to the Municipal Health Services. That means that consultations
between physicians working in hospital and physicians and TB nurses from the
Municipal Health Services do take place. In chapter 10 the factors are described
that possibly played a part in the implemention of the recommendation to
shorten the treatment duration of pulmonary tuberculosis with three months.
Also general factors, that are always coming into a process of change, were play-
ing a part in here as well. Those factors include the scale of the problem, the
unfamiliarity with the matter, the lack of belief in the necessity as well as the fact
that tuberculosis treating physicians and nurses are members of various differ-
ent organisations, as there are the Municipal Health Service (GGD), the Royal
Netherlands Tuberculosis Association (KNCV) and the hospitals. It can be
foreseen that, when people gain insight into these aspects and into the grounds
on which the treatment recommendation has been established, also given the
current legal quality standards for treating physicians, the implementation of
the treatment recommendation for extrapulmonary forms of tuberculosis will
soon be established.
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Tuberculose is een infectieziekte veroorzaakt door de Mycobacterium tubercu-
losis, die vanuit alle organen ziekteverschijnselen kan geven. Van alle vormen
van tuberculose komt longtuberculose het meeste voor. Bij 70% van de patiën-
ten met tuberculose is er sprake van longtuberculose. Longtuberculose is
tevens de meest bekende vorm, omdat de patiënt door hoesten besmettelijk kan
zijn voor zijn omgeving. Het doel van de behandeling is dat de patiënt geneest in
de kortst mogelijke tijd en dat de ziekte later niet recidiveert. De chemothera-
peutische behandeling van tuberculose ontwikkelde zich in de periode 1940-
1950: streptomycine (1941), PAS (1948), isoniazide (1952), ethambutol (1961),
rifampicine (1965) en pyrazinamide (1978). Pyrazinamide werd in de jaren vijf-
tig toegepast in hoge dosering. Dit leidde tot onacceptabele bijwerkingen.
Sedert 1978 vond toepassing plaats in therapeutisch adequate dosering. Er
bestaat niet één behandeling, die alle tuberkelbacteriën gelijktijdig kan oprui-
men, omdat de tuberkelbacteriën in een tuberculosepatiënt zich op wisselende
niveaus van metabole activiteit bevinden. De duur van de behandeling hangt
wel samen met de soort tuberculostatica die men gebruikt. Een 9 maanden
durende behandeling met isoniazide en rifampicine gaf een recidiefpercentage
van 1%. Na de herintroductie van pyrazinamide in 1978 werd al snel duidelijk dat
de 9 maanden durende behandeling met alleen isoniazide en rifampicine ver-
kort kon worden, mits men pyrazinamide gedurende de eerste 2 maanden er bij
gaf. Gezien het werkingsmechanisme van de tuberculostatica kan pyrazinami-
de na 2 maanden gestopt worden, maar de vraag is hoelang vervolgens isoniazi-
de en rifampicine gecontinueerd moeten worden. Een kortere therapie is goed-
koper en bovendien beter vol te houden voor de patiënt. In de tachtiger jaren
zijn er studies gedaan in landen waar tuberculose endemisch is naar 6 maanden
en zelfs korter durende therapieschema’s. De AIDS-en resistentieproblematiek
speelde toen nog niet. De meeste studies zijn gedaan bij patiënten met longtu-
berculose. Op basis van deze studies werd eind jaren 80 internationaal geadvi-
seerd om patiënten met longtuberculose 6 maanden te behandelen. Voor de
extrapulmonale vormen werd vaak nog een langere behandelduur geadviseerd
omdat hierover minder onderzoekgegevens beschikbaar waren. In Nederland
bleef men patiënten met longtuberculose gewoon 9 maanden behandelen met
isoniazide en rifampicine. Aan deze medicatie werd pyrazinamide gedurende
de eerste twee maanden toegevoegd.
Na 1987 werd er wereldwijd een toename gezien van het aantal tuberculosepa-
tiënten, waarbij tuberculose met name gezien werd bij AIDS-patiënten, in lan-
den waar tuberculose al endemisch was. De toename van tuberculose, die in
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Nederland gezien werd na 1987 hing rechtstreeks samen met de migratie van
personen afkomstig uit voor tuberculose hoogendemische gebieden. In Neder-
land zijn er jaarlijks ongeveer 1500 nieuw gediagnosticeerde patiënten met
tuberculose. De sociaal-culturele verschillen en de grote mobiliteit van met
name asielzoekers in Nederland maakt optimale therapiebewaking moeilijk.
Op dat moment rees de vraag of ook in Nederland niet overgegaan moest wor-
den op een 6 maanden durende behandeling. Een eenduidig therapiebeleid
onder behandelaars op de GGD-en en in de kliniek alsmede een korte therapie
zou de kans op therapietrouw vergroten. Het belang van de therapietrouw om
resistentie vorming te voorkómen alsmede het feit dat men internationaal al
lang 6 maanden behandelde  hebben er toe geleid dat besloten is tot een syste-
matisch onderzoek naar de resultaten van een 6 maanden of langer durende
behandeling van patiënten met tuberculose, waarbij het behandelschema iso-
niazide, rifampicine en pyrazinamide moest bevatten. De resultaten van de sys-
tematische literatuurstudies worden beschreven in hoofdstuk 2, 3b, 4, 6 en 7.
Steeds is dezelfde werkwijze gevolgd. Een uitvoerige literatuursearch werd
gedaan via Medline database, waarbij publicaties verschenen na 1978 (introduc-
tie van pyrazinamide) in beschouwing werden genomen. Referenties werden
nagetrokken. Er was geen restrictie met betrekking tot de taal en op basis van de
abstracts zijn artikelen opgevraagd. Omdat een 9 maanden durende behande-
ling met isoniazide en rifampicine goede behandelresultaten gaf zijn er inter-
nationaal geen vergelijkende studies gedaan naar de behandeling van 9 maan-
den en 6 maanden met isoniazide, rifampicine en pyrazinamide bij patiënten
met long-, meningitis-, bot-en niertuberculose. Alleen bij patiënten met lymp-
hadenitis tuberculose werden in één studie de behandelresultaten  met elkaar
vergeleken van 66 patiënten, die  6 maanden werden behandeld en 70 patiënten,
die 9 maanden werden behandeld. Doordat vergelijk van behandelresultaten
van 9 en 6 maanden niet mogelijk was op basis van  gerandomiseerde gecon-
troleerde studies is gekozen voor vergelijk van patiëntengroepen, die voldeden
aan vooraf opgestelde inclusie –en exclusiecriteria. Het hanteren van een
checklist heeft er toe geleid, dat alleen die studies voor analyse in aanmerking
zijn gekomen, waarin op zorgvuldige wijze de patiëntenkarakteristieken zijn
beschreven alsmede het therapieschema en de behandelresultaten. Een be-
schrijving en vergelijking van de uitkomsten van de onderzochte patiëntengroe-
pen uit de verschillende studies waren hierdoor mogelijk. Dit noemt men een
meta-analyse. Conclusies konden hierdoor getrokken worden als waren alle
studies onderdeel van één groot onderzoek. De meeste artikelen, die voor
analyse in aanmerking kwamen waren Engelstalig. Alleen voor meningitis
tuberculosa zijn de auteurs aangeschreven. Dit is gedaan omdat niet duidelijk
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werd uit de studies op basis waarvan men een langer dan 6 maanden behande-
ling adviseerde.
Als maat voor de effectiviteit van behandeling werd gekeken naar het aantal
patiënten, dat een recidief tuberculose kreeg nadat de patiënten tenminste 12
maanden na het beëindigen van een succesvolle therapie gevolgd waren. Het
recidiefpercentage alsmede het 95%-betrouwbaarheidsinterval werd berekend.
Een absolute norm voor een recidiefpercentage is er niet. In de studies waren
zowel kinderen als volwassenen opgenomen, maar bij longtuberculose en nier-
tuberculose betrof het uitsluitend volwassenen. Er waren geen HIV-positieve
patiënten, voor zover daarop getest was. Bij long-en niertuberculose konden
patiëntengroepen met elkaar vergeleken worden, bij wie de diagnose bij alle
patiënten bacteriologisch bewezen was en kon het resultaat van de behandeling
bacteriologisch geëvalueerd worden. Bij patiënten met lymphadenitis tubercu-
losa, meningitis- en bottuberculose was de diagnose bacteriologisch bewezen
bij respectievelijk 50%, 28% en 31%. Er waren geen resistente stammen voor
zover bepaald. Indien geen bacteriologisch bewijs voor handen was werd de
diagnose gesteld op basis van histologische, epidemiologische, klinische, labo-
ratoria en radiologische gegevens.  
Een recidief tuberculose na een 6 maanden behandeling kregen 116/4833 (2,4%;
95% C.I. 2,0-2,8) van de patiënten met longtuberculose, 13/422 (3,3%; 95% C.I.
1,7-5,5) van de patiënten met halskliertuberculose, 2/131 (1,5%; 95% C.I. 0,2-5,5)
van de patiënten met meningitis tuberculosa, 0/56 (0%; 95% C.I. 0,0-6,4) van
de patiënten met bottuberculose en 1/170 (0,6%; 95% C.I. 0,0-3,2) van de
patiënten met niertuberculose. In de onderzoeken van de patiënten met longtu-
berculose met een controleperiode van 18-36 maanden na het beëindigen van de
therapie trad 75% van de recidieven op in het eerste jaar na het stoppen van de
medicatie. Bij geen van de patiëntengroepen met tuberculose, ongeacht de
hoofddiagnose was het behandelresultaat na 6 maanden therapie slechter in
vergelijk met de resultaten van de groep patiënten, die langer dan 6 maanden
was behandeld. In alle studies werd het belang van een bacteriologisch bewijs
onderstreept. Na definitieve typering kan bepaald worden of de tuberkelbacte-
rie normaal gevoelig is voor de gebruikelijke tuberculostatica. Bij de patiënten
met een recidief tuberculose werd voor zover bepaald steeds weer een normaal
gevoelige tuberkelbacterie gevonden. 
De meeste studies zijn gedaan in landen waar tuberculose hoogendemisch is en
waar de laboratoriumfaciliteiten niet te vergelijken zijn met de mogelijkheden
in Nederland. Desalniettemin was het voor het stellen van de diagnose ook in
die landen het allerbelangrijkste dat men tuberculose hoog in de differentiaal-
diagnose had staan, waarbij de bevinding van een granulomateuze ontsteking
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met verkazende necrose in het punctaat of de biopsie altijd leidde tot het starten
van de tuberculostatische therapie. Uitstel van de behandeling, in afwachting
van de kweek geeft progressie van het ziektebeeld waarbij irreversibele orgaan-
schade kan optreden. Het langer doorgeven van tuberculostatica nadat men te
laat gestart is kan nooit meer deze schade ongedaan maken. Dit heeft ertoe
geleid dat in hoofdstuk 3a ook voor de Nederlandse situatie op het belang van de
macroscopische en histologische bevindingen van het punctaat of de biopsie
wordt gewezen. 
De medicamenteuze behandeling is bij alle vormen van tuberculose obligatoir,
maar ernstige restschade kan chirurgisch ingrijpen bij met name bot-en niertu-
berculose noodzakelijk maken. Dit is waarschijnlijk de verklaring voor het feit
dat in de artikelen over bottuberculose de nadruk met name ligt op de techniek
van de chirurgische interventie. Onzekerheid of de tuberculostatica de infectie-
haard wel bereiken heeft er toe geleid dat per orgaan de behandelresultaten in
kaart zijn gebracht. Diezelfde onzekerheid is een verklaring voor het feit dat
men met name bij meningitis tuberculose de medicatie in een hogere dosering
werd gegeven dan bij andere vormen van tuberculose. Uit de in hoofdstuk 5
beschreven behandelresultaten van Nederlandse kinderen met tuberculose
blijkt dat een isoniazide dosering van 4-8 mg/kg lichaamsgewicht volstaat. De
resultaten van de studies geven weliswaar geen antwoord op de vraag waarom
de behandeling effectief is, maar wel óf hij effectief is. 
De studies zijn gedaan in landen waar tuberculose veel voorkomt. Dit betekent,
dat de kans bestaat, dat een patiënt na een succesvolle behandeling opnieuw
aangehoest wordt en een actieve tuberculose ontwikkelt, die dan ten onrechte
geduid  wordt als een recidief tuberculose, een falen van de eerdere behande-
ling. Met DNA fingerprint techniek, zoals in hoofdstuk 9b beschreven is het
tegenwoordig mogelijk na te gaan of patiënten met dezelfde tuberkelbacterie
geïnfecteerd zijn. Onderscheid tussen een recidief tuberculose tengevolge van
een endogene reactivatie of exogene reïnfectie is op deze wijze mogelijk. Boven-
dien geeft het inzicht in de import en verspreiding van tuberkelbacteriën in
Nederland. Dit is niet alleen een kwaliteitsmaat voor de effectiviteit van de
behandeling van tuberculosepatiënten, maar toont ook verbanden aan tussen
patiënten, die niet door het traditionele  bron-en contactonderzoek van de
GGD zijn gelegd. Het traditionele bron-en contactonderzoek is beschreven in
hoofdstuk 9a. Het onderzoek vond plaats rond een asielzoeker, bij wie bij bin-
nenkomst een longtuberculose werd vastgesteld. De volstrekt inadequate
opvang in slecht ventilerende ruimtes van de groep asielzoekers, waartoe deze
patiënt behoorde heeft er toe geleid dat medeasielzoekers en Nederlandse hulp-
verleners geïnfecteerd zijn. Zeker gezien de kans heden ten dage op import van
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resistente tuberkelbacteriën is een dergelijk opvangbeleid onverantwoord.
Naast het individuele belang van de patiënt speelt bij tuberculose ook het alge-
mene volksgezondheidsbelang. Dit is dan ook de reden dat elke tuberculosepa-
tiënt in Nederland gemeld moet worden bij de GGD, van waaruit bron- en con-
tactonderzoek gestart wordt. Bovendien wordt de patiënt mede begeleid door
de GGD tijdens de duur van de therapie. In de geanalyseerde studies over de
behandelresultaten van patiënten met tuberculose werd de medicatie meestal
niet onder volledige supervisie gegeven. Wel was de voorlichting aan en de bege-
leiding van de patiënten heel intensief. 
In hoofdstuk 8 wordt beschreven hoe uit de gegevens van de Nederlandse
Tuberculose Registratie (NTR) in vergelijk met de gegevens van het Genees-
middelen Informatie Project van het College voor zorgverzekeringen bleek dat
er een grote overeenkomst was tussen het aantal dagen geregistreerd pyrazi-
namide gebruik in de NTR en de afgeleverde dagelijks dosering pyrazinamide
door de apothekers. Hieruit werd geconcludeerd dat de patiënten met tubercu-
lose in Nederland ook daadwerkelijk gemeld worden en bekend zijn bij de
GGD. Overleg tussen de klinisch werkzame artsen en artsen en sociaalver-
pleegkundige werkzaam op een GGD vindt dus plaats. In hoofdstuk 10 wordt
beschreven welke factoren mogelijk een rol hebben gespeeld bij de implementa-
tie van het advies om de behandeling van longtuberculose in Nederland met 3
maanden te verkorten. Algemene factoren, die altijd spelen bij een verande-
ringsproces speelden ook hier; factoren zoals de omvang van het probleem,
onbekendheid met de materie, niet overtuigd zijn van de noodzaak, alsmede het
feit dat behandelaars van tuberculose tot verschillende organisaties behoren, nl.
een GGD, de KNCV en de ziekenhuizen. Het ligt in de lijn der verwachting, dat
door inzicht in deze factoren en inzicht op basis waarvan een behandeladvies
tot stand is gekomen alsmede door de wettelijk kwaliteit eis die tegenwoordig
aan behandelaars wordt gesteld de implementatie van het behandeladvies voor
de extrapulmonale vormen van tuberculose snel tot stand komt.
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Abbreviations
ATS American Thoracic Society
BTS British Thoracic Society
COA the agency for the reception of asylum seekers (Centraal Orgaan
opvang Asielzoekers)
CPT National Tuberculosis Policy Committee (Commissie voor Praktis-
che Tuberculosebestrijding )
CRL Commissie Richtlijnen Longziekten
CVZ Health Care Insurrance Board ( College voor zorgverzekeringen )
DDD Defined Daily Dose
DOT Direct Observed Treatment
GIP Dutch Drug Information Project
IUATLD International Union Against Tuberculosis and Lung Disease
KNCV Royal Netherlands Tuberculosis Association (Koninklijke Neder-
landse Centrale Vereniging tot bestrijding der tuberculose )
MHS Municipal Health Service (GGD)
NTR Netherlands Tuberculosis Register
NVALT Nederlandse Vereniging van Artsen voor Longziekten en 
Tuberculose
RIVM National Institute of Public Health and Environment 
(Rijksinstituut voor Volksgezondheid en Milieu)
WHO World Health Organisation
H isoniazid
R rifampicin
Z pyrazinamide
E ethambutol
S streptomycin
2HRZE/4H 2 R 2 Treatment Regimen:  numbers before a group of letters rep-
resent the number of months on that type of drug, numbers
after a letter or group of letters represent the number of doses
of the drug(s) per week, 
2HRZE/4HR and if a letter or group of letters is not followed by any num-
bers then the drug(s) were given daily
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Dankwoord
Tuberculose is een infectieziekte met een levenslange incubatietijd. Zo lang
heeft het tot stand komen van dit proefschrift gelukkig niet geduurd, maar de
snelheid waarmee de hoofdstukken tot stand zijn gekomen zijn te vergelijken
met de wisselende niveaus van metabole activiteit  van de tuberkelbacteriën. De
laatste 18 maanden was er duidelijk sprake van een groeispurt dank zij de ruimte
die mij door de medewerkers van de GGD Regio Nijmegen werd gegeven. De
inzet van Annemieke Sintenie-Hendriks voor het maken van de tabellen in
hoofdstuk 2 was enorm.
Veel heb ik te danken aan Paul Oude Vrielink en Dr. Jaap Veen, die van meet af
aan bij het tot stand komen van dit proefschrift zijn betrokken evenals Prof. Dr.
Jos van der Meer, Prof. Dr. André Verbeek en Prof. Dr. Cees van Herwaarden.
Beste Paul, op elk willekeurig moment van de werkdag kon ik op de GGD bij jou
binnen lopen. Jij dacht altijd kritisch mee, waardoor ik weer verder kon. Je hielp
mij met de verschillende databaseprogramma’s en maakte de figuren, toen nog
in Harvard Graphics. Beste Jaap, snel en efficiënt maakte jij mij wegwijs in de
tuberculoseliteratuur, waarbij je consequent de systematisch aanpak bewaakte.
Vaak kwam je me tegemoet in het overbruggen van de afstand Den Haag –
Nijmegen, ofwel door zelf te komen ofwel door zorgvuldig geplande telefonische
afspraken. Beste Jos, je weinige woorden werkten inspirerend en bezorgden mij
geregeld veel werk. Je commentaar op de conceptartikelen was volledig, zorg-
vuldig, kritisch, maar altijd opbouwend. Jij verwees mij ook naar Prof. Dr.
André Verbeek, die een deel van het voorwerk uitbesteedde aan Robert Laheij.
Beste André, jouw werkwijze is grondig, waardoor nuancering mogelijk is. Op
een bord met een krijtje maak je snel alles inzichtelijk. Beste Robert, aanvanke-
lijk bezweek ik bijna onder de enorme literatuurberg, die jij met Leo van Ros-
sum aandroeg. Marja de Zwaan van de KNCV was heel behulpzaam bij het
opvragen van moeilijk verkrijgbare artikelen. Robert, jij leerde mij samen met
André uit de veelheid van gegevens alleen de essentiële zaken naar voren halen.
Jullie bewaakten de strakke maar volledige beantwoording van de onderzoeks-
vraag en toen deze in het Engels verwoord moest worden brachten jullie mij in
contact met Judith Abma-Hill. Beste Judith van de referenten kreeg ik altijd
lovend commentaar over het Engels. Om alles op tijd vertaald te hebben bleek in
de laatste fase de hulp van Karin ter Haar-van den Berg en Titia Meesters
onontbeerlijk. Maar voor het zover was bood Prof. Cees van Herwaarden mij
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de mogelijkheid knelpunten voor de klinisch werkzame longarts op te sporen
tijdens verschillende refereeravonden in Dekkerswald. Heel veel heb ik gehad
aan de inhoudelijke discussies met Clemens Richter, die de tuberculosepatiënt
zo goed kent uit eigen ervaring. Dit geldt ook voor de tuberculoseartsen werk-
zaam op de GGD-en en de longartsen van de twee sanatoria in Nederland,
Richard van Altena en Wiel de Lange. Jullie waren voor mij een klankbord. Met
Reinout van Crevel resoneerde het goed. We promoveren bijna gelijktijdig.
Alleen het symposium ligt er tussen. Of is dit de eerste van de Nederlandse
Tuberculose Wetenschapsdagen, waarvan Martin Boeree droomt? Voor het
inzichtelijk maken van de omvang van de tuberculoseproblematiek in Neder-
land heb ik dankbaar gebruik gemaakt van de gegevens, zoals die door de tuber-
culosemedewerkers van de GGD-en worden aangeleverd ten behoeve van de
Nederlandse Tuberculose Register (NTR). Dankzij de fantastische medewer-
king van Nico Kalisvaart konden de onderzoeksvragen op basis van deze NTR
gegevens worden beantwoord. De KNCV ondersteunt hiermee op unieke wijze
de kwaliteit van de zorg rond de tuberculosepatiënt. Voor problemen rond de
farmacotherapie kon ik altijd terecht bij Prof. Dr. Chiel Hekster, maar ook bij
Jos van Loenhout. Lieve Jos, door jou leerde ik weer hoe internisten dachten. In
feite ben jij al die jaren mijn enige echte promotor geweest, hoewel je in Marijn
voor een uitstekende kloon hebt gezorgd. Ik hoop maar dat jullie tevreden zijn.
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Curriculum vitae
De auteur van dit proefschrift werd geboren op 2 augustus 1952 te Helmond. 
Na het behalen van het diploma Gymnasium B aan het Carolus Borromeus
College te Helmond in 1970, studeerde zij Geneeskunde aan de Katholieke 
Universiteit te Nijmegen. Het artsexamen werd behaald in 1978. In 1979 werd
begonnen met de opleiding tot internist in het Canisius Wilhelmina Ziekenhuis
(hoofd: Dr. J.H.J. Enneking). In 1982 werd de opleiding voortgezet in het 
Universitair Medisch Centrum St. Radboud (hoofd: Prof. Dr. A. van ‘t Laar),
waarna in september 1983 begonnen werd met de specialisatie longziekten in
het Universitair Longcentrum Medisch Centrum Dekkerswald / Dr. van Spanje-
kliniek / UMC St. Radboud. (hoofd Prof. C.M.Jongerius en in 1987 Prof. 
Dr. C.L.A. van Herwaarden). Na de registratie tot longarts in december 1986
werd tot maart 1988 parttime gewerkt als longarts in het UMC St.Radboud.
Vanaf augustus 1987 tot mei  1988 werd als tuberculosearts gewerkt op de GGD
Utrecht, daarna op de GGD Haarlem, Gooi-en Vechtstreek en Flevoland en
vanaf januari 1990 tot heden op de GGD Regio Nijmegen. Sedert september
2001 ook werkzaam op de GGD Rivierenland in Tiel. In 1990 werd begonnen
met de opleiding Sociale Geneeskunde, tak Algemene Gezondheidszorg en
met de module infectieziekten (opleider J.van Steenbergen) te Utrecht, Stich-
ting voor Sociale Gezondheidszorg. In oktober 1993 vond de inschrijving in het
specialistenregister Sociaal Geneeskundigen, tak Algemene Gezondheidszorg
plaats.
Zij is gehuwd met Jos van Loenhout. Samen hebben zij een zoon Marijn.
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